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ABSTRACT
The Toll-like receptor (TLR) family plays a crucial role in innate immunity by 
mediating the recognition of, and response to a variety of microorganisms. 
Dysregulation of TLR-mediated inflammatory responses may, however, lead to a 
variety of acute and chronic inflammatory conditions. The description of a naturally 
occurring soluble form of TLR2 (sTLR2), and the observation that sTLR2-depleted 
serum renders leukocytes hypersensitive to TLR2-mediated stimulation, demanded a 
full assessment of sTLR2’s regulatory capacity and an investigation of the underlying 
mechanism and therapeutic potential. The present study addressed these issues, and 
reports that cells overexpressing sTLR2, or stimulated in the presence of the sTLR2 
protein, are TLR2 hyposensitive. Regulation was TLR2-specific, affected NF-kB 
activation, phagocytosis and superoxide production. Mice administered sTLR2 with 
Gram-positive bacteria-derived components showed lower levels of the neutrophil 
(PMN) chemoattractant, keratinocyte-derived chemokine; lower PMN numbers and late 
apoptotic PMN. Mononuclear cell recruitment was not affected, and endogenous 
peritoneal sTLR2 levels increased. Notably, the anti-inflammatory effect of sTLR2 did 
not compromise the capacity of mice to clear a live infection. sTLR2 interfered with the 
mobilisation of TLR2 to lipid rafts, acted as a decoy receptor, and disrupted the receptor 
(TLR2)-co-receptor (CD 14) interaction by associating with CD 14. In order to identify 
the region(s) of sTLR2 involved in the interaction with CD 14, the leucine-rich repeats 
(LRRs) of TLR2 were mutated, and the ability of these mutants to affect CD 14- 
dependent signalling was evaluated. Peptides representing the LRR6 and LRR20 were 
found to specifically inhibit CD 14-dependent TLR2 triggering, indicating that these 
LRRs are directly involved in the TLR2-CD14 interaction. This study defines sTLR2 as 
an efficient regulator of TLR2-mediated inflammatory responses. The capacity of 
sTLR2 and TLR2-derived peptides to exert regulatory effects by targeting CD 14 may 
inform the design of therapeutics against inflammatory conditions that will aim at 
disrupting the co-receptor's activity, thus blunting, but not abrogating, microbial 
recognition and host responses.
A B B R E V IA T IO N S
Ab: Antibody
Ag: Antigen
AP-1: Activating protein-1
APCs: Antigen presenting cells
BIR: Baculovirus inhibitor of apoptosis protein repeat domain
BLP: Bacterial lipopepides
BSA : Bovine serum albumin
CARD: Caspase activation and recruitment domain
CFU: Colony-forming unit
CL: Collectin
CRD: Carbohydrate recognition domain
CRP: C-reactive protein
DCs: Dentritic cells
Dif: Dorsal-related immunity factor
dsRNA: Double-stranded RNA
ECD: Extracellular domain
FADD: Fas-associated protein with dead domain
FCS: Foetal calf serum
FRET: Fluorescence resonance energy transfer
GM-CSF: Granulocyte-macrophage colony-stimulating factor
GNBP: Gram-negative binding protein
His-rhsTLR2: 6x histidine-tagged recombinant human soluble TLR2
HKLM: Heat-killed Listeria monocytogenes
HMGB: High-mobility group B
HRP: Horseradish peroxidase
IE-DAP: y-D-glutamyl-meso-diaminopimelic acid
IFN: Interferon
Igs: Immunoglobulins
IKK: IkB kinase
IL-1R: IL-1 receptor
Imd: Immune deficiency
IPAF: ICE protease-activating factor
IRAK: Interleukin-receptor-associated kinase
IRF: Interferon response factor
ISRE: Interferon-stimulated response element motifs
JKN: c-Jun N-terminal kinase
KC: Keratinocyte-derived chemokine
LBP: LPS-binding protein
LDL: Low-density lipoproteins
LAM: Lipoarabinomannan
LM: Lipomannan
LPS: Lipopolysaccharide
LRR: Leucine-rich repeat
LTA: Lipoteichoic acid
m: Membrane-bound
MAC: Membrane attack complex
Mai: MyD88 adaptor-like
MALP: Macrophage-activating lipopeptide
ManLAM: Mannosyl-capped lipoarabinomannan
MAPK: Mitogen-activated protein kinase
MARCO: Macrophage receptor with collagenous structure
MASP: Mannose-binding-lectin-associated serine protease
MBL: Mannose-binding lectin
MCMV: Murine cytomegalovirus
MCP-1 : Monocyte chemoattractant protein-1
MDA: Melanoma differentiation associated gene
MDP: Muramyl dipepdtide
MFI: Mean of fluorescence intensity
MHC: Major histocompatibility complex
MIP: Macrophage inflammatory protein
MKK: MAPK kinase
MMR: Macrophage mannose receptor
MNC: Mononuclear cells
MUC: Mucin-like glycoprotein
MyD8 8 : Myeloid differentiation primary response protein 8 8
NAIPs: Neuronal apoptosis inhibitor proteins
NEMO: NF-kB essential modulator
NF-kB: Nuclear factor-xB
NLR: Nucleotide-binding oligomerisation domain-like receptor
NO: Nitric oxide
NOD: Nucleotide-binding oligomerisation domain
NS: Non-structural protein
Ni-NTA: Nitrilotriacetic acid
OAS: Oligoadenylate synthase
ODN: Oligodeoxynucleotide
P arleys: Trypalmitoyl-cysteinyl-seryl-(lysyl)3 -lysine (Pam3 -Cys-Ser-Lys4 )
PAMPs: Pathogen-associated molecular patterns
PBMC: Peripheral blood mononuclear cells
PFU: Plaque-forming unit
PGN: Peptidoglycan
PIAS: Protein inhibitor of the activated signal transducer and activator of
transcription
PILAM: Phosphoinositol-capped lipoarabinomannan
PI3K: Phosphoinositide 3-kinase
PMN: Polymorphonuclear cells
poly(I:C): Polyinosine-deoxicytidylic acid
PRGP: Peptidoglycan recognition protein
PRRs: Pattern recognition receptors
PSM: Phenol soluble modulin
PTX: Pentraxin
RANTES: Regulated upon activation, normal T-cell expressed, and secreted
RIG: Retinoid-inducible gene protein
RIP: Receptor-interacting protein
ROS: Reactive oxygen species
s: Soluble
SAP: Serum amyloid protein
SARM: Sterile alpha and HE AT-Armadillo motifs-containing protein
SES: Staphylococcus epidermidis cell-free culture supernatant
SHP: Src homology-2 (SH-2)- containing tyrosine phosphatase
SIGIRR: Single immunoglobulin IL-lR-related molecule
SIKE: Supressor of IkB kinase e
SOCS: Suppressor of cytokine signaling
SP: Surfactant protein
SR: Scavenger receptor
SRCL: Scavenger receptor with C type lectin
srMD-2: Soluble recombinant MD-2
TAB: Transforming growth factor-|3-activated kinase -1 binding proteins
TAK: Transforming growth factor-(3-activated kinase
TBK: TRAF-family-member-associated-NF-icB activator -binding kinase
TGF-|3: Transforming growth factor-|3
Th: T helper
TICAM: TIR-containing adapter molecule
TIR: Toll/interleukin-1 receptor
TIRAP: TIR domain-containing adapter
TLR: Toll-like receptor
TNF: Tumour necrosis factor
TOLLIP: Toll-interacting protein
TRAF: TNF-a-receptor-associated factor
TRAIL: TNF-related apoptosis-inducing ligand
TRAILR: TNF-related apoptosis-inducing ligand receptor
TRAM: TRIF-related adaptor molecule
TRIF: TIR domain-containing adaptor inducing interferon-p
Ubcl3: Ubiquitin-conjugating enzyme 13
UevlA: Ubiquitin-conjugating enzyme E2 variant 1
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1. INTRODUCTION
1.1 Overview of the innate and adaptive immune response
Resolution of a microbial infection requires an efficient as well as controlled 
immune response, which is based on the activity of the innate immune system -  a 
universal and ancient form of host defence -  and the more specific, adaptive immune 
system (Janeway and Medzhitov, 2002).
The fine specificity of adaptive immune responses is ensured by the work of two 
types of specialised cells, B-lymphocytes and T-lymphocytes, through their somatically- 
generated receptors for antigens (Ags), whose expressions depend upon gene 
arrangement (Medzhitov and Janeway, 2000). This mechanism involves a clonal 
distribution of receptors, each cell displaying a unique receptor capable of recognising a 
specific Ag.
Ag recognition by a receptor leads to activation of the specific lymphocyte (B or T) and 
subsequent cell proliferation (clonal expansion), thus ensuring a strong and highly 
specific immune response. Furthermore, the clonal expression of Ag receptors in 
lymphocytes provides the basis of immunological memory, which allows for a faster, 
stronger and more specific response to re-encountered Ags.
In spite of being a very specific and powerful defence mechanism, the process of 
building up an adaptive immune response is relatively long, taking between 2 to 5 days 
after the initial contact with the Ag. This time constitutes a considerable delay when 
combating fast replicating microbial pathogens.
In addition to pathogen-derived Ags, the adaptive immune system also recognises and 
responds to elements from the environment or from self. Uncontrolled response to such 
Ags may lead to allergies and autoimmune diseases, respectively.
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Although lacking the specificity of the adaptive immune system, the innate 
immune system provides an immediate, yet efficient, answer to a microbial challenge. 
The cells of the innate immune system express germ-line-encoded receptors specific for 
highly conserved molecular structures present in a variety of microorganisms, termed 
pathogen-associated molecular patterns (PAMPs) (Janeway and Medzhitov, 2002). This 
is a misnomer, as these molecular patterns are not exclusive of pathogens. Importantly, 
the innate immune response targets mainly microbial pathogens, as mostly they, and not 
the host, produce these patterns. The fact that a given PAMP is expressed by a range of 
microorganisms allows a single innate immune receptor to sense different microbes. 
Moreover, given that PAMPs are essential either to microbial survival or pathogenicity 
it makes it more difficult for the pathogen to escape innate immune recognition by 
mutation.
The innate immune receptors recognising PAMPs are called pattern recognition 
receptors (PRRs). In general, PRR triggering by PAMPs induces, either directly or 
indirectly, immediate cell activation. The activated cell performs its effector function 
instantly, thus providing the host organism with a first line of defence against the 
pathogen.
Although innate and adaptive immunity can be considered two distinct systems, as they 
rely on different receptors and effector cells, the immune response is often presented as 
an organisational continuum (Fearon and Locksley, 1996). Indeed, dentritic cells (DCs) 
act as antigen presenting cells (APCs): they recognise and phagocyte pathogens through 
their PRRs, degrade them, and subsequently, display pathogen-derived Ags at their 
surface. APCs then interact with T-lymphocytes to initiate an Ag-specific adaptive 
immune response, and such cells form a crucial link between the innate and adaptive
3
Table 1.1. Overview of human antimicrobial peptides
Antimicrobial peptide Activities Origin
a-defensins:
Human neutrophil defensins 
precursor 1 to 3 
(HNP-1 to -3)
Antibacterial, antifungal, antiviral 
activity.
Chemotactic effect on monocytes, 
T cells, dendritic cells.
Neutrophils,
macrophages
Human defensin 5 and 6 
(HD-5 and -6)
Antibacterial activity, activates 
mast cells.
Paneth cells
B-defensins
Human p-defensins 1 to 4 
(HBD-1 to -4)
Antibacterial activity.
Chemotactic effect on monocytes, 
T cells, dendritic cells.
Epithelial cells
Bacterial Permeability Increasing 
protein (BPI)
Binding to lipopolysaccharides. 
Gram negative antibacterial 
activity.
Neutrophils
Cathelicidins
LL-37
Binding to lipopolysaccharides. 
Antibacterial activity.
Chemotactic effect on monocytes, 
T cells, mast cells.
Neutrophils, 
epithelial cells
Histatins 
Histatin 1 to 3 Metal-binding properties. 
Antibacterial and antifungal 
activity.
Parotid gland
Lactoferrin Iron sequester.
Antibacterial and antifungal 
activity.
Neutrophils, 
mammary gland
Lysozyme Hydrolysis of peptidoglycan. 
Antibacterial activity (mainly Gram 
postive).
Non-specific opsonin.
Neutrophils, 
macrophages, 
monocytes 
epithelial cells
Phospholipase A-2 (PLA-2) Antibacterial activity.
Cleavage of bacterial cell wall 
phospholipids.
Neutrophils, 
macrophages, 
epithelial cells, 
paneth cells
immunity (Banchereau and Steinman, 1998). Cells of the innate immune system may 
also express co-stimulatory molecules and produce cytokines and chemokines, which 
are essential for the activation of the adaptive immune system (Janeway and Medzhitov, 
2002).
1.2 Mediators of innate immune responses
The capacity of the innate immune system to respond to a microbial challenge in 
a prompt and efficient manner depends, in the first place, on the production of small 
protein mediators with diverse structures and functions, which are able to interact 
directly with and inactivate pathogens. The innate immune mediators include: 
antimicrobial peptides, antimicrobial chemokines, angiogenins and the complement 
system.
1.2.1 Antimicrobial peptides
Antimicrobial peptides are phylogenetically ancient 'weapons' present in both 
the vegetal and animal kingdom (Zasloff, 2002). The ability of these peptides to destroy 
pathogens lies in their cationic and amphiphilic nature. Their overall positive charge 
allows the peptides to interact with the negative outer leaflet of the microbial bilayer, 
which consists of lipids with negatively charged phospholipid headgroups. After 
insertion into the membrane, antimicrobial peptides either disrupt the integrity of the 
microbial bilayer -  affecting its barrier function -  or diffuse from the cell membrane to 
intracellular membranes (Hancock and Sahl, 2006). Because most microbial membranes 
have a negatively charged outer leaflet, antimicrobial peptides have a very broad 
spectrum of action. Susceptibility to antimicrobial peptides, however, varies among
4
Table 1.2. Human chemokines with antimicrobial properties
Chemokine Microorganism reported to be susceptible
CXC family
CXCL-4 or platelet factor-4 
(PF-4)
CXCL-7 or transporter- 
associated with antigen 
processing-2 (TAP-2)
CXCL-9 or mitogen 
inducible gene (MIG)
CXCL-10 or interferon-y - 
induced protein of 10 kDa 
(IP-10)
CXCL-11 or interferon- 
inducible T-cell a- 
chemoattractant (I-TAC)
Connective tissue activating 
peptide 3 (CTAP-3)
Esherichia coli, Staphylococcus aureus, Cryptococcus 
neoformans, Candida albicans.
Bacillus subtilis, Escherichia coli, Staphylococcus aureus, 
Lactococcus, Cryptococcus neoformans.
Esherichia coli, Listeria monocytogenes.
Esherichia coli, Listeria monocytogenes.
Esherichia coli, Listeria monocytogenes.
Esherichia coli, Staphylococcus aureus, Cryptococcus 
neoformans.
CC family
Esherichia coli, Staphylococcus aureus, Cryptococcus 
neoformans, Candida albicans.
Pseudomonas aeruginosa, Klebsiella pneumoniae, 
Streptococcus mutans, Staphylococcus aureus, Candida 
albicans.
CCL-5 or ‘Regulated upon 
activation, normal T-cell 
expressed, and secreted’ 
(RANTES)
CCL-28
different bacterial species (Zasloff, 2002), and it is believed that any mammalian 
organism may have a considerable number of different peptides to ensure the best 
possible response to any microbial challenge (Hancock and Sahl, 2006). By contrast, 
antimicrobial peptides have very little action on mammalian membranes, because their 
outer leaflet usually presents no net charge and the presence of cholesterol stabilises 
their structure. Thus, cationic peptides combine the wide range of action and the 
specificity required for an efficient first line of antimicrobial defence. It is now 
accepted, however, that their action is not limited to pathogen destruction, and that they 
possess important immunomodulatory properties (Durr and Peschel, 2002; Hancock and 
Sahl, 2006), including direct chemoattraction of immune cells, induction of chemokine 
release and modulation of monocyte gene expression. Table 1.1 presents an overview of 
the human antimicrobial peptides, their activities and origins.
1.2.2 Antimicrobial chemokines
Chemokines are small (8-14 kDa), mostly cationic, polypeptides known to play 
pivotal roles in immunity by regulating migration and activation of leukocytes 
(Hieshima et al., 2003). In addition, direct antimicrobial properties have lately been 
attributed to several chemokines: CXCL-9, CXCL-10, CXCL-11 (Cole et al., 2001), the 
platelet chemokines CXCL-4, CATP-3 and CCL-5 (Tang et al., 2002), as well as 
CXCL-7 -  also stored in platelets (Durr and Peschel, 2002) -  and CCL-28 (Hieshima et 
al., 2003), produced at high levels in mucosal tissues such as exocrine glands, the 
respiratory tract and colon. These chemokines act, as most antimicrobial peptides, by 
perturbing the integrity of the microbial membrane (Table 1.2).
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C3 convertase
C5
convertase
Factor 1 
Factor H 
CD46 
CD55
C5b C3b
CD59
Clusterin
C3a C5a
Lectin pathwayClassical pathway
Opsonisation 
o f pathogens
M embrane 
attack com plex
Alternative pathway
MASP-1 and MASP-2 
cleave C2
Abs bind pathogen 
surface Ags
Spontaneous 
hydrolysis o f  C3
Mediation of inflammation, 
phagocyte recruitment
MBL binds 
carbohydrates on 
pathogen surfaces
C lq  binds to Ab:Ag 
complexes or directly 
to pathogen surface
Figure 1.1. Schematic overview o f the complement cascade
In the three pathways o f  complement activation, a series o f  protein cleavage reactions converge in the formation 
of the C3 convertase, which cleaves C3 into C3a and C3b (plain black arrows). C3b binds to the C3 convertase 
to form the C5 convertase, which cleaves C5 into C5a and C5b (dotted black arrows). C3a and C5a are powerful 
peptides mediators o f  inflammation. C3b binds to and opsonises pathogens and, together with C5b, initiates the 
formation o f the membrane attack complex (MAC) that can damage pathogen membrane. M AC’s formation can 
be inhibited by a number o f  complement regulators (red). Ab, antibody; Ag, antigen; MBL, mannose-binding 
lectin; MASP, mannose-binding-lectin-associated serine protease.
It has become apparent that antimicrobial peptides and chemokines have overlapping 
functions, as some members of the two groups contribute to recruitment of immune 
cells and direct neutralisation of pathogens (Durr and Peschel, 2002).
1.2.3 Angiogenins
Angiogenins are members of the ribonuclease superfamily that have long been 
known to be involved in vasculogenesis and tumour angiogenesis. Both human and 
mouse angiogenins have later been found to exert a microbicidal activity against 
bacterial and fungal pathogens in vitro (Hooper et al., 2003). However, this 
antimicrobial effect of angiogenins has lately been challenged, as it appeared to be 
limited, and nonspecific (Avdeeva et al., 2006). Thus, whether or not angiogenins 
constitute a class of microbicidal proteins is still unclear.
1.2.4 The complement system
The complement system is made up of many distinct plasma proteins that react 
with one another to destroy pathogens directly and also promote their opsonisation to 
help clear the infection. Many complement proteins are zymogens -  proteases that can 
themselves be activated by proteolytic cleavage -  and their precursors are widely 
distributed in body fluids and tissues without adverse effects for the host (Janeway’s 
immunobiology, 2008)
There are three established pathways of complement activation: the direct, the mannose- 
binding lectin (MBL) and the alternative pathways (Fig. 1.1). The direct pathway is 
triggered when Clq, the first protein in the complement cascade, binds to the surface of 
a pathogen, either directly or to antibody:antigen complexes. The MBL pathway is
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initiated by binding of MBL to mannose-containing carbohydrates present on bacteria 
and viruses. MBL forms a complex with the mannose-binding-lectin-associated serine 
proteases (MASPs)-l and -2, which in turn activate the complement cascade by 
cleaving the component C2. The alternative pathway is stimulated by the spontaneous 
hydrolysis of the complement component C3 (Lambris et al., 2008).
After activation, each pathway follows a different sequence of enzymatic 
cleavages, all leading to the generation of the same complement protease called C3 
convertase (Fig. 1.1). This protease cleaves C3 to generate C3a, a mediator of 
inflammation, and C3b, a major effector molecule of the complement system. C3b acts 
in two ways : 1) as an opsonin, it binds to the pathogen and so targets it for destruction 
by phagocytes expressing the C3b receptor. 2) C3b binds to the C3 convertase to create 
a C5 convertase complex, which cleaves C5 into C5a and C5b. C5b interacts with the 
other terminal complement components, C6, Cl, C8 and C9, to form a membrane attack 
complex (MAC), which is capable of creating pores in the membrane of certain 
pathogens, leading to their destruction (Janeway’s immunobiology 2008 and Fig. 1.1). 
Notably, the activity of a number of complement regulators (Clusterin, CD46, CD55, 
CD59, Factor 1, Factor H) prevents MAC from damaging the host cells (McDonald and 
Nelsestuen, 1997; Gelderman et al., 2002; Janeway’s immunobiology, 2008).
The anaphylatoxins C3a and C5a, released during complement activation, bind to 
immune cells and trigger a range of chemotactic and pro-inflammatory responses. This 
results in the recruitment of inflammatory cells and the activation of downstream 
immune mechanisms (Lambris et al., 2008).
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1.3 Receptors of the innate immune system
The innate immune system uses a variety of PRRs. Recognition of a PAMP by 
these receptors induces an immediate response aimed at the destruction of the pathogen 
in many different ways, including: opsonisation, phagocytosis, triggering of 
complement, activation of pro-inflammatory signalling pathways and induction of 
apoptosis. PRRs are expressed either as soluble receptors (secreted proteins), in 
intracellular compartments or at the cell surface.
1.3.1 Soluble PRRs
Typical soluble PRRs include members of the collectin, ficolin and pentraxin 
families.
Collectins are an important group of PRRs present in plasma and on mucosal 
membranes. Seven soluble members of this family have been identified: MBL, 
surfactant protein (SP)-A and -D, conglutin, collectin (CL)-43, CL-46 and CL-K1. They 
belong to a family of mammalian lectins which contain collagen-like regions and a C- 
type lectin carbohydrate recognition domain (CRD) (Janeway and Medzhitov, 2002) . 
Collectins bind to a wide range of glycoconjugates on microbial surfaces, thanks to an 
open and flexible binding pocket in their CRD (Gupta and Surolia, 2007). Upon 
recognition of the infectious agents, collectins put into action different effector 
mechanisms to ensure the destruction of the pathogen. Some mechanisms are common 
to the seven secreted collectins (Gupta and Surolia, 2007), like agglutination or 
opsonisation of pathogens, both leading to an enhanced phagocytosis. More specific 
ways to ensure microbial destruction are however used by specific collectins: MBL, a
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plasma protein, can initiate the activation of the complement system and enhance 
chemokine production by macrophages. The pulmonary collectins SP-A and SP-D have 
a more direct antimicrobial action, as they can kill Gram-negative bacteria by disrupting 
their membrane integrity. They can also act as chemoattractants for phagocytes at the 
infection site. In addition to their antimicrobial activities, MBL, SP-A and SP-D also 
exert a host protective role. They ensure an enhanced clearance of apoptotic cells by 
acting as opsonins for free DNA and RNA, inhibiting pro-inflammatory cytokine 
production (MBL), or sequestering Clq to block complement activation (SP-A) (Gupta 
and Surolia, 2007). Furthermore, SP-A and SP-D can affect the adaptive immune 
response by inhibiting T-cell proliferation (Borron et al., 1996) or modulating the 
differentiation of immature DCs. Indeed, SP-D was found to associate with immature 
DCs, facilitate their interaction with bacterial pathogen, and enhance their cell-surface 
Ag presentation capacity (Brinker et al., 2001), whereas SP-A was found to reduce the 
expression of major histocompatibility complex (MHC) class II on DCs, and thus 
inhibiting the allostimulation of T cells by DCs (Brinker et al., 2003). CL-Kl’s cDNA 
was detected by screening human liver databases, and RT-PCR analysis showed that 
most human tissues express CL-K1 mRNA -  with the exception of skeletal muscles and 
bone marrow (Keshi et al., 2006). CL-K1 was found capable of binding to LPS from 
several Gram-negative bacterial strains and mannan from Saccharomyces cerevisiae, 
but the relevance of this binding in terms of antimicrobial activity remains to be 
evaluated.
Conglutin, CL-43 and CL-46 are bovine collectins, which provide a first line of defence 
against rumen microbes by using the common effector mechanisms, i.e. agglutination 
and opsonisation.
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Members of the ficolin family are related to MBL (Endo et al., 2007), and have 
been shown to be involved in non-self clearance. Depending on the species of 
mammals, two or three kinds of ficolin have been identified. They are produced by 
different cell types, and have different affinity for different bacterial carbohydrates. In 
humans, the first member of the ficolin family, termed L-ficolin, was isolated from 
plasma and shown to recognise N-acetylglucosamine residues in sugar chains 
(Matsushita et al., 1996). The second human ficolin, M-ficolin, was identified by 
genome comparison with L-ficolin. M-ficolin is 76% identical to L-ficolin, is not 
expressed in plasma, but mainly in peripheral monocytes, lung and spleen (Endo et al., 
1996). The latest human ficolin to be identified was isolated as a serum Ag recognised 
by an autoantibody in patients with systemic lupus erythematosus (Sugimoto et al., 
1998). It was first termed Hakata antigen, and later renamed H-ficolin. H-ficolin is 
produced mainly by the liver and lungs, and is secreted in the blood and bile duct. Upon 
binding to the ligand, ficolins can activate complement through the lectin pathway by 
binding to MBL-associated serine proteases (MASPs), or induce opsonophagocytosis 
(Endo et al., 2007).
C-reactive protein (CRP), serum amyloid protein (SAP) and pentraxin 3 (PTX-
3) are members of the pentraxin family. They function as opsonins upon binding to 
phosphorylcholine on bacterial membranes (Janeway and Medzhitov, 2002; Lee and 
Kim, 2007). CRP and SAP can also bind to Clq and, thus, activate the classical 
pathway of complement activation.
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1.3.2 Intracellular PRRs
Viruses and some bacteria can gain access to intracellular compartments, and 
several PRRs expressed in the cytosol can detect these intracellular pathogens: the 2’- 
5’-oligoadenylate synthase (OAS), the protein kinase R (PKR), the melanoma 
differentiation associated gene-5 (MDA-5), the retinoid-inducible gene protein-1 (RIG- 
1) and members of the the nucleotide-binding oligomerisation domain (NOD)-like 
receptors (NLRs).
OAS is activated by binding to viral double-stranded RNA (dsRNA), and 
produces a nucleotide messenger, 2’-5’ oligoadenylate, which in turn activates the 
ribonuclease (RNase) L. This RNase digests both viral and cellular RNAs, leading to 
viral destruction and apoptosis of the infected cells (Janeway and Medzhitov, 2002).
PKR is a TNF-a-induced dsRNA-dependent serine threonine kinase (Garcia et 
al., 2007). Upon binding to dsRNA, PKR phosphorylates and inactivates the translation 
initiation factor eIF2a. This blocks both viral and cellular synthesis, leading to the
destruction of the virus and the infected cell. In addition to its translational regulatory 
function, PKR can also activate NF-kB, leading to the induction of various pro- 
inflammatory genes (Garcia et al., 2007).
MDA-5 and RIG-1 are cytoplasmic caspase activation and recruiting domain 
(CARD) helicases, containing a RNA helicase domain involved in RNA recognition 
and two CARDs responsible for initiating dowstream signalling (Lee and Kim, 2007) 
leading to viral RNA destruction. In vivo experiments have demonstrated that MDA-5 is 
the main receptor for the viral double-stranded RNA (dsRNA) mimic polyinosinic- 
polycytidylic acid (poly I:C, also a TLR3 ligand, see section 1.3.3.B.2.5), whereas RIG-
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1 recognises single-stranded (ss) 5'-triphosphorylated and uncapped RNA (Takeuchi 
and Akira, 2008). As most of the 5' ends of host mRNAs are capped, RIG-1 is able to 
discriminate viral and host RNAs.
Contrary to the specific recognition of viruses by OAS, MDA-5 and RIG-1, 
NLRs are mainly involved in antibacterial defence. The NLRs constitute a large family 
of receptors, more than 20 in mammals. They consist of three distinct domains: a C- 
terminal leucine-rich repeat (LRR) domain -  mediating ligand binding -  , a NACHT 
central domain -  involved in self oligomerisation -  (NACHT stands for domain present 
in: neuronal apoptosis inhibitor proteins (NAIPs), class II transactivator (CUTA), the 
plant het product involved in vegetative incompatibility HET-E and telomerase 
associated protein-1 (TP-1)), and an N-terminal effector domain for protein-protein 
interaction, which initiates downstream signalling. NLRs have been grouped into three 
subfamilies, depending on their effector and NACHT domains: 1) NOD-1, NOD-2 and 
the ICE protease-activating factor (IPAF) contain a CARD domain, 2) NAIPs have 
three baculovirus inhibitor of apoptosis protein repeat (BIR) domains (Lee and Kim, 
2007), and 3) NALPs (NATCH, LRR, PYD) possess a pyrin effector domain (PYD) 
(Lee and Kim, 2007).
Human NOD-1 and -2 recognise the different peptidoglycan (PGN) fragments y-D- 
glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP), 
respectively. NOD-1 acts mainly as a sensor for Gram-negative bacteria, as most Gram- 
positive PGNs do not contain iE-DAP. On the contrary, because PGNs from both Gram- 
positive and Gram-negative bacteria contain MDP, NOD-2 has a broader spectrum of 
action (Strober et al., 2006). Ligand recognition by NODs can activate both NF-kB and 
MAP kinase pathways (Underhill, 2007). NOD-1 or -2 deficiency increases murine
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sensitivity to gastrointestinal bacterial infections (Strober et al., 2006), and LRR 
mutations in NODs have been linked with inflammatory disorders such as Crohn’s 
disease in humans.
Recently, IPAF and NAIP-5 (murine paralogue of NAIP) have been shown to recognise 
cytosolic flagellin (Miao et al., 2006), the principal protein of bacterial flagella -  known 
to be a ligand for TLR5 (see section 1.3.3.B.2.1). Activation of IPAF or NAIP-5 leads 
to Caspase-1-mediated secretion of IL-lp and macrophage cell death. It is believed that 
NAIP-5 collaborates with IPAF to achieve macrophage cell death (Miao et al., 2006). 
Fourteen members of the NALP family have been identified, and the function of most 
of them remains to be investigated. Various stimuli activating human NALP-3 were 
recently identified. These include various exogenous stimuli such as bacterial RNA, 
antiviral compounds (R848 and R837), and bacteria {Staphylococcus aureus and 
Listeria monocytogenes, but not Salmonella typhimurium or Francisella tularensis), as 
well as endogenous ligands that act as ‘danger’ signals such as uric acid crystals formed 
after the release of uric acid from dying cells, and extracellular ATP released by dying 
cells. Upon ligand recognition, NALP-3 recruits Caspase-1 via interaction with the 
CARD-containing adaptors Cardinal and Asc, forming a so-called inflammasome (Lee 
and Kim, 2007). The close proximity of the caspases in the inflammasome is thought to 
promote maturation of pro-inflammatory cytokines such as IL-ip and IL-18, and 
subsequent cell apoptosis (Lee and Kim, 2007).
Several members of the Toll-like receptor (TLR) family capable of recognising 
viral and bacterial RNA and DNA are also intracellularly located. They will be 
described, as the rest of the TLR family, in the next section.
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1.3.3 Cell membrane PRRs
Cell-membrane-expressed PRRs include: Dectin-1, the macrophage mannose 
receptor (MMR), scavenger receptors (SRs), and the Toll-like receptors (TLRs).
Dectin-1, a C-type lectin, is able to induce intracellular signalling by itself (Lee 
and Kim, 2007). It is expressed on DCs, macrophages and neutrophils. Dectin-1 
recognises P-l,3-glucan in the core of the fungal cell wall, which is exposed upon 
separation of budding yeast cells. Macrophages from Dectin "/_ animals have been used 
to demonstrate that this receptor is essential for the phagocytosis of zymosan (a glucan 
from the yeast cell wall) and live fungi as well as for the production of antimicrobial 
reactive oxygen species (ROS). It has also been shown that Dectin-1 co-operates with 
TLR2 for the zymosan-induced production of TNF-a and IL-12p40 by macrophages, 
and IL-2 and IL-10 by DCs (Rogers et al., 2005).
MMR is a C-type lectin which binds carbohydrates on the surface of pathogens. 
Its structure and recognition properties are very similar to those of MBL (section 1.3.1), 
but because MMR has a transmembrane domain, it can act as a direct phagocytic 
receptor (Fraser et al., 1998).
SRs are capable of binding to a variety of microbial ligands as well as to host- 
derived molecules, such as modified low-density lipoproteins (LDL), promoting their 
phagocytosis (Mukhopadhyay and Gordon, 2004). SRs are expressed mainly at the cell 
surface of macrophages, DCs and some selected endothelial cells. SR-A, one of the best 
described SR, has been shown to recognise different bacterial ligands, such as 
lipopolysaccharide (LPS) -  a component of the outer membrane of Gram-negative 
bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, and bacterial CpG DNA.
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The SR termed macrophage receptor with collagenous structure (MARCO) also binds a 
wide range of Gram-positive and Gram-negative ligands, but it is only expressed in 
subpopulations of macrophages, such as resident peritoneal macrophages. Other SRs are 
involved in viral recognition and phagocytosis: gp-340, identified in both saliva and 
lung surfactant (Mukhopadhyay and Gordon, 2004), has been shown to neutralise 
different strains of the influenza-A virus, and the human immunodeficiency virus-1. 
SRs are not only involved in pathogen destruction. For example, MARCO and the SR 
with C-type lectin-1 (SRCL-1) ensure the removal of modified host molecules such as 
oxidised-LDL (Ox-LDL), a metabolite generated by host cells and trapped in the 
subendothelial spaces. Failure to remove oxidised-LDL from the subendothelial spaces 
typically leads to atherosclerosis (Mukhopadhyay and Gordon, 2004).
TLRs are also membrane-bound PRRs. They are of critical importance to host 
defence and the subject matter of the present study. Therefore, they will be described in 
more detail in the next section.
1.3.3.A The Toll receptors
Toll-like receptors take their name from the Toll family of receptors. 
The Toll receptors are evolutionary conserved, and homologous receptors are found in 
plants, insects and vertebrates (Lemaitre et al., 1996). The first member of this family 
was identified in the fruit fly Drosophila melanogaster in 1984 and named Toll, the 
german word for ‘strange, bizarre’, because fly larvas bearing a mutation in the toll 
gene were very strange looking, as the ventral portion of their body was 
underdeveloped. Indeed, Toll was first discovered as part of a pathway required for
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Figure 1.2. The Drosophila Imd and Toll pathways
Comparison o f  the mechanims involved in ligand recognition and subsequent signalling by the Imd pathway and 
the Toll pathway in Drosophila immunity. Dif, Dorsal-related immunity factor; Dnr-1, defence repressor 1; 
FADD; Fas-associated protein with dead domain; GNBP-1, Gram-negative binding protein-1; IKK, IkB kinase 
complex; Imd, Immuno-deficiency; JNK, c-Jun N-terminal kinase; MyD88, myeloid differentiation primary 
response protein 88; PGRP, peptidoglycan recognition protein; TAK-1, transforming growth factor-P-activated 
kinase-1. Green and red arrows indicate activation and inhibition processes, respectively.
dorso-ventral axis differentiation in the fly embryo (Anderson and Nusslein-Volhard, 
1984). The observation that the intracellular (C-terminal) domain of Toll was closely 
related to that of the vertebrate IL-1 receptor (IL-1R), which is involved in the 
signalling cascade leading to NF-kB activation and the release of immune defence 
proteins during infection (Gay and Keith, 1991), was critical. Indeed, it suggested that 
Toll may be involved in signalling processes related not only to insect development, but 
also to immune defence mechanisms. These findings therefore prompted Lemaitre and 
co-workers to investigate the role of Toll in insect immunity.
Multiple self defence mechanisms contribute to the insect innate immunity, 
including entrapment of pathogens by deposition of melanine, engulfment by blood 
cells, and killing by ROS and antimicrobial peptides (Tanji and Ip, 2005). The 
expression of these peptides is induced by the presence of pathogens, and Lemaitre and 
co-workers showed that two different pathways control their production: the Immune 
deficiency (Imd) and Toll pathways (Lemaitre et al., 1996 and Fig. 1.2).
The Imd pathway governs the expression of antimicrobial peptide genes in 
response to Gram-negative bacterial infections. Imd is not a PRR, but an adaptor protein 
homologous to the mammalian tumour necrosis factor (TNF) receptor interacting 
protein. There are two identified PRRs activating the Imd pathway: the peptidoglycan 
recognition proteins (PRGP)-LC and -LE, which co-operate to recognise and respond to 
various PGNs and possibly LPS from Gram-negative bacteria (Tanji and Ip, 2005). Imd 
triggering recruits transforming growth factor-(3-activated kinase-1 (TAK-1), the most 
upstream kinase of the cascade identified so far. TAK-1 activates the Drosophila IkB 
kinase (IKK) complex, which in turn directs the site-specific proteolytic cleavage and 
activation of the inducible transactivactor Relish. This releases the REL-68 subunit of
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Relish, which translocates to the nucleus and binds to icB-like enhancer elements in the 
promoter of antimicrobial genes (Fig. 1.2). This mechanism is considered homologous 
to the processing of NF-kB by the IKK complex in mammals (Tanji and Ip, 2005).
The homologue of the mammalian Fas-associated protein with dead domain (FADD) 
and the Drosophila caspase homologue Dredd, are also involved in the Imd-mediated 
antimicrobial response in Drosophila. They act downstream of Imd, but upstream of 
Relish, and not through TAK-1 and IKK, thus constituting a separate Imd pathway. 
Activation of the FADD-Dredd pathway is controlled by at least two regulators: Sickie 
-  which induces Dredd-mediated activation of Relish -  , and defence repressor-1 (Dnr- 
1) -  which negatively regulates this process. A third pathway of Imd-mediated 
signalling involves the Hemipterous (Hep)-c-Jun N-terminal kinase (JKN) cascade, 
which acts downstream of TAK-1 (Silverman et al., 2003). Although this pathway is not 
required for the production of antimicrobial peptides, it regulates other immune genes, 
such as Relish, and activates immediate early genes after septic injury before being shut 
off by a Relish-dependent mechanism (Tanji and Ip, 2005).
Upon infection by Gram-positive bacteria or fungi, the Toll pathway is activated, 
leading to antimicrobial peptide synthesis (Fig. 1.2). Gram-positive bacteria-derived 
peptidoglycan is recognised by multiple host proteins, PRGP-SA, -SD, and Gram- 
negative binding protein-1 (GNBP-1). Like for the Imd pathway, it is believed that these 
molecules co-operate to recognise a wide range of microorganisms. In the case of a 
fungal infection, pathogen recognition involves a serine protease, Persephone, and a 
protease inhibitor, Necrotic. Notably, the upstream regulatory cascades in dorso-ventral 
differentiation, and the response to Gram-positive bacteria and the fungi all lead to the 
processing of the Toll ligand Spatzle. The Spatzle protein is secreted as a precursor,
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pro-Spatzle, which is cleaved as a result of a serine-protease activation cascade induced 
following ligand recognition by PRGP-SA, -SD and GNBP-1 (Weber et al., 2003). The 
truncated form of Spatzle has been shown to bind to Toll and activate the Toll pathway, 
indicating that Spatzle as acts a unique Toll ligand in Drosophila immunity (Tanji and 
Ip, 2005).
Toll triggering involves multimerisation of the receptor, and in vitro studies have 
demonstrated that Spatzle binds to Toll with a stoichiometry of one Spatzle dimer to 
two Toll monomers (Weber et al., 2003), suggesting that Spatzle may induce Toll 
dimerisation for signalling. Activated Toll associates with the myeloid differentiation 
primary response protein 88 (MyD88), a cytoplasmic adaptor protein with a 
Toll/interleukin-1 receptor (TIR) domain that interacts with the TIR domain of Toll. 
Subsequently, Tube, another adaptor protein, and Pelle, a serine-threonine kinase, are 
recruited to form the signalling complex. Activation of Pelle leads to the processing of 
the cytoplasmic Dorsal-Cactus and Dorsal-related immunity factor (Dif)-Cactus 
complexes. Dif and Dorsal are NF-kB homologues and are retained in the cytoplasm by 
the IxB-related inhibitor Cactus. After the signal-induced degradation of Cactus, Dif 
and Dorsal translocate to the nucleus and activate the transcription of antimicrobial 
genes, leading to the production of anti-Gram-positive bacterial and anti-fungal peptides 
(Tanji and Ip, 2005).
1.3.3.B The mammalian Toll-like receptors
A year after Drosophila Toll (dToll) was demonstrated to play an 
important role in insect innate immunity, the first mammalian Toll was identified in 
humans, and called human Toll (hToll) (Medzhitov et al., 1997). Like dToll, hToll is a
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Figure 1.3. Schematic structure o f  Toll and Toll-like receptors
Comparative diagram o f Toll and Toll-like receptor structure showing their extracellular domain (ectodomain), 
consisting o f leucine-rich repeat (LRR) domains, a short transmembrane domain, and the intracellular domain 
containing the Toll/Interleukin 1 receptor (TIR) critical for signalling. LRR, leucine-rich repeat.
type I transmembrane protein, with an extracellular domain consisting of a series of 
leucine-rich repeat (LRR) domains, and a cytoplasmic domain homologous to that of 
IL-1R, hence its name Toll/interleukin-1 receptor (TIR) domain (Fig. 1.3). No ligands 
for hToll were yet known, but using a constitutively active mutant of hToll, Medzhitov 
and co-workers showed that activation of hToll leads to NF-kB activation and NF-kB- 
controlled gene expression of the pro-inflammatory cytokines IL-1, IL-6 and IL-8. 
Within a year, five human Toll-like receptors (TLRs) were identified by genomic 
sequence comparison, and named TLR1 to TLR5, hToll corresponding to TLR4 (Rock 
et al., 1998), human TLR6 to TLR 10 were characterised later (Takeda et al., 2003).
1.3.3.B.1 TLR tissue distribution
Consistent with their function in early pathogen 
recognition, TLRs are widely expressed in immune cells and tissues in constant contact 
with microorganisms. Notably, TLR1, 2, 4, 5 and 6 are mainly expressed at the cell 
surface, whereas TLR3, 7, 8 and 9 are mainly present intracellularly (Watts, 2008).
Within peripheral blood leukocytes, professional phagocytes express the greatest 
variety of TLRs. Neutrophils, monocytes and macrophages were indeed found to 
express mRNA for all TLRs but TLR3 (Muzio et al., 2000; Sandor and Buc, 2005). 
TLR3 mRNA is mainly expressed by DCs (Muzio et al., 2000; Homung et al., 2002). 
Interestingly, immature DCs do not express TLR3, they acquire it during their 
maturation following stimulation with various microbial components, while the 
expression of TLR1, 2, 4 and 5 starts decreasing (Muzio et al., 2000; Homung et al., 
2002; Sandor and Buc, 2005). Myeloid DCs have been shown to express TLR1-6, 8 and 
10, whereas plasmacytoid DCs were reported to express high amounts of TLR7 and
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TLR9, and lower levels of TLR1 and TLR 10 (Iwasaki and Medzhitov, 2004). 
Eosinophils express TLR1, 2, 4, 6, 7, 9 and 10 mRNAs constitutively, whereas 
basophils express TLR2 and TLR4, and mast cells TLR1, 2 and 6 mRNAs.
Lymphocytes have also been shown to express TLRs. NK cells -  major players in the 
antiviral response -  express TLR3 together with TLR2, 5 and 9. B-lymphocytes show 
high expression levels of TLR1, 6, 9 and 10, and lower levels of TLR2, 4 and 7. 
Differential TLR expression has been detected on T cell subsets. TLR3, 5, 6, 7 and 9 
mRNAs have been detected in CD4+ T cells, and TLR2 and TLR4 proteins can be 
detected at the surface of activated and memory T cells, however, naive CD4+ do not 
show significant levels of expression. There is also evidence that regulatory T cell 
(Treg) activity can be directly modulated by TLRs. TLR2 activation on Tregs has been 
shown to induce proliferation of otherwise anergic Tregs and transiently reverts their 
suppressive activity (Sutmuller et al., 2006). However, opposite effects were observed 
by Zanin-Zhorov and co-workers, who reported that TLR2 triggering enhanced Tregs’ 
suppressive activity (Zanin-Zhorov et al., 2006). Similarly, depending on the dose of 
agonist used, TLR5 was shown to supress (low dose) or enhance (high dose) Tregs’ 
regulatory activity (Crellin et al., 2005). TLR8 triggering was also shown to revert the 
suppressive function of Tregs in vivo (Peng et al., 2005).
In addition to leukocytes, TLRs are expressed in epithelial tissues including the 
skin, respiratory, intestinal and genitourinary tracts. These are potential routes of entry 
of pathogens into the host organism.
Keratinocytes express TLR 1-5 constitutively, and mRNAs for TLR2 and TLR4 were 
detected in nasal mucosa, adenoids and salivary glands (Sandor and Buc, 2005; 
Kuroishi et al., 2007). Immunohistochemical staining of human airways revealed
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expression of TLR2 throughout the epithelium, and TLR4 has been shown to be 
expressed in pulmonary epithelial cells as well as corneal epithelium.
Intestinal epithelial cells are in constant contact with bacteria on their apical surface, 
and yet, only pathogens invading the basolateral compartment of the epithelium elicit an 
inflammatory response. Consistent with these observations, these cells express very low 
levels of TLR2 and TLR4, and TLR5 is only expressed on the basolateral surface.
With regards to the genitourinary tract, TLR1, 2, 3, 5 and 6 mRNAs were found in the 
lower female genital tract. Endothelial cells may also have a role in detecting pathogens, 
as they have been shown to express TLR2, 4 and 5 (Sandor and Buc, 2005). TLR2 on 
endothelial cells is thought to promote the development of atherosclerosis, as TLR2 
deficiency results in decreased lesion burden. Notably, atherosclerosis-associated 
lesions do not develop uniformly throughout the arterial tree, but at sites of disturbed 
flow -  i.e. vessel bifurcations and the lesser curvature of the aortic arch. It has been 
shown that endothelial TLR2 expression is only found in these regions of disturbed flow 
and that this local TLR2 expression increases with the development of atherosclerosis 
(Dunzendorfer et al., 2004). By recreating the flow conditions observed in the aortic 
arch in vitro, the authors found that laminar flow, not disturbed/low flow, induced 
phosporylation of the transcription factor signal protein-1 (Sp-1) and thereby blocked 
its binding to the TLR2 promoter, which is required for TLR2 expression 
(Dunzendorfer et al., 2004). It was demonstrated that TLR2 on epithelial cells can be 
activated by endogenous ligands, such as high-mobility group B1 (HMGB-1), 
hyaluronic acid fragments and serum amyloid A, but not by exogenous TLR2 agonist, 
which specifically trigger TLR2-mediated activation of bone-marrow-derived cells 
(Mullick et al., 2005). It is possible that TLR2-mediated activation of endothelial cells
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Figure 1.4. Amino acid sequence of TLR2
The first twenty amino acids (italics) correspond to the putative leader peptide o f TLR2. The twenty LRR 
domains are underlined. The four N-glycosylation sites are indicated by the symbol —CHO- and the acceptor N 
in red. The putative transmembrane domain is shown in green, and the TIR cytoplasmic domain in blue.
leads to the recruitment of bone-marrow-derived cells -  such as neutrophils, monocytes 
and macrophages -  which could in turn be activated in response to potential exogenous 
TLR2 agonists. Thus, it is thought that TLR2 promotes atherosclerosis by exacerbating 
the local inflammation process in response to endogenous ligands and/or exogenous 
microbial ligands.
1.3.3.B.2 TLR structure and ligand specificity
The extracellular domain (ECD) of TLRs is responsible 
for ligand recognition. It is composed of 19 to 25 leucine-rich repeat (LRR) domains 
which are 24 to 29 amino acids long and contain a consensus motif: 
LXXLXXLXLXXN (X, any amino acid) or a LRR-like motif -  characterised by a 
minimal requirement of two matches within an LRR core motif (Kirschning and 
Schumann, 2002). As an example, the human TLR2 ECD contains 20 LRR/LRR-like 
domains (Fig. 1.4). Each LRR consists of a (3-strand and a a-helix connected by loops.
Molecular modelling predicted a horseshoe-like structure for the LRR domain of several 
TLRs (LeBouder et al., 2003; Akira and Takeda, 2004). This predicted structure has 
lately been confirmed by the description of the crystal structure of TLR3 (Choe et al., 
2005), TLR4 (Kim et al., 2007), and TLR2/TLR1 complexes (Jin et al., 2007). 
Although it has long been thought that the TLR ligand would interact with the concave 
part of the horseshoe, resolution of the crystal srtucture of the TLR2/ligand complex 
showed that the lipopeptidic ligand was bound to the convex surface of TLR2 (Jin et al.,
2007). Similarly, TLR3 crystal structure revealed a glycosylation-free, positively 
charged, domain on the convex surface of TLR3 which was predicted to be the binding
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Figure 1.5. Schematic representation o f bacterial cell walls
The lipid bilayer cell membrane o f Gram-positive bacteria is covered by a poreous peptidoglycan layer, 
containing lipoproteins and lipoteichoic acids. In Gram-negative bacteria, the peptidoglycan layer is thiner, but 
an additional outer membrane containing lipopolysaccharides (LPS) and porins is present. Mycobacteria produce 
a thick mycolate-rich outer covering that ensures a very efficient barrier function. LAM, lipoarabinomannan.
site of RNA to TLR3 (Choe et al., 2005). The question of how general this model is can 
only be answered by the crystallographic analysis of other TLRs.
Through their LRR domains, TLRs specifically recognise a wide range of microbial and 
host components.
1) Bacterial ligands
Cell wall components
Bacteria can be classified into two major groups, Gram-positive and Gram- 
negative depending on the composition and, thus, Gram staining characteristics of their 
cell wall. Some of the cell wall components are unique to one group of bacteria and 
recognised specifically by individual TLRs. The Gram-positive cell wall is 
characterised by the presence of a very thick peptidoglycan (PGN) layer, also 
containing lipoproteins and lipoteichoic acids. In contrast, the peptidoglycan layer of the 
Gram-negative cell wall is very thin, but Gram-negative bacteria are surrounded by an 
additional outer membrane composed mainly of phospholipids and lipopolysaccharides 
(LPS). Mycobacterial species share a characteristic mycolate-rich, thick and 
hydrophobic cell wall (Fig. 1.5).
LPS, also known as endotoxin, is the major component of the outer wall of 
Gram-negative bacteria. It is made up of a lipid A portion, a core oligosaccharide and an 
O-antigen (Brade and Galanos, 1983). Studies using TLR4 mutated (C3H/HeJ) or 
deficient mice have shown that TLR4 is crucial for LPS responsiveness (Poltorak et al., 
1998; Hoshino et al., 1999). The use of highly purified natural or synthetic lipid A 
helped to conclude that lipid A is indeed the part of LPS responsible for TLR4 
activation (Ogawa et al., 2002). Different strains of bacteria produce structurally
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different LPS, varying in their phosphate patterns, number of acylations and fatty acid 
composition. These variations account for the varied biological activities of lipid A 
from different origins (Akira et al., 2006). Notably, some bacteria can escape the 
immune system by modulating the structure of their lipid A upon invasion (Hajjar et al., 
2002). It is important to note that, for an efficient recognition by TLR4, LPS has to be 
in monomeric form. The acute phase response serum protein, LPS binding protein 
(LBP), is responsible for converting oligomeric micelles of LPS to LPS monomers, thus 
facilitating its transfer to the TLR4 co-receptor, CD 14, and subsequent recognition by 
the TLR4 signalling complex (Pugin et al., 1993; Hailman et al., 1994). The possibility 
of the existence of another LPS transfer molecule was suggested as LBP-deficient mice 
showed an almost normal inflammatory response after LPS injection (Wurfel et al., 
1997). This possibility was confirmed by the observation that high mobility group-1 
protein (HMGB-1) -  a nuclear protein involved in nucleosome stabilisation and gene 
transcription -  works in concert with LPS to increase the production of TNF-a by
monocytes (Youn et al., 2008). Youn and co-workers also demonstrated that HMGB-1 
binds to and catalytically disaggregates LPS, thus, facilitating its transfer to CD 14 
(Youn et al., 2008).
Interestingly, the non-enteric bacteria Leptospira interrogans, Helicobacter pylori and 
Porphyromonas gingivalis produce atypic LPS, which have been shown to induce 
inflammation through TLR2 and not TLR4 (Takeda and Akira, 2005). However, the 
difficulty of removing TLR2 contaminants from LPS preparations makes these results 
controversial.
Components of Gram-positive bacteria cell wall can also trigger TLRs. 
Lipoteichoic acids (LTA) is a negatively-charged glycolipid believed to be the
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counterpart of LPS of Gram-negative bacteria. The biological activity of LTA has long 
been controversial, due to the high levels of endotoxin present in the commercial LTA 
preparations that have been purified from Staphylococcus aureus or Enterococcus hirae. 
However, the use of a synthetic analogue of LTA from S. aureus showed that LTA on 
its own is biologically active and induces cell activation via TLR2 (Morath et al., 2002), 
in collaboration with TLR6 (Alexopoulou et al., 2002).
Peptidoglycan (PGN) is composed of long linear sugar chains of alternating N-acetyl 
glucosamine and N-acetyl muramic acid. Although present in Gram-negative bacteria, 
PGN is most abundant in the cell wall of Gram-positive bacteria and has been shown to 
induce cell activation via TLR2, in association with TLR1 (Takeuchi et al., 2001; Iwaki 
et al., 2002). Like in the case of LTA, this observation remains controversial (Uematsu 
and Akira, 2008), due to the possible presence of contaminants in the PGN preparations 
purified from bacteria. PGN from S. aureus has been proven to bind directly to the 
extracellular domain of TLR2, both using a plate-based assay and by sedimentation 
experiments (Iwaki et al., 2002).
Phenol soluble modulin (PSM), an inflammatory polypeptide complex secreted by 
Staphylococcus epidermidis has also been shown to trigger cell activation via TLR2 
(Mehlin et al., 1999; Hajjar et al., 2001; Liles et al., 2001). The S. epidermidis PSM is 
constituted of three strongly hydrophobic active polypeptides: PSM-a, PSM-|3 and 
PSM-y, each of them with a molecular mass of < 5 kDa.
Lipoproteins and lipopeptides, present on both Gram-negative and Gram- 
positive bacteria, are potent immunostimulants. TLR2 responds to lipopeptides from a 
wide range of pathogens (Carpenter and O'Neill, 2007). Lipid modification seems to be 
critical for TLR2 activation, since the unlipidated outer-surface protein A (OspA)
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lipoprotein purified from Borrelia burgdorfer cannot activate TLR2 cell transfectants 
(Hirschfeld et al., 1999). To confirm the importance of the lipid modification, a 
trypalmitoylated (Pams), lipopeptide (Pani3)-Cys-Ser-Lys4  (Pam3 CSK4or Pan^Cys) was 
synthesised and demonstrated to be a potent TLR2 agonist. Pan^Cys is now commonly 
used as a prototypic TLR2 ligand, and has been shown to bind directly to the TLR2 
ECD (Vasselon et al., 2004). Importantly, discrimination of subtle changes in the lipid 
portion of lipoproteins is ensured by the collaboration of TLR2 with TLR1 or TLR6. 
Indeed, macrophages from TLR6-deficient animals proved to be insensitive to the 
presence of the diacylated mycobacterial macrophage activating lipopeptide-2kDa 
(MALP-2), whereas they produced TNF-a at similar levels to wild-type cells in
response to triacylated lipopeptides, such as Pan^Cys (Takeuchi et al., 2001), indicating 
that TLR6 is involved in diacylated lipopeptide recognition. A year later, Takeuchi and 
co-workers confirmed the involvement of TLR1 in triacylated lipopeptides recognition 
by TLR2 (Takeuchi et al., 2002).
Porins, the major outer membrane proteins of the pathogenic neisserial species, have 
been shown to trigger B-lymphocyte activation, as indicated by the upregulation of 
MHC class II molecules (Massari et al., 2002). However, B-lymphocytes from TLR2- 
deficient mice were found unresponsive to porins from Neisseria meningitidis, 
indicating that B-cell activation by porins is TLR2-mediated (Massari et al., 2002).
Flagellin
Flagellin, the major constituent of bacteria flagella, is a potent activator of innate 
immune responses. Analysis of the crystal structure of the Salmonella's flagellin shows 
different domains: N- and C-terminal a  helix chains (DO), the central a  helix chain (Dl)
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and a hypervariable central region with |3 sheets (Akira et al., 2006). TLR5 is 
responsible for the detection of flagellin, through recognition of the D1 constant domain 
-  highly conserved among different species (Hayashi et al., 2001). Some bacteria, such 
as Helicobacter pylori and Campylobacter jejuni produce flagellin lacking pro- 
inflammatory properties -  because of mutations within a specific region of the D1 
domain (amino acids 89 to 96) -  and, therefore, escape the flagellin-specific host 
immune response (Andersen-Nissen et al., 2005). Notably, these 8 amino acids (89-96) 
of the D1 domain were also found critical to flagellar filament formation and bacterial 
mobility. To preserve mobility, H. pylori and C. jejuni possess compensatory amino 
acid changes in another region of the flagellin molecule (Andersen-Nissen et al., 2005).
Bacterial DNA
Bacterial genomic DNA is also a stimulator of the host immune response, and is 
recognised by TLR9 (Hemmi et al., 2000; Carpenter and O'Neill, 2007). TLR9 
recognises unmethylated CpG dinucleotides, which are very abundant in bacterial 
genomes. By contrast, mammalian CpG motifs are highly methylated and are not 
recognised by TLR9 (Akira et al., 2006). This discrimination ensures that the host DNA 
does not induce TLR9 activation.
Since TLR9 resides in the endosome, bacterial DNA must be delivered to this 
intracellular compartment where the acidic and reducing conditions lead to the 
degradation of double-stranded sDNA into multiple single-stranded CpG-motif- 
containing regions that will interact with TLR9 (Akira et al., 2006). This results in the 
multiplication of the inflammatory signal from a single molecule of bacterial DNA. The 
use of compounds blocking endosomal acidification, such as chloroquine or
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bafilomycin, has shown that an acidic pH is required for DNA digestion and optimal 
recognition by TLR9. However, this model has recently been challenged by the 
observation that a chimeric TLR9 localised at the cell surface is still capable of 
recognising non methylated CpG-DNA, suggesting that DNA degradation in the 
endosome may not be critical for TLR9 triggering (Barton et al., 2006).
Miscellaneous ligands
The pathogenic Yersinia species (Gram-negative bacteria) is recognised by the 
immune system via TLR4, thus triggering a pro-inflammatory response. However, 
Yersinia releases a virulence factor,V antigen (LcrV), which stimulates the production 
of the anti-inflammatory cytokine IL-10 via TLR2 and suppresses production of TNF-a 
and IFN-y, thus exploiting TLR2 activation as a way to evade the host’s immune 
system. As a consequence mechanism, TLR2~h mice are actually less susceptible to oral 
infection with Yersinia enterocolitica (Sing et al., 2002).
It is worth noting that an unknown component of uropathogenic E. coli activates 
murine TLR11 (Zhang et al., 2004a). It is suggested that susceptibility to uropathogenic 
E. coli in humans may result from the fact that human TLR11 is not functional.
Malaria parasites within red blood cells digest host hemoglobin into a 
hydrophobic heme polymer, known as hemozoin, which was found to induce pro- 
inflammatory responses in vivo in a TLR9-dependent manner (Coban et al., 2005). A 
more recent study, however, reported that highly purified Malaria hemozoin is 
immunologically inert, but dramatically enhances innate responses by presenting 
malaria DNA to TLR9 (Parroche et al., 2007).
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2) Mycobacterial ligands
The mycobacterial cell wall is composed of a thick mixture of lipids and 
polysaccharides (Fig. 1.5) and a high content of mycolic acid. Lipomannan (LM), and 
its arabinosylated form, lipoarabinomannan (LAM), are potent immunomodulatory 
lipoglycans. The arabinan domain is capped by either a mannosyl (ManLAM) or a 
phosphoinositol residue (PILAM). LM -  found on both pathogenic and non-pathogenic 
species -  and PILAM -  present on fast-growing non-pathogenic species -  are potent 
TLR2 activators, whereas ManLAM, characteristic of slow-growing virulent 
microorganisms, such as Mycobacterium tuberculosis, is a strong anti-inflammatory 
molecule. It is thought that pathogenic and non-pathogenic mycobacteria are 
discriminated according to the ManLAM/LM ratio in their cell wall (Akira et al., 2006). 
The mycobacterial diacylated lipopeptide, MALP-2, is also recognised by TLR2 -  in 
collaboration with TLR6. Indeed, as described previously in this section, the 
TLR2/TLR6 complex detects diacylated lipopeptides, often associated with 
mycobacteria. In addition, the TLR2/TLR1 heterodimer recognises a 19-kDa cell-wall 
associated and secreted lipoprotein initially purified from M. tuberculosis, and also 
present in M. leprae, that induces cell activation. It is reported that a mutation in the 
intracellular domain of TLR2 (Arg677Trp) is associated with lepromatous leprosy in the 
Korean population, confirming the involvement of TLR2 in M. leprae recognition 
(Takeuchi et al., 2002; Malhotra et al., 2005).
Unmethylated CpG mycobacterial DNA is recognised by TLR9 (Akira et al., 2006).
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3) Fungal ligands
The observation that Toll-deficient Drosophila are highly susceptible to fungal 
infection suggested that mammalian TLRs may also be involved in fungal recognition. 
This was confirmed by the demonstration that TLR4 recognises mannans from 
Saccharomyces cerevisiae and Candica albicans (Shoham et al., 2001), as well as 
glucoronoxylomannan from Cryptococcus neoformans (Netea et al., 2004). It was also 
shown that zymosan, a S. cerevisiae cell-wall component, is phagocytosed by 
macrophages via the mannose receptor and then activates TLR2 present on phagosomes 
(Underhill et al., 1999). In addition, direct binding of zymosan to the 125I-labelled TLR2 
ectodomain was demonstrated (Sato et al., 2003). TLR2 also collaborates with another 
PRR, Dectin-1, to optimise the recognition of fungal (3-glucans (Brown et al., 2003 and 
section 1.3.3.B.3, page 43).
T-cell helper 1 (Thl) responses are critical to the protection against fungi, and it has 
been shown that most TLR-mediated signals induce Thl-directed responses. TLR2 
activation -  including that induced by fungal ligands -  appears to favour Th2 responses 
through the induction of IL-10 production (Agrawal et al., 2003). In fact, in vivo studies 
using TLR-deficient mice suggest differential roles of TLR2 and TLR4 in fungal 
infections. While TLR4 7 animals showed an increased susceptibility to C. albicans, 
TLR2 deficiency increased mice resistance. TNF-a and IL-l-P levels were found 
unaffected in TLR27' animals, but the release of IL-10 was strongly impaired, indicating 
that C. albicans induces immunosuppression through the anti-inflammatory cytokine 
IL-10. A similar escape mechanism is also observed with the hyphae form of 
Aspergillus fumigatus, which specifically activates TLR2 and not TLR4, as opposed to 
the conidia form (Netea et al., 2004).
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4) Protozoan parasite ligands
Trypanosoma-derived molecules, such as glycosylphosphatidylinositol-mucin, 
glycoinositolphospholipids and genomic DNA have been reported to activate TLR2, 
TLR4 and TLR9, respectively.
Profillins -  small ubiquitous proteins thought to be involved in parasite mobility
and/or invasion -  appear to activate TLRs. Indeed, a profillin-like molecule from
Toxoplasma gondii was identified as the first ligand for murine TLR11 (Yarovinsky et 
al., 2005). In humans, however, TLR11 is not functional due to the presence of an 
additional stop codon in its gene.
Notably, mice deficient in individual TLRs do not show impaired responses to live 
protozoan parasites, as opposed to those deficient in MyD88 -  a signal adaptor common 
to most TLRs (Adachi et al., 2001). This suggests that several TLRs are involved in the 
response against protozoan parasites.
5) Viral ligands
Viruses contain genetic material, either DNA or RNA, encoding viral structural 
components and enzymes for replication and protein synthesis. TLRs are involved in the 
recognition of various viral PAMPs, including viral DNA, ssRNA, dsRNA and surface 
glycoproteins.
Viral DNA
The genome of DNA viruses, like that of herpes simplex virus (HSV)-l, HSV-2 
and murine cytomegalovirus (MCMV), is rich in CpG-DNA motifs which are 
recognised by TLR9 and lead to the production of type 1 IFNs (Akira et al., 2006).
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The obsevation that mice lacking TLR9 or MyD88 can still control HSV-1 infection 
indicates that an effective viral response can be ensured in a TLR9- and MyD88- 
independent manner (Krug et al., 2004).
Single-stranded RNA
Uridin-rich and uridin/guanosine-rich ssRNA from the host or of viral origin is 
recognised by mouse TLR7 and human TLR7 and TLR8 -  mouse TLR8 is non 
functional -  (Hemmi et al., 2002; Heil et al., 2004). Notably, although human TLR7 and 
human TLR8 are structurally related and both recognise ssRNA, their functions are not 
redundant. Indeed, ssRNA recognition by human TLR7 or human TLR8 seems to 
depend on the number of uridine (U) residues in the ssRNA sequence: TLR7 
recognising U-low sequences and TLR8 U-rich sequences (Sioud, 2006; Gantier et al.,
2008). Furthermore, it has been shown that human TLR7 triggering stimulates DCs to 
produce mainly IFN-a, whereas activation of TLR8 leads to pro-inflammatory 
cytokines production by monocytes (Gorden et al., 2005). However, a more recent study 
suggested that ssRNA sequence-dependent ligand recognition can be modulated by the 
relative expression of human TLR7 and TLR8, and that these two receptors collaborate 
for an effective ssRNA recognition (Gantier et al., 2008).
Human/mouse TLR7 and human TLR8 are also activated by synthetic antiviral 
components, e.g. R848, Imiquimod. In addition, human TLR7 can be activated by 
guanine nucleotide analogs e.g. loxoribine (Hemmi et al., 2002; Gantier et al., 2008). 
TLR7 and TLR8 genes show high homology, and both receptors are expressed within 
the endosome membrane. This location ensures high ligand accessibility, since many 
enveloped viruses traffic into the cytosol through the endosomal compartment. Like in
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the case of TLR9, an acidic environment is of critical importance for TLR7 and TLR8 
activity, as it ensures -  together with degradation enzymes -  the destruction of viral 
particles, the release of ssRNA and subsequent recognition by these receptors (Akira et 
al., 2006).
Importantly, unlike viral RNAs which are protected by a capside, host RNAs are 
degraded by extracellular RNases and rarely reach the endocytic compartment, thus, 
allowing for self/non-self discrimination.
Double-stranded RNA
During viral infection, dsRNA can be generated as a replication intermediate of 
ssRNA viruses, or as a by product of symmetrical transcription in DNA viruses. This 
makes dsRNA a universal viral PAMP. Alexopoulou and co-workers have shown that 
dsRNA and its synthetic analog, polyinosine-deoxicytidylic acid (poly I:C), are 
recognised by TLR3 and induce secretion of IFN-a by DCs (Alexopoulou et al., 2001).
Reported evidence indicates, however, that TLR3 is not required for the initial 
recognition of viral infection that induces the first wave of IFN-a (Lopez et al., 2004).
Consistent with this finding, mice lacking TLR3 do not show increased sensitivity to 
infection by MCMV, VSV, lymphocytic choriomeningitis virus (LCMV) and reoviruses 
(Akira et al., 2006). Furthermore, TLR3 7 animals are more resistant than wild-type to 
West Nile virus infection, suggesting that this virus benefits from its interaction with 
TLR3 (Akira et al., 2006). Thus, the exact role of TLR3 in viral infection remains to be 
clarified.
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Viral glycoproteins
Different components of the viral envelope have been identified as TLR ligands. 
For instance, TLR4-deficient mice showed lower levels of infiltrating mononuclear cells 
and reduced production of IL-12 following infection with the respiratory syncytial virus 
(RSV). Indeed, the fusion protein from RSV was found to activate TLR4 (Kurt-Jones et 
al., 2000). Similarly, TLR2 is activated by viral components such as Measles virus 
hemagglutinin protein, and non-identified components from human CMV and HSV-1 
(Bieback et al., 2002; Akira et al., 2006).
TLR4 is also thought to recognise the envelope protein (Env) of mouse mammary 
tumour virus (MMTV). Notably, Env appears to benefit from this interaction, as it 
results in the overexpression of the MMTV entry receptor, CD71 on DCs (Burzyn et al., 
2004).
Triggering of TLR2 and TLR4 by viral glycoproteins does not lead to the production of 
IFN-a, but to that of pro-inflammatory cytokines which direct the response towards a
general inflammation rather than to a specific antiviral action.
6) Host derived ligands
In addition to the recognition of pathogens, TLRs also detect endogenous 
ligands, thus signalling other types of 'danger' conditions.
One of the most well established endogenous TLR ligands are host nucleic acids, 
which can be recognised by TLR9 (DNA), TLR3 (dsRNA), TLR7 and TLR8 (ssRNA). 
As described previously, host RNAs are normally not accessible to TLRs, but under 
certain condition, like tissue/cell necrosis or injury, they may become available for 
recognition by these receptors. Recognition of host nucleic acids leads to pro-
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inflammatory cytokine production, recruitment of phagocytes and a rapid clearance of 
the necrotic cells (Tsan and Gao, 2004).
Patients suffering from systemic lupus erythematosus (SLE) and other systemic 
autoimmune diseases produce a wide range of autoantibodies. Very frequently these 
autoantibodies bind to chromatin or other subcellular nucleic acid-protein particles. B 
cells expressing an antigen receptor specific for self-immunoglobulin-y (IgG) make a 
type of autoantibody known as rheumatoid factor (RF). IgG2a-chromatin immune 
complexes have been shown to mediate RF+ B cell activation, which could be blocked 
by inhibitors of TLR9 sigalling (Leadbetter et al., 2002). This data suggests a potent 
synergistic functional interaction between the B-cell receptor and TLR9 mediated by 
chromatin-containing immune complexes. It is postulated that B-cell receptor 
engagement by an autoantibody-chromatin immune complex triggers the endocytosis of 
the immune complex-associated antigen, and that this results in the highly efficient 
delivery of chromatin fragments to endosome-associated TLR9 (Leadbetter et al., 
2002).
The use of animals deficient in or mutated for individual TLRs have lead to the 
indentification of other endogenous TLR ligands, which mainly signal through TLR2 
and/or TLR4.
Hyaluronan, one of the major structural components of the extracellular matrix, 
is a high-molecular-weight polymer that undergoes rapid degradation at sites of tissue 
injury. Low-molecular weight products of hyaluronan have been shown to initiate 
inflammatory responses through TLR2 and TLR4. In addition, by using in vivo models 
of lung injury, it was demonstrated that activation of TLR2 and TLR4 by hyaluronan 
fragments promotes wound defence and repair by enhancing transepithelial migration of
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Table 1.3. Human Toll-like receptors and their ligands
TLR Ligand Source,
TLR2 (in association with Lipoprotein/1 ipopeptides Bacteria, mycobacteria
TLR1 or TLR6) Triacyl lipopeptides 
(Pam3CSK4)
Bacteria, mycobacteria
Diacyl lipopeptides Mycoplasma
Diacyl lipopeptides 
(Pam2CSK4 and MALP2SK4)
Synthetic compound
Peptidoglycan Gram-positive bacteria (not 
accessible in gram negative)
Lipoteichoic acid (LTA) Gram-positive bacteria
Lipoarabinomannan (LAM) Mycobacteria
A phenol-soluble modulin Staphylococcus epidermidis
Glycoinositolphospholipids Trypanosoma cruzi
Glycolipids Treponema maltophilum
Porins Neisseria meningitidis
Virulence factor LcrV Yersinia species
Zymosan Fungi
Atypical LPS Leptospira interrogans
Atypical LPS Porphyromonas gingivalis
Hsp70 Host
Hyaluronan Host
Hemagglutinin Measles virus
TLR3 dsRNA Viruses
Poly I:C Synthetic compound
TLR4 LPS Gram-negative bacteria
Fusion protein Respiratory syncytial virus
Envelope proteins Mouse mammary tumor virus
Hsp60 Chlamydia pneumoniae
Hsp60 Host
Hsp70 Host
Type III repeat extra domain 
A of fibronectin
Host
Oligosaccharides of 
hyaluronic acid
Host
Polysaccharide fragments of 
heparan sulfate
Host
Fibrinogen Host
TLR5 Flagellin Bacteria
TLR7 ssRNA Viruses
Imidazoquinolines 
(imiquimod, R-848)
Synthetic compounds
Guanos ine analogs Synthetic compounds
TLR8 ssRNA Viruses
R-848 Synthetic compounds
TLR9 Unmethylated CpG DNA Bacteria, virus, yeast, insects
Chromatin-IgG complexes Host
neutrophils and inhibiting epithelial cell apoptosis (Jiang et al., 2005). The involvement 
of TLRs in tissue repair has been supported by the observation that LPS helped tissue 
regeneration following ethidium-bromide induced brain damage (Glezer et al., 2006).
Other extracellular matrix breakdown products, i.e. heparan sulfate, the extra 
domain A of fibronectin, fibrinogen, SP-A and HMGB-1, have been shown to activate 
TLR4. HMGB-1 is also recognised by TLR2. These endogenous ligands are exposed 
during cellular injury and matrix remodelling, thus constituting 'danger' signals for the 
innate immune system.
The cellular chaperones heat shock proteins 60 and 70 (Hsp 60 and 70) are 
released by mammalian cells or bacteria following cellular stress. The use of both cell 
extracts and recombinant Hsp has shown that they are ligand for both TLR2 and TLR4, 
and thus may signal cellular stress or damage to the immune system (Tsan and Gao, 
2004).
Recognition of endogenous ligands is, however, not always beneficial to the 
host, as it may promote autoimmunity. Indeed, it is thought that the induction of pro- 
inflammatory cytokines by Hsp60 and Hsp70 may contribute to the development of a 
number of autoimmune diseases, such as type I diabetes, Crohn’s disease and 
atherosclerosis. Furthermore, the reported recognition of SP-A and fibrinogen by TLR4 
may be deleterious to the host, as these TLR ligands are constitutively present at 
significant concentrations in the circulation (fibrinogen) and the lung (SP-A) (Zhang 
and Schluesener, 2006).
Table 1.3 presents a summary of the ligands described here for each human
TLR.
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1.3.3.B.3 TLR triggering, signalling and their 
regulation
1) TLR triggering 
TLR oligomerisation
The basic mechanism of triggering used by TLRs and Toll appears to involve 
ligand induced (hetero/homo) dimerisation or oligomerisation. The first evidence of this 
mechanism comes from the observation that Spaztle crosslinks two Drosophila Toll to 
induce signalling. Chimaeric TLR4 molecules in which the ECD is replaced by that of 
Toll can also be activated by Spaztle, suggesting that the TIR domains of two TLR4 
molecules can establish downstream signalling if the receptors are arranged in a 
symmetrical ligand-crosslinked complex manner (Gay et al., 2006). Furthermore, TLRs 
have often been reported to form homo-, or heterodimers. Cross-linking experiments 
have led to the conclusion that TLR4 dimerisises in the presence of the ligand LPS 
(Kim et al., 2007), whereas co-immunoprecipitation experiments have shown that TLR2 
associates with TLR6 (Ozinsky et al., 2000) and TLR1 (Nakata et al., 2006), even in the 
absence of ligand. Fluorescence resonance energy transfer (FRET) experiments seem to 
indicate that the TLR2/TLR1 or TLR2/TLR6 dimers form bigger oligomers in response 
to their ligands (Triantafilou et al., 2006).
Although receptor crosslinking is crucial, it was shown that the process of 
activation induces conformational changes in the receptor ectodomains that are required 
for signal triggering (Gay and Gangloff, 2007). Truncations in the Toll N-terminus 
sequence allow the formation of a stable dimeric complex and induces constitutive 
cellular activation, suggesting that the N-terminal region of the Toll ectodomain exerts a 
steric constraint and prevents self association of the receptor. Therefore, binding of
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Figure 1.6. Model o f  the ligand-induced TLR conformational rearrangement
Binding o f  the ligand to the N-terminus domain o f  a TLR is thought to induce a conformational change in the C- 
terminus part o f  the ectodomain that allows for a successful contact between the two TLRs T1R domains. The 
BB loop o f  the signalling T1R domain is likely to be involved in receptor—receptor contacts. Formation o f  the 
signalling complex is proposed to generate a new interface for the recruitment o f  signal adaptors. ECD, 
ectodomain; CX/N T, C/N-terminus; TIR domain, Toll/interleukin-1 receptor domain; TLR, T oll-like receptor.
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Spatzle must alter the receptor’s conformation in order to relieve this constraint (Gay et 
al., 2006). Notably, point mutations in the C-terminal capping structure of the 
juxtamembrane region of Toll (Fig. 1.3) result in constitutive activation, showing that 
the integrity of this region is essential to control autodimerisation and signalling. 
Furthermore, while chimaeric Toll-TLR4 receptors containing the Toll juxtamembrane 
region are only activated in response to Spatzle, Toll-TLR4 receptors containing the 
TLR4 juxtamembrane region, although still activated by Spatzle, show a substantial 
constitutive activation (Weber et al., 2005). This suggests that there is an important role 
for the Toll juxtamembrane region in suppressing signalling activity and that there are 
significant mechanistic differences in the activation of the Drosophila Toll and TLR4 
pathways.
Indication that a triggering mechanism similar to that used by Toll may be involved in 
TLR triggering comes from the fact that many TLR-specific antibodies can crosslink 
two TLR molecules together without inducing signalling (Shimazu et al., 1999; 
Matsumoto et al., 2002). This indicated that dimerisation is not sufficient to ensure 
signal transduction, and that correct orientation of the receptors with respect to each 
other may be required.
By considering these observations, Gay and co-workers (Gay et al., 2006), 
propose a model of sequential activation of TLRs in which ligand binding at the N- 
terminus induces a conformational change at the C-terminal region of the TLR ECD, 
and this change allows for a stable receptor-receptor interaction. This in turn promotes 
the rearrangement of the transmembrane helices of the receptor dimer so that 
downstream signalling is initiated (Fig. 1.6).
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TLR co-receptors
Fully efficient microbial recognition by some TLRs requires the activity of 
accessory molecules, also termed co-receptors. Sensitive cell response to most ligands 
activating via TLR2, 3 and 4 requires the activity of the co-receptor CD 14, and TLR4 
additionally requires the accessory molecule MD-2 for ligand recognition and 
responses.
■ CD14
CD 14 is a 55-kDa glycosyl-phosphatydil-inositol (GPI)-anchored cell- 
surface glycoprotein found on the surface of myeloid cells and, to a lesser extent, on B- 
lymphocytes and non-immune cells such as mammary cells, placental trophoblasts and 
gingival fibroblasts (Antal-Szalmas, 2000). The mature CD 14 protein is 356 amino acid 
long, possesses seven LRR domains, nine cysteine residues and four potential N- 
glycosylation sites (Goyert et al., 1988).
In addition to the membrane bound form (mCD14), a soluble form of CD 14 (sCD14) 
that lacks the GPI anchor has been detected in plasma -  at pg/ml concentrations -  and in 
human milk -  at levels up to 100 times higher than in plasma (Durieux et al., 1994; 
Labeta et al., 2000). CD 14 (mCD14 or sCD14) has been shown to increase sensitivity to 
stimulation via TLR2, 3 and 4 substantially (Frey et al., 1992; Schroder et al., 2003; Lee 
et al., 2006; Nakata et al., 2006) and mCD14 and sCD14 were found to bind to Gram- 
negative and Gram-positive cell-wall components (Akashi et al., 2003; Nakata et al., 
2006). For example, LPS-induced monocyte activation can be blocked by some anti- 
CD 14 antibodies in such a dramatic way that CD 14 was first believed to be the main 
receptor for LPS, before the discovery of TLR4 (Wright et al., 1990). Later, the use of
39
CD14 a animals helped to confirm the importance of CD 14 for ligand recognition via 
TLR2, TLR3 and TLR4 in vivo. Indeed, animals lacking CD14 were found to be less 
sensitive to LPS (Haziot et al., 1996; Brass et al., 2007), or to live Gram-negative 
bacteria (Yang et al., 2002). Similarly, susceptibility to live Listeria monocytogenes, a 
pathogen recognised by TLR2, was found greatly increased in CD 14-deficient mice 
(Janot et al., 2008).
dsRNA-induced IL-12p40 production and IFN-p promoter activity were also found 
dramatically reduced in CD14 ; animals (Lee et al., 2006), indicating that CD14 is also 
required for efficient TLR3 triggering.
The precise mechanism by which CD 14 enhances TLR activation is still unclear, 
although several mechanisms have been proposed. It was first thought that CD 14 may 
induce conformational changes in the TLR molecule leading to signal triggering 
(Schromm et al., 2001). A later study proposed a model in which CD14 helps loading 
LPS onto the TLR4/MD2 complex (Akashi et al., 2003). This is consistent with the 
model proposed by Nakata and co-workers to explain the enhancing effect of CD 14 on 
TLR2 triggering (Nakata et al., 2006). Indeed, these authors concluded that CD14 helps 
the TLR2/TLR1 dimer to recognise triacylated lipopetides without binding to the 
complex. However, a direct interaction of sCD14 with TLR2 has been reported by our 
laboratory (LeBouder et al., 2003) and Iwaki and co-workers (Iwaki et al., 2005), and 
similar observations will be described in the present study. Similarly, the co- 
immunoprecipitation of sCD14 and TLR3 has been reported (Lee et al., 2006), thus 
demonstrating a direct interaction between the co-receptor and the signalling receptor.
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In addition to its role in TLR activation, CD 14 was also reported to modulate T 
and B cell responses (Rey Nores et al., 1999; Arias et al., 2000). The mechanism 
underlying such modulatory activity remains to be clarified.
■ MD-2
Even in the presence of CD 14, TLR4 transfected cells have still been found 
unable to respond to LPS (Shimazu et al., 1999). By sequence homology comparison 
with MD-1 - an accessory molecule of radioprotective 105 (RP105) involved in B- 
lymphocyte responses to LPS - a small protein, MD-2, was isolated and found to be 
required for TLR4 function (Shimazu et al., 1999). MD-2 is a secreted protein of about 
18 kDa that contains two N-glycosylation sites and seven cystein residues. The 
interaction of MD-2 with TLR4 was first shown by co-immunoprecipitation (Shimazu 
et al., 1999), and has lately been confirmed by co-purification (Kim et al., 2007). 
According to this later study, the stoichiometry of the TLR4/MD-2 complex is 1:1, but a 
dimer of dimers is formed in the presence of LPS. In addition to binding to TLR4 with 
an apparent Kd of 12 nM, free MD-2 also binds to LPS, although with a weaker affinity 
(Visintin et al., 2005).
A number of in vitro studies have now demonstrated LPS hyporesponsiveness in cells 
expressing TLR4 alone or TLR4 and mutated MD-2. The importance of MD-2 has been 
confirmed in vivo, as mice lacking MD-2 did not respond to LPS, and were resistant to 
endotoxin shock (Miyake, 2003). Futhermore, inhibition of responses to LPS by 
targeting MD-2 has been proposed as a therapeutic strategy against septic shock and 
severe inflammation (Visintin et al., 2005). Like in the case of CD14, the mechanism by 
which MD-2 collaborates with TLR4 for signalling is still unclear. Kim and co-workers
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Figure 1.7. Model o f the TLR4/MD-2 tetramer after binding o f LPS to MD-2
Grey and magenta surfaces represent TLR4 and MD-2, respectively. Elements o f  the second TLR4-MD-2 dimer 
of the complex are marked with an asterix. A, Schematic presentation of the MD-2/TLR4/LPS complex. Binding 
of LPS to MD-2 induces a conformational change in the F126-H155 region o f MD-2 which results in the 
interaction o f MD-2 with a second TLR4 molecule. B, Three dimensional representation o f the model presented 
in A. Nt/Ct , N/C terminus.
proposed that LPS binding to MD-2, in a 1:1 complex with TLR4, induces a structural 
change in the Phel26 -  His 155 edge of MD-2, and that this change promotes the 
interaction of MD-2 with a second TLR4 (Kim et al., 2007 and Fig. 1.7).
Other than LPS, Taxol (a plant-derived anti-mitotic compound), hsp60 and fibronectin 
domain A have also been shown to require MD-2 to induce signalling via TLR4 (Hajjar 
et al., 2002; Miyake, 2003).
TLR heterodimerisation and collaboration with other PRRs 
■ TLR heterodimerisation
In addition to the heterodimerisation of TLR2 with TLR1 and TLR6 for 
ligand discrimination and signalling, there is evidence that other TLRs may also 
collaborate, although the exact conditions for collaboration are still unknown.
The observation that TLR4-negative/ TLR5-positive cells do not produce NO in 
response to flagellin, a TLR5 ligand, suggested a collaboration between TLR4 and 
TLR5 (Mizel et al., 2003). Consistent with this possibility, Mizel and co-workers also 
demonstrated the direct interaction between TLR4 and TLR5 by co- 
immunoprecipitation (Mizel et al., 2003).
A subsequent study showed that stimulation of mouse macrophages with both 
poly I:C, a TLR3 ligand, and CpG DNA, a TLR9 ligand, induced more than additive 
levels of TNFa, IL-6 and IL12p40, thus supporting the concept that co-operation 
between certain TLRs may occur (Whitmore et al., 2004).
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■ Collaboration with other receptors
There is growing evidence that TLRs may collaborate with other PRRs for 
PAMP recognition.
Overexpression of the (3-glucan receptor, Dectin-1, was found to enhance 
zymosan- and live fungi-mediated TNF-a production in macrophages, while TLR2 /_ 
macrophages were found unable to induce TNF-a production in response to zymosan 
(Brown et al., 2003). These findings, together with the fact that TLR2 and Dectin-1 co- 
localise at the cell surface, suggest that TLR2 and Dectin-1 collaborate for an efficient 
recognition of fungal pathogens or their components (Brown et al., 2003). Notably, 
Gantner and co-workers reported the collaboration between TLR2 and Dectin-1 for the 
zymosan-induced production of cytokines by macrophages, but also showed that TLR2 
is not required for phagocytosis of zymosan and zymosan-induced ROS production 
(Gantner et al., 2003). These findings indicated that Dectin-1 can directly trigger 
phagocytosis and ROS production, and that different pathways are involved in pro- 
inflammatory responses to, and killing of fungal pathogens.
In addition to its role in anti-fungal response, Dectin-1 has also been shown to 
collaborate with TLR2 for mycoplasmal recognition (Yadav and Schorey, 2006; Shin et 
al., 2008). There is indication that collaboration of TLR2 and Dectin-1 may require 
physical interaction, as these two PRRs could be co-immunoprecipitated from 
mycobacterial-activated macrophages (Shin et al., 2008).
The observation that macrophages from CD36 7 animals produced less TNF-a 
than their wild-type counterparts in response to MALP-2 and LTA, but not to zymosan 
or the triacylated lipopeptide Pam3Cys, or ligands for TLRs other than TLR2 (Hoebe et 
al., 2005), suggested that CD36 plays a role in cell activation mediated by the
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TLR2/TLR6 complex (MALP-2- or LTA-induced). Notably, the LTA-induced secretion 
of TNF-a by CD36 7 macrophages was higher than that by TLR2 ; macrophages.. 
Furthermore, CD36 ' mice injected with live S. aureus are more susceptible and die 
faster than wild-type animals, but not as fast as TLR2’7’ animals (Hoebe et al., 2005). 
Thus, CD36 appears to act as a facilitator for diacylglyceride recognition by the 
TLR2/TLR6 complex, but is not absolutely required for LT A/M ALP-2 sensing by 
TLR2.
A recent study suggested that vitronectin and integrin-ayp3 are also required for 
the recognition of bacterial lipopeptides (BLP) by TLR2. Vitronectin is a glycoprotein 
present in the extracellular matrix and in blood. It has been known to be involved in 
platelet aggregation, coagulation, and fibrinolysis (Preissner, 1991). It is also known to 
regulate mechanisms of the immune response such as cell migration and complement 
activation, and to opsonise bacteria (Chhatwal et al., 1987). The main receptor for 
vitronectin is integrin-avP3 , which is expressed on many cell types, including 
monocytes. Integrin-avP3 participates in diverse immune processes such as cell 
migration, opsonisation of bacteria and clearance of apoptotic cells by phagocytes 
(Hynes, 2002; Scibelli et al., 2007).
It was found that vitronectin promotes BLP-induced TNF-a production by monocytes, 
and that this activity can be abrogated by blocking integrin-avP3 with a specific Ab 
(Gerold et al., 2008). These in vitro observations were consistent with the fact that 
monocytes from patients with Glanzmann thrombasthenia -  who lack integrin-ayp3 -
were largely insensitive to BLP activation. Mechanistically, Gerold and co-workers 
demonstrated that vitronectin can interact with BLP, and that TLR2 and integrin-ayp3 
form a complex that dissociates after BLP stimulation. The authors propose a model in
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which vitronectin concentrates TLR2 agonists at the signalling complex composed of 
TLR2 and integrin-avP3 . BLP is then transferred to TLR2, and integrin-avp3 dissociates
and is degraded.
2) TLR signalling pathways
Following ligand binding, the formation of TLR oligomers results in the 
recruitment of specific signalling adaptors to the TLRs’ cytoplamic TIR domain 
(O'Neill, 2006). The TIR domain is between 135 and 160 amino acids long, and its 
molecular structure -  resolved for the TIR of TLR1, TLR2 and TLR 10 -  shows a 
central, five-stranded, parallel p-sheet which is surrounded by a total of 5 a-helices on 
both sides (Xu et al., 2000). In terms of sequence, each TIR domain contains three 
conserved regions named Box 1, Box 2 and Box 3. The Box 1 sequence is common to 
all TLRs, Box 2 contains a large and conserved surface with consensus sequences 
((F/Y)-(V/L/I)-(P/G)) present in all TLRs as well as in the adaptor MyD88 -  the BB 
loop -  , and Box 3 contains amino acids that have been identified as important for IL- 
1R signalling. Notably, a proline to histidine natural point mutation of the conserved 
proline of the TLR4 BB loop in C3H/HeJ mice was shown to be responsible for the 
absence of signal transduction via TLR4 in these animals (Poltorak et al., 1998). This 
was the first indication of the importance of the BB loop in TLR signal transduction. 
The BB loop has emerged as key to the TIR domain-mediated homotypic protein- 
protein interaction (Bartfai et al., 2003). However, a computer-predicted docking model 
(Fig. 1.8, A) suggested that the BB loop of TLR1 interacts with the DD loop of TLR2 -  
another loop located at the opposite side of the BB loop -  , therefore leading to 
heterodimerisation and subsequent signalling initiation (Gautam et al., 2006). The first
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Figure 1.8. Computer-predicted models o f  asymmetrical and symmetrical interactions o f  TLR TIR domains 
A, Model o f  asymmetrical heterodimerisation o f  the TIR domain o f  TLR I (blue) with the TIR domain o f TLR2 
(purple). The ribbon diagram shows structural features, including the proximity o f  the TLR1 BB to the TLR2 
DD loop. B, Model o f  symmetrical homodimerisation o f  the TIR domains o f  two TLR 10 molecules (beige and 
green). The ribbon diagram shows structural features, including the proximity o f  the two TLR 10 BB loops. Part 
o f  the DD-loop o f  the left TLR10 monomer is disordered and not resolved, thus, it is not shown. NT/CT, N/C- 
terminus.
direct structural data regarding the formation of a symetrical TIR-TIR domain upon 
TLR homodimerisation was obtained following the resolution of the human TLR 10 
cytoplasmic domain crystal structure. Based on this structure (Fig. 1.8, B), two TLR 10 
TIR domains are predicted to interact through their BB loops (Nyman et al., 2008). 
Thus, it is possible that TLR homodimerisation involves only TLR BB loops, while 
TLR asymmetrical heterodimerisation involves the BB loop of one receptor and the DD 
loop of the other receptor (Fig. 1.8).
It is now well established that the TIR-TIR platform formed by the dimerisation 
of two TLRs promotes homotypic protein-protein interactions with additional 
cytoplasmic adapter molecules, resulting in an active signalling complex. These 
adaptors initiate a chain of phosphorylation and ubiquitination events that lead to 
activation of the transcription factor NF-kB, mitogen-activated protein kinases 
(MAPKs), and interferon-response factors (IRFs) (Watts, 2008).
To date, five TLRs adaptor proteins have been identified: 1) MyD88, 2) MyD88 
adaptor-like (Mai; also known as TIR domain-containing adaptor protein (TIRAP)), 3) 
TIR domain-containing adaptor inducing IFNp (TRIF; also known as TIR-containing 
adapter molecule-1 (TICAM-1)), 4) TRIF-related adaptor molecule (TRAM; also 
known as TIC AM-2), and 5) sterile-alpha and HEAT-Armadillo motifs-containing 
protein (SARM). The differential recruitment of these adaptor proteins to the TLRs 
forms the basis of the specificity in the signalling processes activated by TLRs.
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Fig 1.9. TLR signalling pathways
Schematic representation o f the MyD88- and TRIF-dependent pathways for TLR signalling (see description in 
the text). AP-1, activating protein-1; DD, death domain; IkB , inhibitor o f NF-kB; IKK, IkB kinases; IL, 
interleukin; IL-1R, interleukin-1 receptor; INF, interferon; IRAK, interleukin-receptor-associated kinase; IRF, 
interferon-response factor; ISRE, IFN-stimulated response element motifs JNK, c-jun-N-terminal kinase; Mai, 
MyD88 adaptor-like; MKKs, mitogen-activated protein-kinase kinases; MyD88, myeloid differentiation primary 
response protein 88; NEMO, NF-kB essential modulator; NF-kB, nuclear factor-kappa B; RIP-1, receptor 
interacting protein-1; TAB, TAK-1 binding protein; TAK-1, TGF-P-activated kinase-1; TBK-1, TRAF-family 
member-associated-NF-KB activator (TANK)-binding kinase-1; TIR, Toll/interleukin-1 receptor domain; TLR, 
Toll-like receptor; TNF-a, tumour necrosis factor-a; TRAF, TNF-a-receptor-associated factor-6 TRAM, TRIF- 
related adaptor molecule; TRIF, TIR domain containing adaptor inducing INF-P; Ub C l3, ubiquitin-conjugating 
enzyme 13; Uev 1A, ubiquitin-conjugating enzyme E2 variant 1.
The MyD88-dependent signalling pathway
The TLR adaptor MyD88 was first found expressed in myeloid tissues, and its 
RNA levels were used as a marker for differentiation, hence its name, as MyD stands 
for Myeloid Differentiation, and 88 is the number of the gene expressing the MyD88 
protein. MyD88 was the first adaptor described as a member of the Toll/IL-1 receptor 
family (Hultmark, 1994), and its function was found to be crucial for signalling induced 
by several TLRs (Bonnert et al., 1997; Medzhitov et al., 1998). By using MyD88- 
deficient mice, it was demonstrated that MyD88 is involved in TLR signalling in 
response to different microbial components: LPS and PGN from different strains of 
bacteria, cell wall preparations from the Gram-positive bacteria S. aureus, whole extract 
from M. tuberculosis (Takeuchi et al., 2000b), and live S. aureus (Takeuchi et al., 
2000a). This confirmed the involvement of MyD88 in TLR2- and TLR4-induced 
signalling. It is now known that MyD88 mediates signalling for all TLRs, except for 
TLR3 (Doyle and O'Neill, 2006 and Fig. 1.9).
MyD88 contains a death domain (DD) at its N-terminus and a TIR domain at the C- 
terminus. The DD domain of MyD88 interacts with the BB loop of TLRs cytoplasmic 
domain (Gautam et al., 2006). Following TLR ligand-induced binding of MyD88 to the 
TLR dimer, MyD88 recruits the first kinase of the signalling cascade, interleukin- 
receptor-associated kinase-4 (IRAK-4). The presence of IRAK-4 is required for the 
recruitment of IRAK-1, and mediates its phosphorylation (Fig. 1.9). Phosphorylated 
IRAK-1 then dissociates from the TLR/MyD88/IRAK-4 complex, and associates with 
TNF-a-receptor-associated factor-6 (TRAF-6). It was demonstrated using deletion 
mutants that efficient LPS signalling requires the activity of another member of the 
IRAK family, IRAK-2 (Zhang et al., 1999). Recently, the use of IRAK-2 loss-of-
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function mutants revealed that IRAK-2 was involved in NF-kB activation via TLR2, 5, 
7, 8 and 9. IRAK-2 was shown to interact with TRAF-6 directly, and initiate its 
polyubiquitination (Keating et al., 2007). Unlike IRAK-1, however, IRAK-2 was found 
unable to activate interferon response factors (IRFs).
TRAF-6, the next signalling intermediate after IRAK, links the IL-lR/IRAKs or 
TLR/IRAKs complexes with the activation of the NF-kB and the MAPK cascade. It 
interacts with the ubiquitin-conjugating enzyme E2 variant 1 (UevlA) and enzyme 13 
(Ubcl3), becomes polyubiquitinated, oligomerises, and consequently becomes activated 
(Chen, 2005). Subsequently, activated TRAF-6 associates with four downstream 
proteins: TGF-(3-activated kinase-1 (TAK-1), and the TAK-1 binding proteins-1, -2 and 
-3 (TAB-1, TAB-2, TAB-3). The formation of this complex leads to the ubiquitination 
of TAK-1, and ubiquitinated TAK-1 in turn phosporylates the inhibitor of NF-kB (I-kB) 
kinases (IKK) complex. IKK is also ubiquitinated by the Uevl/Ubcl3/TRAF-6 complex 
(Doyle and O'Neill, 2006). The IKK complex consists of three subunits, IKKa, IKK|3 
and IKKy (Brikos and O'Neill, 2008). IKKy (also called NF-kB essential modulator, 
NEMO), is a scaffold protein for the other subunits, and links the complex to I-kB. 
IKKa and IKKp are the kinases of the complex, and their role is to phosphorylate I-kB 
proteins that are associated with NF-kB in the cytoplasm of resting cells. N F-kB 
consists of a dimer of the subunit p50 -  which links NF-kB to I-kB -  and the subunit 
p65 -  that is needed for transactivation of gene expression. Phosphorylation of I-kB by 
IKKa and IKKp liberates N F-kB, which then translocates to the nucleus where it binds 
to and activate the promoters of genes responsible for inflammatory responses (Fig. 1.9 
and Doyle and O'Neill, 2006).
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Notably, the cytoplasmic adaptor IRAK-1 can also be found in the nucleus, and a recent 
study suggests that nuclear IRAK-1 binds to the promoter of the NF-KB-regulated gene, 
IkB-ol, and enhances binding of the NF-kB p65 subunit to NF-kB responsive elements 
within the IicB-a promoter (Liu et al., 2008).
TAK-1 also activates the MAPKs cascade. TAK-1 phosphorylates MAPK 
kinases (MKKs), which in turn phosphorylate and activate the MAPKs p38 and c-jun- 
N-terminal kinase (JNK). Activated p38 and JNK then activate the transcription factor, 
activating protein-1 (AP-1) that, like NF-kB, initiates the transcription of genes coding 
for pro-inflammatory cytokines (Fig. 1.9).
In addition to this general signalling pathway, the MyD88-dependent pathway 
also activates members of the interferon response factor (IRF) family (Fig. 1.9). Indeed, 
after TLR7 or TLR9 triggering, IRF-7 has been found to associate with the 
MyD88/IRAK-4/IRAK-l complex. Most likely upon phosphorylation by IRAK-1, IRF- 
7 translocates to the nucleus where it binds IFN-stimulated response element motifs 
(ISRE), thus activating type-1 IFNs production (Uematsu et al., 2005). Similarly, IRF-5 
was shown to associate with MyD88 and TRAF-6, after TLR4 and TLR9-induced cell 
activation. Subsequently, it moves to the nucleus, binds to ISRE motifs, and induces the 
production of IL-6, IL-12 and TNF-a.
The observation that NF-kB activation in response to TLR4 agonists in mice 
lacking MyD88 was only delayed initiated the search for other adaptors involved in 
TLR signalling (Doyle and O'Neill, 2006).
Mai (also known as TIRAP) was identified based on its sequence similarity with 
MyD88, and was initially shown to have a role in TLR4 signalling, because a mutation
49
in the BB loop of Mai could inhibit TLR4-, but not IL-lR-induced signalling. In 
addition, Mal-deficient animals behaved similarly to those MyD88-deficient, as they 
showed a delayed response to TLR4 agonists. Notably, Mai mice responded similarly 
to wild-type animals when challenged with IL-1 or any other TLR ligand except for 
those for TLR2. In fact, the lack of Mai was found to cause a more pronounced effect 
on signalling via TLR2 than via TLR4 (Brikos and O'Neill, 2008). Recent studies have 
shown that Mai possesses a binding domain for a major component of the plasma 
membrane, phosphatidylinositol-4,5-biphosphate (PIP-2) (Kagan and Medzhitov, 2006). 
The interaction of Mai with PIP-2 facilitates the recruitment of MyD88 to the TLR4 
complex (Kagan and Medzhitov, 2006). In addition, and unlike MyD88, Mai can 
associate with TRAF-6, and thus appears to be responsible for the recruitment of 
TRAF-6 to the TLR2 and TLR4 signalling complexes.
Although Mai was shown to be part of the TLR4 MyD88-dependent activation 
pathway, animals lacking both MyD88 and Mai were still capable of responding, 
although with some delay, to a challenge via TLR4 (Yamamoto et al., 2002). This 
suggested that, in addition to TLR3, TLR4 may also signal through an MyD88- 
independent pathway.
MyD88-independent signalling: the TRIFpathway
Following the observation that TLR3 and TLR4 can signal independently of
MyD88, Yamamoto and co-workers searched databases for TIR-containing proteins, 
and identified TRIF as the essential adaptor for MyD88-independent TLR signalling 
(Yamamoto et al., 2002). Overexpression of TRIF resulted in a similar activation of NF- 
kB to that via MyD88/Mal. However, unlike MyD88/Mal, activation of TRIF also leads 
to the activation of the IFN-p promoter. Recently, cytokine production in animals
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lacking TRIF was found reduced in response to TLR4 activation, but unaffected 
following TLR2, TLR7 or TLR9 triggering (Brikos and O'Neill, 2008). In addition, 
TRIF/MyD88 double mutant mice were unable to activate NF-kB, showing that TRIF 
was responsible for the delayed activation of NF-kB in MyDSS’7’ animals.
In order to signal downstream the TLR3 and TLR4 pathways, TRIF forms a complex 
with the IKK-like kinase termed TRAF-family-member-associated-NF-KB activator 
(TANK)-binding kinase 1 (TBK-1), the IKK homologue IKKe, and IRF-3 or IRF-7 
(Fig. 1.9). The formation of this complex results in the phosphorylation of IRF-3 or 
IRF-7 by TBK-1 and IKKe, and the activated IRF then binds to INF-stimulated 
response element motifs (ISRE) on its target genes, inducing the production of class I 
IFNs. Similarly, TBK-1 and IKKe phosphorylate IRF-5, which then bind to ISREs and 
initiates IL-6, IL-12 and TNF-a.
In TLR3 signalling, TRIF has also been shown to activate NF-kB through its binding to 
the TRAF-6/TAK-1/TAB-2 complex which activates IKK. However, the exact role of 
TRAF-6 in NF-kB activation through TRIF is still unclear. To signal to NF-kB, TRIF 
also interacts with the receptor interacting protein-1 (RIP-1), which then binds to and 
activates the IKK complex (Fig. 1.9).
A major difference between the activation of the TRIF pathway by TLR3 and 
TLR4 is that TLR3 interacts with TRIF directly, whereas TLR4 requires the presence of 
the fourth adaptor protein, TRAM. Thus, TRAM is also a bridging adaptor, like Mai, 
but it is only utilised by TLR4 (Doyle and O'Neill, 2006; Brikos and O'Neill, 2008). 
Thus, unlike TLR3, which signals exclusively through TRIF, TLR4 is the only TLR to 
activate both the MyD88 and TRIF pathways. There is now evidence that TLR4 does 
induce the MyD88/Mal and TRIF/TRAM pathways sequentially, rather than
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Fig 1.10. Negative regulation o f TLR activation
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simultaneously. Kagan and co-workers proposed that following an initial phase of 
MyD88-dependent signalling, TLR4 is internalised and starts off a second phase, TRIF- 
dependent, signalling via TRIF molecules located in the endosomes (Kagan et al., 
2008).
SARM -  the fifth and latest TLR adaptor to be identified -  acts as a negative 
regulator of TLR signalling (Carty et al., 2006). Therefore, it will be described in the 
next section, dedicated to the regulators of TLR activation.
3) Regulation of TLR activation
Activation of the immune system has to be tightly regulated to avoid excessive 
and inappropriate responses, which could be detrimental to the host. In the case of 
TLRs, excessive TLR-mediated responses resulting from overactivation of the receptor 
or dysregulation of intracellular signalling pathways may lead to severe, acute and 
chronic inflammatory conditions, such as myocardial dysfunction, respiratory, renal and 
multiorgan failure, septic shock, arthritis, asthma and autoimmunity (Zuany-Amorim et 
al., 2002; O'Neill, 2003). Therefore, TLR-mediated responses are controlled by a 
number of mechanisms, including: apoptosis of the activated cells, reduction of TLR 
expression, prevention of ligand binding to its TLR, and inhibition of TLR signalling 
(Fig. 1.10).
TLR regulation by apoptosis
TLRs can also function as death receptors, and TLR-induced apoptosis plays a 
role in the control of TLR response. Indeed, TLR4 was the first TLR to be reported as a
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death receptor, as it was demonstrated that LPS can induce macrophage apoptosis (Choi 
et al., 1998). Similarly, the interaction of TLR2 with microbial agonists triggers 
apoptosis in macrophages and epithelial cells (Aliprantis et al., 1999). A loss-of- 
function mutation of MyD88 -  but not TRAF-6 or IKK-P -  was found to inhibit TLR2- 
mediated cell apoptosis, indicating that the TLR signalling pathway to NF-kB and the 
TLR apoptotic pathway bifurcate at the level of MyD88. (Aliprantis et al., 2000). The 
authors provided further insight into the mechanism involved in the TLR apoptotic 
pathway by showing that MyD88 can interact with and recruit FADD (Aliprantis et al., 
2000). FADD then binds to pro-caspase 8 and induces enzyme maturation and 
subsequent cell death, as previously described (Muzio et al., 1998). A more recent study 
suggested that NF-kB activation and induction of cell apoptosis by TLRs were not 
simultaneous, but sequential phenomenons. Indeed, TLR2 ligand recognition was found 
to induce MyD88-mediated NF-kB activation as an early event, and MyD88/FADD- 
mediated cell apoptosis as a later event (Into et al., 2004).
Activation of apoptosis via TLRs may serve different purposes: the clearance of 
activated cells can help to reduce the level of inflammation, and may help in host 
defence by destroying the host-infected cells.
Reduction of TLR expression
Reduction of TLR expression can be achieved by protein degradation, mainly 
through ubiquitination. Triad-3 A -  the most abundant member of the Triad-3 family of 
RING-finger E3 ligases -  was found to bind to the cytoplasmic domain of TLR4 and 
TLR9, but not TLR2 (Chuang and Ulevitch, 2004). Triad-3 A promotes ubiquitination of 
TLR4 and TLR9 and their subsequent proteolytic cleavage. Consistent with these
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findings, it was demonstrated that overexpression of Triad-3 A significantly reduces 
TLR activation in response to LPS (TLR4 ligand), CpG DNA (TLR9 ligand), but not to 
bacterial lipopeptide (TLR2 ligand). Thus, Triad-3 A selectively modulates activation of 
certain TLRs by promoting their degradation through ubiquitination.
Reduction of TLR levels can also be achieved by inhibiting their expression. Indeed, the 
anti-inflammatory cytokine transforming growth factor-|3 (TGF-(3) has been shown to 
suppress LPS-mediated function by down-regulating TLR4 expression (McCartney- 
Francis et al., 2004). Granulocyte-macrophage colony-stimulating factor (GM-CSF) has 
been found to influence TLR2 expression. Treatment with GM-CSF was found to 
reduce the expression of TLR2 on granulocytes (Flo et al., 2001). However, Kurt and 
co-workers reported an increase in TLR2 expression on neutrophils upon treatment with 
GM-CSF (Kurt-Jones et al., 2002). By contrast, these authors and Flo and co-workers 
found increased TLR2 expression on macrophages and monocytes following GM-CSF 
treatment (Flo et al., 2001; Kurt-Jones et al., 2002). IL-4, IFN-y and TNF-a were found 
to reduce TLR2 expression on monocytes (Flo et al., 2001).
Very low levels of TLR expression are observed in intestinal epithelial cells, this 
is believed to ensure tolerance, or a low-level response to commensal bacteria in the 
gut. However, the mechanism by which commensal bacteria (or their products) inhibit 
TLR expression remains to be clarified.
Soluble TLRs as decoy microbial receptors
A powerful way of negatively regulating TLR-induced pro-inflammatory 
responses is to reduce TLR triggering by preventing the interaction of the receptor with
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its ligand. Soluble forms of TLR (sTLR) 2, 3, and 4, have been shown to inhibit 
activation of their repective membrane-bound counterparts.
■ Soluble TLR4
The first observation on the existence and activity of a soluble form of a 
TLR was made by Iwami and co-workers (Iwami et al., 2000). Although there is only 
one copy of the TLR4 gene, several TLR4 mRNA isoforms can be detected. In an 
attempt to identify these different isoforms, Iwami and co-workers screened a mouse 
macrophage cDNA library. In addition to the published mouse TLR4 cDNA sequence, a 
cDNA containing a 144-bp insertion between the reported second and third exon 
sequences was detected. This 144-bp sequence was found in the reported genomic 
DNA, and matched the AG/GT rule, suggesting that it was produced by alternative 
splicing. This novel exon contained an in-frame stop codon at 110 pb, and the predicted 
protein sequence indicated that the alternatively spliced cDNA encodes a 122-amino 
acid protein, whose first 86 amino acids were indentical to those of the TLR4 ECD. In 
order to study the activity of this putative soluble protein, the alternatively spliced 
cDNA was cloned, Flag-tagged, and transfected into CHO cells. A soluble 20-kDa 
protein was detected in culture supernatants using an anti-Flag mAb. This sTLR4- 
encoding cDNA was also introduced in a mouse macrophage cell line, and proved to be 
capable of inhibiting LPS-induced NF-kB activation and TNF-a production by these 
cells. It remains to be established, however, whether this putative soluble TLR4 protein 
fragment is naturally expressed and released by normal mouse cells.
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■ Soluble TLR2
A soluble form of human TLR2 (sTLR2) was first detected and characterised 
by our laboratory (LeBouder et al., 2003; Heggelund et al., 2004; Ueland et al., 2006). 
Unlike sTLR4, sTLR2 occurs naturally, as it is constitutively released by normal 
monocytes, and present in normal human plasma, breast milk (LeBouder et al., 2003), 
saliva (Kuroishi et al., 2007), mouse peritoneal lavage fluids (this study), and plasma, as 
well as bovine and porcine plasma (our unpublished observations). Other than sTLR2, 
no naturally occurring soluble form of a mammalian TLR has so far been identified. 
Western blot analysis showed six sTLR2 isoforms (25 to 83 kDa) present in human 
plasma, with a major polypeptide band of ~66 kDa. Because blood monocytes express 
the highest levels of membrane-bound TLR2 (mTLR2), it was speculated that they are 
the main source of sTLR2 in plasma. Consistent with this possibility, Western blot 
analysis of culture supernatants from freshly-isolated human monocytes showed a 
sTLR2 pattern similar to that of plasma sTLR2. Similar experiments failed to 
demonstrate the release of detectable amounts of sTLR2 by tonsillar B cells, B cell lines 
and peripheral T cells (LeBouder et al., 2003).
RT-PCR and Southern blot analyses of human monocyte RNA did not show the 
presence of splice variants, deletions or mutations of the TLR2 gene, indicating that 
sTLR2 originates from a post-translational modification of mTLR2. Indeed, following 
cell-surface monocyte biotinylation, biotinylated sTLR2 was detected in the cell culture 
supernatant, and increased levels of sTLR2 correlated with lower levels of mTLR2 over 
the time following cell activation. Furthermore, monensin -  an antibiotic that blocks 
processing events taking place in internal acidic compartments -  was found to affect the 
release of sTLR2, and an intracellular pool of sTLR2 was found in monocytes
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(LeBouder et al., 2003). Together, these findings indicated that sTLR2 results from 
post-translational modification of the TLR2 protein, most likely by proteolytic cleavage 
of endocytosed mTLR2.
Notably, although non-activated monocytes constitutively produce sTLR2, in vitro 
activation was found to increase the kinetics of sTLR2 release. Thus, cell activation 
seems to modulate the production of sTLR2 (LeBouder et al., 2003). Modulation of 
sTLR2 levels in vivo during infection was also observed (LeBouder et al., 2003; 
Heggelund et al., 2004; Kuroishi et al., 2007).
The biological activity and physiological relevance of naturally occurring sTLR2 was 
evaluated by depleting sTLR2 from plasma using a TLR2-specific mAb. It was found 
that sTLR2-depleted plasma confers higher sensitivity to TLR2-mediated PBMC 
stimulation (LeBouder et al., 2003), indicating that plasma sTLR2 may act as a natural 
regulator of cell activation via TLR2.
Given that a direct interaction of the TLR2 ECD with many TLR2 agonists has been 
demonstrated (see section 1.3.3.B.2, pages 25, 26 and 30), it is possible that sTLR2 
inhibits mTLR2-mediated responses by competing for the ligand, thus acting as a decoy 
microbial receptor. However, the fact that sTLR2 and sCD14 could be co- 
immunoprecipitated from breast milk and plasma (LeBouder et al., 2003), indicated that 
they may naturally associate, and suggested that sTLR2 may also modulate TLR2 
triggering by binding to CD 14 and, thus, disrupting its co-receptor function. The 
mechanism underlying sTLR2’s activity was addressed in more details in the present 
study.
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■ Soluble TLR3
Cloning of the cDNA coding for the human TLR3 ECD and subsequent 
transfection in HEK293 cells led to the production of a 110-kDa soluble protein termed 
hTLR3 ECD (Sun et al., 2006). Consistent with the demonstrated activity of sTLR4 and 
sTLR2, hTLR3 ECD was also found to inhibit mTLR3-mediated NF-kB activation in 
response to the synthetic ligand poly(I:C). However, the biological relevance of this 
finding is not evident, as there is no indication that a soluble form of TLR3 naturally 
occurs.
■ Soluble TLR5
Like the mammalian sTLR2, the existence of a TLR5-like soluble protein 
naturally present in the rainbow trout and a variety of other fish species was reported 
(Tsujita et al., 2006). By using a recombinant form of sTLR5, Tsujita and co-workers 
showed that sTLR5 can directly bind to the TLR5 ligand, flagellin. Interestingly, sTLR5 
was not found to inhibit, but to enhance flagellin-induced TLR5-mediated cell 
stimulation. The authors proposed that sTLR5 binds to flagellin and then helps its 
recognition by mTLR5. sTLR5 has not been found in humans. The presence of sTLR5 
in the rainbow trout may reflect a prototype of humoral immunity in the fish, which 
may be required for a very sensitive recognition of flagellated microorganisms (Tsujita 
et al., 2006).
■ Soluble MD-2
As MD-2 is essential for LPS recognition via TLR4, and has been found to 
directly interact with LPS, Kuroki and co-workers sought the possibility of dampening 
TLR4 triggering using a soluble recombinant form of human MD-2 (srMD-2) together
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with sTLR4 (Mitsuzawa et al., 2006). They showed that sTLR4 does not interact with 
the lipid A fraction of LPS, whereas srMD-2 does, and that the binding of lipid A to 
srMD-2 increases when srMD-2 is in a complex with sTLR4. Consistent with this 
observation, they found that sTLR4 did not inhibit LPS-induced NF-kB activation and 
IL-8 release by a mouse macrophage cell line. srMD-2, however, had a slight inhibitory 
effect on its own, and this inhibitory effect was enhanced in the presence of sTLR4. In 
vivo, the administration of the complex srMD-2/sTLR4 reduced LPS-induced neutrophil 
recruitment and TNF-a production in a mouse model of pulmonary inflammation
(Mitsuzawa et al., 2006). Whether natural sMD-2 regulates mTLR4-mediated responses 
in vivo remains to be evaluated.
Inhibition o f TLR signalling
TLR-mediated responses can also be controlled through several intracellular 
negative regulators of TLR signalling.
■ SARM
SARM is a TIR domain-containing protein, and is the latest TLR adaptor so 
far identified. Unlike other TIR-containing adaptors, SARM acts as an inhibitor of NF- 
kB and IRF activation in response to TLR triggering. Indeed, the knock-down of SARM 
expression using small interfering RNA (siRNA), leads to enhanced production of pro- 
inflammatory cytokines upon stimulation with TLR3 and TLR4 agonists (Carty et al., 
2006). In addition, cell stimulation via TLR3 or TLR4 results in an enhanced expression 
of SARM. Thus, it is likely that SARM is involved in a negative feedback mechanism 
preventing prolonged and excessive pro-inflammatory responses via TLRs.
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It is known that SARM can interact directly with the signalling adaptor TRIF, but 
whether SARM inhibits TRIF activation directly, or by favouring the interaction of 
TRIF with another inhibitory molecule is still unclear (Brikos and O'Neill, 2008; Carty 
et al., 2006).
■ SIGIRR
The single immunoglobulin IL-lR-related molecule (SIGIRR), is a cell 
membrane-bound, TIR domain-containing protein, which has been shown to inhibit IL- 
1R and TLR4 signalling. Indeed, initial studies showed that overexpression of SIGIRR 
inhibited NF-kB activation in response to IL-1, suggesting that SIGIRR could also act 
as an inhibitor of IL-lR-related receptors, like TLRs. This was confirmed in vivo, as 
SIGIRR-deficient mice showed enhanced inflammatory responses to LPS and IL-1 
(Wald et al., 2003). Furthemore, NF-kB and JNK activation were enhanced in 
splenocytes from SIGIRR"A animals in response to both LPS (TLR4 agonist) and CpG 
DNA (TLR9 agonist), indicating that the SIGIRR inhibitory effect is not limited to one 
TLR (Wald et al., 2003). SIGIRR was found to co-immunoprecipitate with TLR4, 5, 9 
and IL-1R, suggesting a TIR-TIR domain interaction. SIGIRR was also shown to 
interact with the TLR signalling intermediate, TRAF-6. Thus, it is thought that SIGIRR 
inhibits TLR activation by preventing the recruitment of signalling adaptors to the TLR 
TIR domain (Wald et al., 2003). Alternatively, SIGIRR may inhibit the dissociation of 
the activated signalling components from the receptor, thus reducing the activation of 
downstream signalling events.
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■ ST-2
ST-2 is another member of the TIR domain-containing family of receptors. It 
was first identified as crucial to Th2-cell activity (Townsend et al., 2000). Regarding 
TLR signalling, overexpression of ST-2 leads to inhibition of MyD88-dependent 
signalling induced via IL-1R and TLR4, but not TLR3 (Brint et al., 2004). Consistent 
with this finding, IL-1, LPS, lipopeptides and CpG DNA, but not poly I:C, were found 
to induce higher levels of pro-inflammatory cytokines by macrophages from ST-2- 
deficient animals (Brint et al., 2004). A recombinant form of ST-2 has been shown to 
interact with Mai and MyD88, but not TRIF, thus it is likely that ST-2 inhibits MyD88- 
dependent TLR signalling by sequestering its adaptors (Brint et al., 2004).
■ TRAILR
TNF-related apoptosis-inducing ligand (TRAIL) receptor (TRAILR) is a 
membrane-bound receptor for TRAIL -  a member of the TNF family of cytokines that 
promotes apoptosis. It does not contain a TIR domain, as it belongs to the TNF-a 
receptors superfamily. Both TRAIL- and TRAILR-deficient animals show increased 
levels of IL-12, IFN-p and IFN-y upon infection with mouse CMV (TLR2 ligand), and 
TRAILR-deficient macrophages were found to produce higher levels of pro- 
inflammatory cytokines in response to activation via TLR2, 3 or 4 (Diehl et al., 2004). 
TRAILR seems to inhibit TLR signalling by stabilising IkB, thus reducing the nuclear 
translocation of NF- kB (Diehl et al., 2004; Liew et al., 2005).
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- Soluble MyD88
Soluble MyD88 (sMyD88) is a naturally-occurring alternatively-spliced 
variant of MyD88 that contains its death domain, but lacks the domain involved in 
binding to IRAK-4. Overexpression of sMyD88 inhibits IL-1 and LPS induced NF-kB 
activation, and promotes the formation of MyD88-sMyD88 complexes. As sMyD88- 
complexed MyD88 cannot bind to IRAK-4, this kinase is not recruited to the signalling 
complex, thus IRAK-1 cannot be phosphorylated and activate downstream processes 
(Liew et al., 2005).
■ TRAF-1 and TRAF-4
Another adaptor-mediated inhibition of TLR signalling involves two 
members of the TRAF family, TRAF-1 and -4. Unlike TRAF-6, which is essential for 
TLR signalling, TRAF-1 and -4 play inhibitory roles (Brikos and O'Neill, 2008). 
Overexpression of TRAF-1 inhibited TRIF- and TLR3-mediated activation of NF-kB, 
ISRE and IFN-p promoter (Su et al., 2006). TRAF-1 has been shown to bind to TRIF, 
which then induces cleavage of TRAF-1. Consequently, TRAF-1 becomes activated and 
inhibits TRIF-dependent signalling (Su et al., 2006).
TRAF-4 can interact not only with TRIF, but also with TRAF-6, and it has been found 
to prevent NF-kB activation induced via a number of TLRs, including TLR2, 3, 4 and 9, 
as well as TLR3 and TLR4-induced IFN-p promoter activation (Takeshita et al., 2005).
■ IRAK-M, IRAK-2c and IRAK-2d
In humans, four members of the IRAK family have been identified: IRAK-1, 
IRAK-2, IRAK-M and IRAK-4. IRAK-1, IRAK-2 and IRAK-4 have been shown to
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participate in the MyD88-dependent pathway of TLR signalling. IRAK-M -  whose 
expression is restricted to monocytes and macrophages (Wesche et al., 1999) -  is an 
inactive kinase, because it lacks a critical aspartate residue in the catatalytic site. IRAK- 
M knock-out mice produced markedly higher levels of pro-inflammatory cytokines than 
the wild-type after a challenge with LPS or CpG DNA (Kobayashi et al., 2002). This 
indicated a negative role of IRAK-M in, at least, TLR4 and TLR9 signalling. In 
addition, expression of IRAK-M was found increased by LPS, suggesting that IRAK-M 
is involved in a negative regulatory feedback in TLR4 signalling (Kobayashi et al.,
2002). Although the exact mechanism of IRAK-M activity has not been determined, it 
is known that it does not interfere with the binding of IRAK-1 to the 
TLR/MyD88/IRAK-4 signalling complex, but inhibits the formation of the IRAK- 
1/TRAF-6 complex. It is believed that IRAK-M blocks the dissociation of IRAK-1 from 
MyD88/IRAK-4, thus preventing the interaction of IRAK-1 with TRAF-6 (Kobayashi 
et al., 2002).
Four splice variants of the mouse (but not human) Irak2 gene have been reported: 
Irak2a, Irak2b, Irak2c and Irak2d (Hardy and O'Neill, 2004). Overexpression of IRAK- 
23 and b have been shown to enhance LPS-induced NF-kB activation, whereas IRAK- 
20 and d had an inhibitory effect (Hardy and O'Neill, 2004). LPS-activation enhanced 
the expression of IRAK-2c, but not IRAK-2a, by a mouse macrophage-like cell line, 
suggesting a negative regulatory feedback of IRAK-2c in TLR4 signalling. However, as 
no animal models for IRAK-2 have been generated, the physiological relevance of 
IRAK-2’s regulatory activity has not been fully assessed.
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■ TOLLIP
Overexpression of the Toll-interacting protein (TOLLIP) results in reduction 
of IL-1R- (Bums et al., 2000), TLR2- and TLR4-mediated NF-kB activation (Bulut et 
al., 2001; Zhang and Ghosh, 2002). TOLLIP has been found to naturally associate with 
IRAK-1 in resting cells (Bums et al., 2000). This association results in TOLLIP 
phosphorylation by IRAK-1, which leads to the release of TOLLIP from the 
TOLLIP/IRAK-1 complex, thus, allowing subsequent signalling and ubiquitination of 
IRAK-1 (Zhang and Ghosh, 2002). However, IRAK-1 ubiquitination promotes its 
degradation and thereby may also inhibit TLR-signalling. In view if these findings, the 
physiological effect of TOLLIP was addressed using TOLLIP-deficient mice. Ex vivo 
experiments showed that cell activation in response to TLR3, 4, 5, and 9 agonists was 
normal in DCs and lymphocytes from TOLLIP'7' animals, suggesting that TLR- 
mediated activation is TOLLIP-independant (Didierlaurent et al., 2006). In vivo 
experiments, however, suggested that TOLLIP controls the magnitude of IL-1R- and 
TLR4-mediated cytokine production. Indeed, Didierlaurent and co-workers showed that 
TOLLIP 7' animals produce less IL-6 and TNF-a in response to relatively low doses of 
IL-1 p or LPS. However, TOLLIP regulatory activity was not observed when a lethal 
concentration of LPS was used. Given the apparent lack of consistency of the in vitro, 
ex vivo and in vivo results, the authors suggest that TOLLIP ‘fine tunes’ optimal 
signalling through IL-1R and TLRs, and predict that the concentration of TOLLIP may 
be critical to its capacity to regulate signalling (Didierlaurent et al., 2006).
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■ PI3K
Phosphoinositide 3-kinase (PI3K) is a heterodimer consisting of a p85 
regulatory subunit and a pi 10 catalytic chain. IL-12 production in response to TLR2, 4 
and 9 ligands was found markedly increased in DCs from animals lacking PI3K, and 
p85-deficient mice showed enhanced TLR signalling (Fukao et al., 2002). Although the 
exact mechanism of PI3K activity is unclear, it is believed that PI3K blocks the MAPK 
pathway. PI3K positively regulates the activation of protein kinase B, a kinase that 
phosphorylates MAPK kinase kinase (MAPKK-K) apoptosis signal-regulating kinase-1 
(ASK-1). Phosphorylation of ASK-1 suppresses its activity, which is required for the 
activation of upstream regulators of p38, MAPK kinases-3 (MKK-3) and MKK-6. 
Therefore, inhibition or lack of PI3K was found to upregulate p38 activity in DCs 
(Fukao and Koyasu, 2003). In vivo, inhibition of PI3K resulted in increased serum levels 
of ILl-p, IL-2, IL-6, IL-10, IL-12, and TNF-a in septic mice, and was associated with 
enhanced disease severity, and decreased survival outcome (Williams et al., 2004). 
Thus, PI3K may play a pivotal role in the maintenance of homeostasis and the integrity 
of the immune response via TLRs.
■ SOCS-1
Several members of the suppressor of cytokine signalling (SOCS) family 
have been shown to suppress cytokine signalling. The macrophages of SOCS-l'7' 
animals produce higher levels of NO and pro-inflammatory cytokines upon stimulation 
with the TLR4 and TLR9 agonists LPS and CpG DNA, respectively. In addition, both 
LPS and CpG DNA enhanced the expression of SOCS-1 in macrophages, suggesting a 
negative feedback mechanism (Kinjyo et al., 2002; Liew et al., 2005). The crucial role
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of SOCS-1 in the negative regulation of inflammatory processes is highlighted by the 
fact that mice lacking SOCS-1 die within three weeks of birth due to multi-organ 
inflammation (Starr et al., 1998). It has been demonstrated that SOCS-1 reduces 
phosphorylation of IkB, p38 and JNK, thus blocking downstream signalling most likely 
by targeting IRAK-1 (Kinjyo et al., 2002).
■ RIP-3
RIP-3, like RIP-1, is a member of the receptor interacting proteins, and can 
also associate with TRIF. Unlike RIP-1, RIP-3 cannot induce downstream signalling, on 
the contrary, RIP-3 was shown to inhibit TLR signalling in two ways. Firstly, RIP-3 
can phosphorylate RIP-1, thus inhibiting NF-kB activation (Meylan et al., 2004). 
Secondly, the authors also showed that RIP-3 acts as an inhibitor of TRIF-induced NF- 
kB activation by competing with the binding of TRIF to RIP-1 (Meylan et al., 2004).
■ IRF-4
As mentioned previously (section 1.3.3.B.3.2), IRF-5 and -7 associate with 
MyD88, leading to the production of type I IFNs and pro-inflammatory cytokines. IRF- 
4 can also bind to MyD88, but this interaction does not result in downstream signalling, 
on the contrary, it prevents the formation of the MyD88/IRF-5 complex. However, IRF- 
4 does not impair the binding of IRF-7 to MyD88. Thus it blocks specifically 
MyD88/IRF-5-mediated signalling, most likely by impairing the translocation of IRF-5 
to the nucleus, as it was shown for TLR9 induced signalling (Negishi et al., 2005). The 
inhibitory activity of IRF-4 in TLR signalling was confirmed in vivo by the observation 
that IRF-4-deficient mice are hypersensitive to DNA-induced shock and show elevated
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serum levels of pro-inflammatory cytokines (Negishi et al., 2005). IRF-4 appears to be 
involved in a negative feedback mechanism, as its mRNA levels increase upon cell 
stimulation with agonists of TLR4, 7 and 9 (Negishi et al., 2005).
■ TGF-P
TGF-(3 has been shown to down-regulate TLR4 expression (section
1.3.3.B.3.3). It is also known that TGF-P induces ubiquitination of MyD88 and its 
subsequent proteosomal degradation. Consistent with this observation, TGF-(3 was 
found to act as an intracellular signalling regulator, as it inhibits the MyD88-dependent 
pathway in response to ligands for TLR2, 4 and 5, whereas the TRIF-dependent 
pathway of TLR4-mediated activation is not affected (Naiki et al., 2005).
■ PIASy
A member of the protein inhibitor of the activated signal transducer and 
activator of transcription (PIAS) family, PIASy, has been shown to suppress TRIF- 
induced NF-kB activation, as well as TRIF-, IRF-3- and IRF-7 induced ISRE activation 
(Zhang et al., 2004b). PIASy was found to interact with TRIF, IRF-3 and IRF-7 (Zhang 
et al., 2004b), suggesting that PIASy may regulate TLR activation by seggregating these 
three signalling intermediates (Zhang et al., 2004b; Brikos and O'Neill, 2008).
■ SIKE
The supressor of IKKe (SIKE) interacts with both TBK-1 and IKKe, and 
blocks their respective association with TRIF and IRF-3. As a consequence, SIKE
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inhibits ISRE and IFN-|3 promoter activation via TLR3, but not the TLR3-induced NF- 
kB activation (Huang et al., 2005).
■ SHP-1 and SHP-2
Src homology-2 (SH-2)-containing tyrosine phosphatase (SHP)-l and -2 
have been shown to modulate TLR activation. SHP-2 was first found to negatively 
regulate TLR4- and TLR3-mediated IFN-p production, but without affecting the 
activation of TLR2, 7 and 9 (An et al., 2006). SHP-2 was also found to inhibit 
poly (I: C)-induced activation of MAP kinase pathways (An et al., 2006). In addition, 
SHP-2 was shown to interact directly with the kinase domain of TBK-1, suggesting that 
SHP-2 specifically regulates TRIF-mediated gene expression in TLR signalling, at least 
in part, by inhibiting TBK1 -activated signal transduction (An et al., 2006). 
SHP-1 was found to inhibit the production of pro-inflammatory cytokines in response to 
agonists of TLR2, 3, 4 and 9 in vitro. Furthermore, SHP-1 deficiency resulted in 
inhibition of TLR3-mediated production of IFN-P (An et al., 2008). Mechanistically, 
SHP-1 was found to bind to and block the activity of the TLR signalling intermediate 
IRAK-1, thus inhibiting the activation of NF-kB and MAPKs. An and co-workers also 
demonstrated that inactivation of IRAK-1 promotes the activation of MyD88- and 
TRIF-dependent production of IFN-P, which is consistent with the fact that SHP-1 
deficiency impaired IFN-p production. The authors also provided evidence of an 
opposite regulatory effect of SHP-1 and SHP-2 in TLR signal transduction through a 
cross-regulation mechanism by which endogenous SHP-2 'antagonises' SHP-1-mediated 
positive regulation of TLR-activated IFN-P expression by reducing the expression of 
mRNA encoding SHP-1 (An et al., 2008).
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■ MUC-1
The transmembrane mucin-like glycoprotein-1 (MUC-1 in humans, muc-1 in 
other species) is expressed in epithelial cells lining various mucosal surfaces as well as 
in hematopoietic cells. Ex vivo experiments have revealed that peritoneal macrophages, 
alveolar macrophages and tracheal surface epithelial cells from muc-l‘A animals were 
more sensitive than their wild-type counterparts to ligands for TLR2, 3, 4, 5, 7 and 9 
(Ueno et al., 2008). The cytoplasmic tail of MUC-1 -  but not its extracellular domain -  
was found critical to MUC-1 regulatory activity, suggesting that MUC-1 targets TLR 
intracellular signalling, rather than extracellular ligand recognition. Although the exact 
mechanism involved in MUC-1 inhibitory ability remains to be determined, Ueno and 
co-workers propose that MUC-1 interacts with and sequesters TLR signalling 
intermediates, thus inhibiting TLR-mediated NF-kB activation (Ueno et al., 2008).
■ A-20
A-20 is a cysteine protease deubiquitinating cytoplasmic enzyme that 
inhibits TLR signalling. Macrophages from the A-20-deficient mice were found to 
produce higher levels of pro-inflammatory cytokines in response to TLR2, 3, 4 and 9 
agonists. A-20 expression is up-regulated by LPS. These observations indicate that A- 
20 may be involved in a negative feedback mechanism preventing TLR overactivation. 
A-20 was demonstrated to cleave the ubiquitin chain of TRAF-6, which is essential for 
its activity. Because TRAF-6 is utilised by all members of the TLR family, A-20 
inhibits NF-kB activation via both the MyD88 and TRIF-dependent pathways (Liew et 
al., 2005).
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■ Virus-derived inhibitors of TLR signalling
A number of viral proteins have been shown to be used by the invading 
pathogens to prevent TLR signalling. They include, A46R, A52R and the HCV non- 
structural proteins (NS)-3, -3/4A, -4B and -5A.
A46R and A52R are two viral proteins expressed by the vaccinia virus that contribute to 
virulence and suppresion of host defence (Harte et al., 2003; Stack et al., 2005). A46R 
contains a TIR domain and can associate with MyD88, Mai, TRAM, TRIF and TLR4 
through its TIR domain and, thus, is capable of impairing signalling through TLR2, 4, 5, 
7 and 9, as well as of inhibiting IRF-3 activation via TLR3 (Stack et al., 2005).
A52R, which does not contain a TIR domain, can interact with IRAK-2 and TRAF-6, 
disrupting signalling complexes containing these proteins and, consequently, 
suppressing NF-kB activation by TLR2, 3, 4 and 5 (Harte et al., 2003).
Overexpression of NS3, NS3/4A, NS4B and NS5A in macrophages was found to inhibit 
MyD88-dependent TLR signalling in response to PGN (TLR2), LPS (TLR4), R837 
(TLR7) and CpG DNA (TLR9) (Abe et al., 2007). In addition, expression of NS5A 
inhibited the TLR-mediated MAPK cascade. NS5A was found to interact with the death 
domain of MyD88, and inhibit recruitment of IRAK-1 to MyD88, thus, blocking 
subsequent signalling (Abe et al., 2007). Notably, NS3/4A was also found to inhibit 
dsRNA-induced IFN production, by cleaving the adaptor molecule TRIF, thereby 
disrupting signalling via TLR3 (Li et al., 2005).
The different levels at which TLR activity can be regulated (summarised in Fig.
1.10) highlight the importance of such regulation to the maintenance of immune 
homeostasis
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4) TLR-based therapeutic strategies
Given that TLRs are central to innate immunity and also control, directly or 
indirectly, the extent and quality of the adaptive immune response, they have become a 
major target for the development of novel therapeutics which, depending on the 
pathological condition, aim at strengthening or dampening the immune response.
Therapeutic applications o f TLR agonists
TLR agonists are mainly used to strengthen or re-establish an immune response.
■ Vaccine adjuvants
The use of TLR agonists as vaccine adjuvants has been extensively 
evaluated. Indeed, linkage of a TLR agonist to an antigen can increase antigen uptake 
by DCs and facilitate antigen processing, antigen presentation, and the subsequent 
development of the adaptive immune response. At present, a number of prophylactic 
and therapeutic TLR-based vaccines against viral infections (hepaptitis B virus, human 
papilloma virus, human immunodeficiency virus, influenza virus), cancer (melanoma, 
lung cancer) and general vaccine adjuvants are being developed and evaluated by 
pharmaceutical companies (Kanzler et al., 2007).
■ Cancer therapy
TLR stimulation may be beneficial to cancer therapies by enhancing: innate 
immunity, T-cell activity, cytotoxic antibody function, and apoptosis of TLR positive 
tumours.
Triggering of the innate immune response induces innate antitumour mechanisms, such 
as activation of NK cells, monocytes and macrophages, and production of antitumoural
71
Table 1.4. Principal TLR targeting therapeutics under development
Company Compound Target Indication Status
3M Aldara (imiquimod) 
cream
TLR7/8 agonist Actinic keratosis; superficial 
basal cell carcinoma; 
external genital warts
Marketed
Follow on compounds TLR7/8 agonist Human papilloma virus; 
cancer
Phase I
Coley ProMune (CPG 7909) TLR9 agonist Melanoma;other cancers Entering Phase III
Actilon (CPG 10101) TLR9 agonist Hepatitis C virus; infectious 
diseases
Entering Phase III
AVE7279 and AVE 0675 TLR9 agonist Asthma; other respiratory 
diseases
Phase I
Vaximmune (vaccine 
adjuvant)
TLR9 agonist Cancer; anthrax; bio warfare Phase I
Dynavax AIC (1018 ISS + ragweed 
allergen)
TLR9 agonist Ragweed allergy Phase II/III
1018 ISS + Hepatitis B 
virus antigen
TLR9 agonist Hepatitis B virus vaccine Entering Phase III
Anadys ANA245 (isatoribine) TLR7 agonist Hepatitis B virus; Hepatitis 
C virus; cancer
Phase II
ANA975 (prodrug of 
ANA245)
TLR7 agonist Hepatitis B virus; Hepatitis 
C virus
Phase I
Hybridon IMOxine (HYB2055) 
vaccine adjuvant
TLR9 agonist Renal cell carcinoma; cancer Phase II
Amplivax (HYB2903) 
Vaccine adjuvant
TLR9 agonist Human immunodeficiency 
virus; vaccine adjuvant
Phase I
Eisai Eritoran (E5564) TLR4 antagonist Severe sepsis Phase III
Takeda
Pharmaceutical
Company
TAK-242 TLR4 antagonist Severe sepsis Phase III
Mologen dSLIM TLR9 agonist Cancer Phase I/II
Corixa CRX-675 TLR4 agonist Seasonal allergic rhinitis Phase I
CRX-567 TLR4 agonist Infectious diseases Phase I
Vaxinnate Preclinical candidates TLR5 agonists; 
others
N/A Preclinical
cytokines such as IFN-a, IFN-y and TNF-a. Activation of innate antitumoural 
mechanisms may also promote, indirectly, T-cell activity by increasing the release of 
antigens by the dying tumor cells. Efficient induction of tumour cell apoptosis via TLRs 
has been demonstrated in vitro for TLR9+ chronic lymphocytic leukemia cells 
(Jahrsdorfer et al., 2005) and TLR3+ breast carcinoma cells (Salaun et al., 2006).
To date, several TLR ligands have shown significant promise for the treatment of 
cancer, and the TLR7 agonist Imiquimod -  developed by 3M Pharma -  is now approved 
for the treatment of basal cell carcinoma (Hoffman et al., 2005 and Table 1.4).
■ Antimicrobial therapy
The use of TLR3, 7, 8 and 9 agonists has shown promise as therapeutic 
strategies against infectious -  in particular viral -  diseases. TLR activation by agonists 
leads to the production of antiviral type I IFNs. The TLR-induced enhancement of NK 
cell cytotoxicity and virus-specific T-cell responses play an equally important role in 
the resolution of the infection. Small agonists of TLR7 are the most advanced, and 
Imiquimod has been approved for the treatment of genital warts caused by the human 
papilloma virus. ANA-975, an oral prodrug of isatoribine from Anadys, is being tested 
for the treatment of chronic hepatitis C virus, although trials were suspended when 
toxicity developed in long-term animal studies (Fletcher et al., 2006 and Table 1.4). 
Ligands for TLR3 are also being developed, mainly for targeting the human 
immunodeficiency virus. The use of TLR agonists as prophylactic treatments to 
increase resistance to and protect from microbial infections is also being considered, 
e.g. the TLR9 ligand, CpG-oligodeoxynucleotide (ODN) (Kanzler et al., 2007).
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■ Allergic diseases
Although inadequate TLR activation is thought to be involved in different 
forms of allergies (Hoffman et al., 2005), the use of TLR agonists can, paradoxically, be 
beneficial to allergic patients. A general feature of allergies is an inappropriate Th2 cell 
response to harmless environmental antigens. It is known that Th2 cell development and 
activity can be inhibited by Thl cytokines, and that TLRs can induce strong Thl 
responses (section 1.3.3.B.2.3). Thus, TLR agonists could, indirectly, inhibit inadequate 
Th2 responses causing allergies. Ligands for TLR4 and TLR9 are being evaluated for 
the treatment of allergic rhinitis (Table 1.4). The administration of CpG-ODN has been 
shown to shift the Th2/Thl ratio, and attenuate allergic reactions in patients allergic to 
ragweed. CpG-ODN has also been proven to be efficient against asthma in both rodent 
and primate models (Serebrisky et al., 2000; Fanucchi et al., 2004).
Therapeutic applications o f TLR antagonists
Most therapeutic strategies to dampen TLR responses use TLR antagonists to 
inhibit TLR ligand recognition, and are based on the use of structural analogs of 
agonists that bind to the TLR but fail to signal, or of TLR blocking Abs, or small 
molecules antagonists selected from compound libraries. Alternative strategies use 
small molecules to block intracellular TLR signalling.
■ Microbial inflammation
Bacterial-induced inflammation may lead to sepsis and septic shock when 
TLR activation gets out of control. Two lipid A analogs acting as potent TLR4
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antagonists are being tested for the treatment of Gram-negative sepsis, Eritoran and 
TAK-242 (Table 1.4).
■ Autoimmunity
One of the challenges of the innate immune system is to differentiate self 
from non-self. To date, endogenous ligands have been described for most TLRs. They 
originate mainly from damaged or infected cells and tissues, and their recognition is 
normally beneficial to the host. However, activation of TLRs by damaged host tissue 
may lead to a cycle of chronic activation and tissue damage by TLR-activated effector 
mechanisms (Kanzler et al., 2007). In such cases, it is reasonable to believe that the use 
of TLR antagonists would reduce self-induced TLR activation. For example, systemic 
lupus erythematosus is an autoimmune disease driven by TLR3, 7 and 9, and 
bifunctional ODN -  blocking both TLR7 and TLR9 -  have proven to be an efficient 
strategy to control autoimmunity in animal models that remains to be tested in humans 
(Barrat et al., 2005).
Sterile inflammation (inflammation not caused by pathogens) occuring during 
bleomycin-induced lung inflammation and ischaemia-reperfusion have also been shown 
to be driven by TLRs recognition of ligands from dying cells. Bleomycin-induced lung 
inflammation is mediated, at least in part, by chemokines and cytokines generated by 
TLR2 and TLR4 recognition of hyaluronan fragments derived from the extracellular 
matrix (Jiang et al., 2005). Similarly, TLR2 and TLR4 appear to contribute to ischemia- 
reperfusion injury, although the specific ligand has not been identified (Mollen et al., 
2006). Thus, appropriate TLR2 and TLR4 antagonists may represent a new class of 
therapeutics for this type of autoimmune driven inflammation (Kanzler et al., 2007).
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Thus, the TLR family of receptors is currently being considered as a major 
therapeutic target for the treatment of a variety of pathological conditions. In particular, 
novel TLR-based therapeutic approaches against acute and chronic microbial-induced 
inflammatory conditions aim at reducing TLR-mediated pro-inflammatory responses 
without eliminating the capacity of TLRs to recognise the pathogen and clear the 
infection.
1.4 Hypotheses and aims of the project
Following the description of a naturally occurring soluble form of TLR2 by our 
laboratory, the assessment of sTLR2’s activity as a negative regulator of TLR responses 
and the evaluation of sTLR2’s potential as a therapeutic against inflammatory 
conditions have become the focus of intense research in our laboratory.
1.4.1 Hypotheses
Given that sTLR2 consists of most of TLR2’s extracellular domain, which is 
involved in ligand binding, it was hypothesised that sTLR2 may play a critical role in 
the control of TLR2-mediated responses by acting as a decoy bacterial receptor, thus 
negatively regulating mTLR2 triggering (LeBouder et al., 2003; Liew et al., 2005; 
Kuroishi et al., 2007). Furthermore, given that sTLR2 and sCD14 naturally associate -  
as they co-immunoprecipitate from plasma and milk -  , it is possible that sTLR2 
regulates mTLR2 signalling not only by acting as a decoy receptor, but also by 
interacting with CD 14 (mCD14 or sCD14) and disrupting its co-receptor activity. If this 
possibility were confirmed, identifying the region(s) within the TLR2 ECD involved in
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the interaction with CD 14 would make possible the design of soluble peptides 
incorporating such region(s). It was hypothesised that, by binding to CD14, these 
peptides may disrupt CD14’s co-receptor activity (reducing pro-inflammatory 
responses) while preserving TLR2’s capacity to respond to microbial ligands.
1.4.2 Aims and objectives
This study thus sought to fully assess the negative regulatory capacity of sTLR2, 
shed light on the underlying mechanism, and evaluate the possibility of targeting the 
TLR co-receptor, CD 14, to reduce pro-inflammatory responses. Specifically it was 
planned to:
I. Use the baculovirus expression system to generate sufficient amounts of human 
recombinant sTLR2 to allow for a full assessment of sTLR2’s biological 
activity.
II. Evaluate the extent of sTLR2’s regulatory capacity in vitro, and in vivo by using 
two established mouse models of peritoneal inflammation.
III. Use biochemical and cell imaging approaches to study the mechanism 
underlying sTLR2’s regulatory activity.
IV. Identify the region(s) of the TLR2 ECD that are involved in the interaction with 
CD 14, design peptides incorporating such region(s) and evaluate their capacity 
to disrupt CD14’s co-receptor activity.
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Figure 2.1.1. Generation o f viral DNA coding for His-rhsTLR2
A, Amino acid sequence o f  6x histidine-tagged recombinant human soluble TLR2 (His-rhsTLR2). The sequence 
encompasses amino acids Glu21 to Arg587 o f the human TLR2 protein (black), a cleavage sequence (green), and a 
6x histidine tag (red). B, Phenomenon o f homologous recombination: transfer o f  the His-rhsTLR2 coding cDNA 
sequence from the pMelBac B vector to the viral Bac-N-Blue ™ DNA.
2.1 Production and purification of recombinant human 
soluble TLR2
The assessment of the modulatory capacity of sTLR2 required a considerable 
amount of purified and biologically active soluble protein. Therefore, the first phase of 
this work consisted in the generation of sufficient amounts of recombinant human 
soluble TLR2 (rhsTLR2). It consisted of the full TLR2 ECD, thus resembling the main 
naturally occurring sTLR2 forms found in plasma and milk (LeBouder et al., 2003).
j
2.1.1 Generation of recombinant human sTLR2
The full-length human TLR2 cDNA -  previously prepared in our laboratory 
(LeBouder et al., 2003) -  was used as a template to prepare a construct coding for the 
putative human TLR2 ECD (Glu21-Arg587) and incorporating a 6x histidine tag at the N- 
terminus (Fig. 2.1.1, A and Materials and Methods, section 4.8.1, page 129). The His- 
rhsTLR2 cDNA construct was introduced in the pMelBac B plasmid, and co-transfected 
with the viral DNA (Bac-N-Blue™ DNA) into Spodoptera frugiperda (Sf9) insect cells 
(Materials and Methods, section 4.8.2, page 131). A sequence encompassing the 
polyhedrin promoter (to ensure high transcription levels), the honeybee-melitin signal 
(for high secretion levels) and the in-frame His-rhsTLR2 cDNA was incorporated into 
the viral DNA by homologous recombination (Fig. 2.1.1, B). Following a series of low- 
multiplicity infections to increase the viral titre, High Five insect cells were infected 
with Sf9 culture supernatants of the optimal viral titre (typically, between 5 x 107 and 2 
x 108 PFU/ml) and cultured for three days before the culture supernatant was collected 
and processed in preparation for His-rhsTLR2 purification, as described under
78
G e n e ra tio n  o f  a v ira l v ec to r co n ta in in g  H is-rhsT L R 2 cDNA
Transfection of Sf9 cells with the His-rhsTLR2 cDNA-containing plasmid and the viral DNA 
Homologous recombination (Fig. 2.1.1)
Collection of supernatant from Sf9 transfectants
I
Viral titration and selection of the cells infected with the His-rhsTLR2 cDNA-containing virus,
(plaque assays)
Increase of viral titre in culture supernatants by low-multiplicity infections of Sf9 cells
Production o f  His-rhsTLR2
I
High-multiplicity infection of High Five insect cells with Sf9 supernatant containing
the recombinant virus
I
Harvest of High Five culture supernatant
Purification o f  His-rhsTLR2
I
Concentration and dialysis (binding buffer) of High Five culture supernatant
Metal-affinity chromatography (Ni-NTA)
Resin washing (10 mM Imidazole)
Elution of His-rhsTLR2 (250 mM Imidazole)
Dialysis (PBS) of pooled fractions
Final preparation
I
Protein concentration assay/ SDS-PAGE and Coomassie blue staining/ 
anti-TLR2 and anti-His immunoblotting, cell activation test
Figure 2.1.2. Summary o f the strategy used for the production o f His-rhsTLR2
Diagram showing the main steps for the production o f His-rhsTLR2 (see detailed description under Materials 
and Methods, section 4.8 and 4.9, pages 129-133).
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Figure 2.1.3. Detection of His- rhsTLR2 eluted from Ni-NTA-coated beads
A and B, Elution profile of His-rhsTLR2 following metal (Ni)-affinity chromatography. Ni-NTA-coated beads 
(200 pi) were washed 16 times with 250 pi o f  10 mM imidazole/ binding buffer before elution of the bound 
protein by successive incubations o f  the beads with 200 pi o f  250 mM imidazole/ binding buffer. The elution o f  
His-rhsTLR2 was monitored by Western blotting using an anti-His5 mAb (A) or an anti-TLR2 polyclonal Ab 
(B). W16, 16th wash; F.P., final preparation.
MWM W16 El
Figure 2.1.4. His-rhsTLR2 purification assessed by Coomassie blue staining
A, Coomassie blue staining of the Ni-NTA-coated beads 16th wash (W16) and first 4 eluted fractions (E1-E4). 
Washing and protein elution were as described in Figure 2.1.3. The mobility of molecular weight markers 
(MWM) is shown. B, Coomassie blue staining pattern of rhsTLR2 final preparation (F.P.), corresponding to the 
pooled and dialysed fractions El to E4.
Materials and Methods (section 4.9, page 133). Figure 2.1.2 shows a schematic 
representation of the strategy used to generate His-rhsTLR2.
2.1.2 Purification of recombinant human sTLR2
Histidine-tagged recombinant human sTLR2 was purified from High Five cell 
culture supernatants by metal (Ni)-affinity chromatography, as described under 
Materials and Methods (section 4.9, page 133). Supernatants from High Five cells were 
concentrated, dialysed (binding buffer), and incubated with Ni-NTA coated beads. 
Following extensive washing with binding buffer, the elution of His-rhsTLR2 was 
achieved by increasing the concentration of imidazole in the buffer to 250 mM. The 
elution of His-rhsTLR2 was monitored by Western blotting using anti-His and anti- 
TLR2 specific Abs (Fig. 2.1.3, A and B). Both Abs detected a major -72-kDa 
polypeptide band, whose elution was completed after three or four washes (depending 
on the preparation) of the nickel-coated beads. The anti-TLR2 Ab (TLR2p) detected 
additional sTLR2 polypeptides of -83 and -90 kDa (Fig. 2.1.3, B). The three sTLR2 
isoforms have previously been described, and most likely correspond to partially (-72 
kDa, Iwaki et al., 2002), fully (-83 kDa, LeBouder et al., 2003), and hyperglycosylated 
(-90 kDa, Weber et al., 2004) glycoforms of the TLR2 ECD. The 90-kDa form 
originates by using the baculovirus expression system.
SDS-PAGE followed by Coomassie blue staining was used to monitor the elution of 
His-rhsTLR2 and evaluate the purity of the preparations (Fig. 2.1.4). Consistent with 
the results of the immunoblotting with the anti-TLR2 Ab (Fig. 2.1.3.B), Coomassie blue 
staining of the eluted fractions also showed -90-, -83-, and -72-kDa sTLR2 
polypeptides (Fig. 2.1.4, A), the 90-kDa glycoform was the most prominent. The final
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Figure 2.1.5. Purified sTLR2 preparations do not induce cell activation.
Cells (1 x 105/well) were cultured in the presence of 10 pg/ml of purified rhsTLR2 or the indicated 
concentrations of the synthetic bacterial lipopeptide. The cultures were supplemented with 500 ng/ml (HEK- 
TLR2) or 200 ng/ml (Mono Mac-6) of sCD14. After incubation (16 h), cell supernatants were collected and 
tested for IL-8 by ELISA. Results are the mean of triplicate cultures (±SD included in the bars) of one 
experiment representative of three.
(pooled and dialysed) preparation (F.P.) showed a staining pattern similar to that of the 
eluted fractions (Fig. 2.1.4, B).
The purity of the rhsTLR2 preparations was tested further. The possibility that 
undetected contaminants in the sTLR2 preparations induce cell activation, thus affecting 
the results of biological assays, was investigated. Human embryonic kidney (HEK) 293 
cell transfectants expressing cell-membrane bound TLR2 (HEK-TLR2, previously 
prepared in our laboratory), and Mono Mac-6 human monocytes -  which express a 
number of TLRs constitutively -  were cultured in the presence of a relatively high 
concentration of rhsTLR2 (10 pg/ml) or the TLR2 agonist synthetic bacterial 
lipopeptide Pani3CysK(Lys) 4  (Par^Cys). As shown in Figure 2.1.5, none of the 
different rhsTLR2 batches tested induced cell activation, as measured by the release of 
IL-8. Cell sensitivity to activation was confirmed by the relatively strong stimulation 
induced by ParniCys. This result indicated that the sTLR2 preparations were free of 
contaminants that could trigger cell activation and thus interfere with the in vitro or in 
vivo functional assays. Figure 2.1.2 shows a schematic representation of the strategy 
used to purify His-rhsTLR2.
2.1.3 Discussion
In the first phase of this project, the preparation of recombinant human sTLR2 
was successfully achieved using the baculovirus expression system.
It has been demonstrated that glycosylation is essential for TLR2 and TLR3 
biological activity (Kataoka et al., 2006; Sun et al., 2006). Furthermore, it has been 
shown that glycosylation is required for cell surface expression of TLR4 (Ohnishi et al.,
2003) and secretion of the TLR2 ECD (Weber et al., 2004). Therefore, a strategy
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ensuring not only substantial amounts of protein, but also glycosylation of the mature 
sTLR2 protein had to be used. Given these requirements, mammalian or bacterial {E. 
Coli) expression systems were not considered for the expression of sTLR2, as 
preliminary work in our laboratory indicated a poor expression of sTLR2 in mammalian 
cell systems and E. Coli expression of sTLR2 would result in a non-glycosylated 
protein. The baculovirus expression system was therefore selected to generate rhsTLR2, 
as it ensures production of relatively high levels of a glycosylated protein (Ailor and 
Betenbaugh, 1999; Kost et al., 2005).
The routine production of a considerable, but not substantial, amount of sTLR2 
protein described here -  i.e. 200 pg per 200 ml of High Five cell culture supernatant -  
reflects the difficulties encountered by laboratories that have sought to produce large 
quantities of TLR proteins for in vivo or crystallographic studies. Poor processing, 
aggregation, and/or insufficient levels of ER chaperons seem to affect the production of 
TLR proteins in particular (Ailor and Betenbaugh, 1999).
The purification of His-rhsTLR2 was efficiently achieved using metal (Ni)- 
affinity chromatography. This technique has been widely used for the purification of 
His-tagged proteins, and is based on the high affinity of the interaction between the 
nickel ions immobilised by the NT A groups of the resin and the imidazole rings of the 
histidine residues present in the protein’s tag (Petty, 2001). A relatively high 
concentration of imidazole (here, 250 mM) is then used to dissociate and elute the 
tagged protein from the resin, as imidazole competes with the histidine tag for binding 
to the Ni2+ ions in the resin. A batch, rather than a column procedure was used for 
purification, since batch purification promotes a more efficient binding of the His- 
tagged protein to the resin (Qiagen protein purification handbook, 2003). This was
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critical for the purification of sTLR2, since sTLR2 was present at a low concentration in 
the insect cell culture supernatants. Given the high protein binding capacity of the Ni- 
NTA resin used, only 200 pi of Ni-NTA agarose beads were routinely required to purify 
sTLR2 from 200 ml of cell culture supernatant. By using a small amount of resin, the 
non-specific binding to the beads of irrelevant proteins present in the cell supernatant 
was reduced to a minimum. The use of the column format in purification would have 
required larger amounts of resin, which would have increased non-specific protein 
binding.
The elution profile of sTLR2 was monitored using anti-His and anti-TLR2 Abs, 
and showed a -72-kDa band as the most prominent sTLR2 polypeptide (Fig. 2.1.3, A 
and B). Additional, minor, bands of -83 and -90 kDa were detected by the anti-TLR2 
polyclonal Ab (TLR2p). A lower sensitivity of the anti-His mAb than that of the anti- 
TLR2 polyclonal Ab most likely explains the different rhsTLR2 pattern obtained by 
using the two Abs. By contrast, the Coomassie blue staining of the eluted fractions and 
final preparations showed the -90-kDa sTLR2 glycoform as the main sTLR2 
polypeptide (Fig. 2.1.4, A and B). It is possible that the hyperglycosylation of the 90- 
kDa sTLR2 isoform affected its staining pattern, as well as its detection by the anti- 
TLR2 and -His Abs.
Having achieved the generation and preparation of sTLR2, the issue of its 
biological activity in vitro and in vivo was addressed next.
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Figure 2.2.1. HEK-TLR2 + sTLR2 stable cell transfectants release sTLR2, and express mTLR2 levels similar to 
those of HEK-TLR2 cells. A, Detection of sTLR2 in lOx concentrated HEK-TLR2 + sTLR2 culture supernatants 
(2 x 106 cells) by Western blot (W.B.) using the anti-TLR2 polyclonal Ab, TLR2p, or the anti-cMyc epitope 
mAb, 9E10 (HEK-TLR2 + sTLR2 cells express an N-terminus c-Myc-tagged sTLR2 protein). For control 
experiments, culture supernatants from HEK-TLR2 + empty expression vector (EV) stable cell transfectants 
were tested. B, Fluorescence profiles of mTLR2 expression in HEK-TLR2 and HEK-TLR2 + sTLR2 cell 
transfectants stained with the PE-conjugated anti-TLR2 mAb, TL2.1, or an isotype-matched control IgG.
2.2 Biological activity of sTLR2 in vitro
Following the reported detection by our laboratory of a naturally occuring 
soluble form of human TLR2 in biological fluids (LeBouder et al., 2003), the 
observation that depletion of sTLR2 from plasma renders PMBC more sensitive to 
TLR2-mediated stimulation (LeBouder et al., 2003) indicated that sTLR2 might play an 
important modulatory role in vivo. This prompted us to fully assess the modulatory 
capacity of sTLR2 in vitro and in vivo by making use of the engineered recombinant 
sTLR2
2.2.1 Effect of overexpressing sTLR2 on cell activation
To test for a possible modulatory activity of sTLR2 in vitro, the effect of 
overexpressing sTLR2 on TLR2-mediated cell stimulation was tested first.
Previously generated HEK293 cell transfectants stably expressing either the 
membrane-bound TLR2 (mTLR2) receptor (HEK-TLR2) or both mTLR2 and sTLR2 -  
the latter tagged at the N-terminus with a Myc epitope (HEK-TLR2 + sTLR2) -  were 
analysed by Western blotting with anti-Myc and anti-TLR2 specific Abs and by flow 
cytometry to confirm that the engineered sTLR2 protein was secreted into the medium 
by HEK-TLR2 + sTLR2 cells (Fig. 2.2.1, A) and that the HEK-TLR2 and HEK-TLR2 + 
sTLR2 cells expressed similar levels of mTLR2 (Fig. 2.2.1, B).
Following this initial confirmatory analysis, a comparative study of the sensitivity of 
HEK-TLR2 and HEK-TLR2 + sTLR2 to TLR2-mediated stimulation was performed. 
HEK-TLR2 + sTLR2 cells were found markedly insensitive to stimulation with 
relatively low and high doses of the TLR2 agonist synthetic bacterial lipopeptide 
Parleys, as judged by the release of the pro-inflammatory chemokine IL-8 (CXCL-8;
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Figure 2.2.2. Overexpression of sTLR2 renders cells hyposensitive to TLR2-mediated stimulation.
Triplicate cultures (1.5 x 105 cells/well) of: A, HEK293 cells stably expressing mTLR2 (HEK-TLR2), mTLR2 
and sTLR2 (HEK-TLR2 + sTLR2), or the empty vector (HEK-EV), were stimulated (16h) with the indicated 
concentrations of the TLR2 agonists Pam3Cys. B, HEK-TLR2 cells transiently transfected with the indicated 
amounts of EV or sTLR2 cDNA were stimulated (16h) with 500 ng/ml of Pam3Cys. C, HEK-TLR2 cells 
transiently transfected with 250 ng of sTLR2 cDNA were stimulated (16h) with the indicated concentrations of 
the TLR2 agonists peptidoglycan (PGN) or heat-killed Listeria monocytogenes (HKLM). All cultures were 
supplemented with 500 ng/ml of sCD14. Culture supernatants were tested for IL-8 by ELISA. Results are means 
+SD of one experiment representative of four (A) or three (B and C). The differences in IL-8 release between 
sTLR2 expressing cells and HEK-TLR2, or HEK-TLR2 + EV (B) were compared using the Student’s t test: ***,
p <  0.0001.
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Figure 2.2.3. sTLR2 renders cells hyposensitive to TLR2-mediated stimulation.
The effect o f 5 pg/ml rhsTLR2 was tested in triplicate cultures (1.5 x 10s cells/well) of cells stimulated for 16h or 
24h (mesothelial cells) with the indicated concentrations of Pam3Cys or dilutions of a cell-free supernatant from 
S. epidermidis, termed SES. Cultures were supplemented or not (Mono Mac-6 cells) with 500 ng/ml sCD14. For 
NF-kB reporter assays (D), HEK-TLR2 cells (3 x 105 cells/well) were transiently transfected with firefly and 
Renilla luciferase reporter plasmids. Forty-eight hours post-transfection, the cells were stimulated with Pam3Cys, 
followed by luciferase activity measurements (as described under Materials and Methods, section 4.16, page 
141). Culture supernatants were tested for IL-8 by ELISA. Results shown are of one experiment (±SD) 
representative of at least three. Differences in IL-8 release or NF-kB activity between sTLR2-treated and non­
treated cultures were significant: **,p < 0.01, ***, p < 0.0001
Fig. 2.2.2, A). To test the sTLR2 cDNA dose-dependency of the inhibitory effect, HEK- 
TLR2 cells were transiently transfected with increasing amounts of sTLR2 cDNA and 
activated with Par^Cys. As shown in Figure 2.2.2, B, increasing the amount of sTLR2 
cDNA transfected lead to a concomitant progressive reduction in IL-8 production, 
indicating that sTLR2 inhibitory activity was concentration-dependent.
The hyporesponsiveness of the sTLR2-overexpressing cells was not limited to 
stimulation with Pan^Cys lipopeptide, since the HEK-TLR2 + sTLR2 cells also showed 
reduced responses to the TLR2 agonists peptydoglycan (PGN) and the whole Gram- 
positive bacterium heat-killed Listeria monocytogenes (HKLM; Fig. 2.2.2, C).
2.2.2 The effect of rhsTLR2
Having observed hyporesponsiveness in cells overexpressing sTLR2, the 
modulatory capacity of the purified recombinant sTLR2 protein was evaluated next.
The effect of rhsTLR2 was tested in cell lines and primary cultures of cells that 
exhibit different levels of expression of TLR2 and the co-receptor, CD 14, and thus 
show different sensitivity to activation via TLR2. HEK-TLR2 cell transfectants do not 
express the co-receptor CD 14, but their sensitivity to TLR2 activation can be increased 
by addition of soluble CD14 (sCD14; Fig. 2.2.3, A). The TLR2-mediated release of IL- 
8 by HEK-TLR2 cells was found reduced in the presence of sTLR2, both in the 
presence and absence of sCD14 (Fig. 2.2.3, A).
The inhibitory effect of sTLR2 was also observed in the human monocyte-like cell line, 
Mono Mac-6, which constitutively expresses high and moderate levels of CD 14 and 
TLR2, respectively (Fig. 2.2.3, B).
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Figure 2.2.4. sTLR2 inhibits TLR2-mediated monocyte activation specifically.
Triplicate cultures (1.5 x 105 cells/well) of Mono Mac-6 cells were activated with 200 ng/ml Pam3Cys, 80 pg/ml 
poly I:C, 10 ng/ml LPS, 5 pg/ml flagellin, 5 ng/ml IL-ip, 10 ng/ml TNF-a or 50 ng/ml PMA + 500 ng/ml 
inonomycin in the absence or presence of 5 pg/ml of sTLR2. Results shown are of one experiment (±SD) 
representative of three. Differences in IL-8 release between sTLR2-treated and non-treated cultures were 
significant: ***,p  < 0.0001.
Peritoneal mesothelial cells were also tested. These CD14' cells -  wiiich express low 
levels of mTLR2 -  play a pivotal role during the course of a peritoneal infection -  like 
the one studied here (section 2.3) -  by secreting chemokines that regulate leukocyte 
infiltration into the peritoneal cavity and by expressing adhesion molecules (Topley et 
al., 1996; Park et al., 2007). It was therefore relevant to evaluate the capacity of sTLR2 
to modulate the TLR2-mediated response of these cells. Mesothelial cells were 
stimulated in the presence of sCD14 with Pau^Cys or dilutions of a cell-free 
supernatant prepared from the Gram-positive bacterium, Staphylococcus epidermidis 
(termed SES, see Materials and Methods, section 4.19.1, page 143). In the presence of 
sTLR2, the release of IL-8 -  a typical human neutrophil chemoattractaiil — was found 
reduced (Fig. 2.2.3, C).
TLR activation leads to the activation and nuclear translocadon of the 
transcription factor NF-kB, which in turn induces the transcription of geiffis that code 
for a wide variety of pro-inflammatory cytokines (Doyle and O'Neill, 2006) . An NF-kB 
reporter assay was, thus, used to test whether sTLR2 affects NF-kB aetirvation. The 
activity of the luciferase reporter was found markedly reduced when HEK-TLR2 cells 
were stimulated with Pam3Cys lipopeptide in the presence of sTLR2 (Fig. 2.2.3, D), 
indicating a profound modulatory effect of sTLR2 on NF-kB activation-
2.2.3 Specificity of the sTLR2 modulatory activity
The specificity of the sTLR2 inhibitory effect was evaluated next It was tested 
whether sTLR2 affects human monocyte (Mono Mac-6) activation induced by 
suboptimal doses of the TLR agonists, viral dsRNA mimic polyinosinic-polycytidylic 
acid (poly I:C), LPS and flagellin, which activate cells via TLR3, TLR4 and TLR5,
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Figure 2.2.5. Bacterial clearance mechanisms can be affected by sTLR2 in vitro.
A, Extent of FITC-labelled bacteria bound (0°C) or phagocytosed (37°C) by RAW264 macrophages (4 x 105 
cells) preincubated or not with 5 pg/ml sTLR2 or an irrelevant protein (BSA, 2 x sTLR2 molarity), as 
determined by flow cytometry. Macrophages were incubated with bacteria (bacteriarcell ratio, 10:1) for 30 min 
at the indicated temperature. To distinguish between cell-surface bound and phagocytosed bacteria, the cell- 
surface fluorescence was quenched with trypan blue before flow cytometric analysis. Results are of one 
representative out of three independent experiments. B, Luminol-dependent chemiluminescence generated by 
superoxide produced over the time by triplicate cultures of human neutrophils (PMN, 2 x 105/well) stimulated 
with 5 pg/ml Pam3Cys or 5 x 106 heat-killed S. epidermidis in the absence or presence of 5 pg/ml sTLR2. 
Results are from one representative experiment out of four.
respectively. In addition, the effect of sTLR2 on signalling via the IL-1R (that shares 
with TLRs the MyD88-dependent signalling pathway), the TLR non-related receptor 
TNFa-R, and on non-receptor-mediated cell stimulation (PMA + ionomycin) was 
tested. Figure 2.2.4 shows that only the TLR2-mediated production of IL-8 by 
monocytes was inhibited by sTLR2, indicating that sTLR2 targets monocyte TLR2 
signalling specifically.
2.2.4 The effect of sTLR2 on bacterial clearance mechanisms
In order to extend the assessment of the negative regulatory potential of sTLR2, 
the capacity of sTLR2 to affect typical mechanisms associated with bacterial clearance, 
namely phagocytosis and superoxide production was tested.
2.2.4.A Effect of sTLR2 on phagocytosis
RAW264 macrophages were used to test macrophage phagocytic 
capacity in the absence and presence of sTLR2. To differentiate binding from 
phagocytic uptake of bacteria by the macrophages, the RAW264 cells were incubated 
with FITC-labelled bacteria at 0°C and 37°C in the presence and absence of trypan blue 
to quench cell-surface fluorescence. In this way, the amount of bacteria bound to (0°C, 
trypan blue-sensitive fluorescence) and phagocytosed by (37°C, trypan blue-resistant 
fluorescence) macrophages was evaluated separately. Figure 2.2.5, A shows that sTLR2 
interfered strongly with the macrophage binding (0°C) of a typical Gram-positive 
bacterium, Staphylococcus aureus. The effect of sTLR2 on phagocytosis (37°C) was 
however comparatively modest.
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2.2.4.B Effect of sTLR2 on superoxide production
Freshly-isolated human neutrophils were used to test the effect of 
sTLR2 on microbial-induced superoxide production (Fig. 2.2.5, B). Upon stimulation 
with Pan^Cys or whole heat-killed S. epidermidis, the production of superoxide by 
neutrophils showed a rapid increase for approximately 40 min (Pani3Cys) or 30 min (S. 
epidermidis). In the presence of sTLR2, however, the capacity of neutrophils to 
generate superoxide over time in response to either Pair^Cys or S. epidermidis was 
substantially reduced.
2.2.5 Discussion
Collectively, the in vitro data described in this section demonstrated the potential 
of sTLR2 to negatively regulate TLR2-mediated cell signalling and effector functions 
that are critical during microbial infection.
sTLR2 was found to modulate the TLR2-mediated responses induced by 
microbial components and whole Gram-positive bacteria in a variety of cells, including 
peritoneal mesothelial cells. These cells are known to play a pivotal role during a 
peritoneal infection -  like the one studied in this project (section 2.3) -  by regulating 
leukocyte infiltration into the peritoneum. Thus, these results suggest that during 
peritoneal infections sTLR2 may also target mesothelial cells for negative regulation.
sTLR2’s inhibitory effect was found to be stronger when sTLR2 was 
overexpressed in cell transfectants than when it was exogenously added as a purified 
protein. This may reflect a difference in sTLR2 local concentration in the two model 
systems. Exogenous rhsTLR2 may be degraded over time, whereas overexpression of
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sTLR2 may ensure that the local concentration of sTLR2 remains relatively high 
throughout the activation period, hence the more efficient inhibitory effect. The 
modulatory effect was not limited to the release of IL-8, since NF-kB activation was 
markedly affected by sTLR2, indicating that sTLR2 has a wide spectrum of effects. 
Furthermore, sTLR2 also demonstrated the capacity to modulate phagocytosis and 
superoxide production -  two effector functions that are critical for microbial clearance. 
The effect on the phagocytic uptake of bacteria (37°C) was modest compared to that on 
binding (0°C) and, most probably, a consequence of the marked effect on bacterial 
binding. It is likely that, at 37°C, the activity of typical phagocytic receptors (e.g. 
scavenger receptors, C-type lectins) compensated for the interfering effect of sTLR2, 
hence the relatively low effect of sTLR2 on phagocytosis. It should be noted that to 
assess sTLR2’s full potential as a regulator of the phagocytic process, the experiments 
were performed in serum-free medium, thereby excluding the contribution of Fc and/or 
complement receptors. It is likely that in vivo these mediators of phagocytosis 
compensate for the inhibitory capacity of sTLR2. Consistent with this possibility, we 
observed that the negative effect of sTLR2 on phagocytosis is significantly reduced in 
the presence of serum (data not shown).
The modulatory capacity of sTLR2 observed in vitro posed the question of its 
activity in vivo. This question was addressed in the next phase of the project.
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Figure 2.3.1. sTLR2 affects PMN recruitment in a mouse peritoneal inflammation model.
Mice were injected i.p. with a defined dose of a cell-free supernatant from S. epidermidis (SES), SES + 100 ng 
sTLR2 or the indicated controls. At the indicated time points, the peritoneal cavity was lavaged and profiles of 
chemokine expression in the lavages were determined by ELISA. To determine cell numbers, differential cell 
counts on cytospin preparations were performed (B, right; results from four independent experiments are shown) 
or leukocytes were double stained with anti-F4/80-FITC and -CDllb-APC mAbs and analysed by flow 
cytometry (B and C, time courses). Values in A-C are expressed as the mean ±SEM (n=5/condition; * ,p  < 0.05, 
** ,p  < 0.01; ***,/? < 0.0001 SES + sTLR2 versus SES).
2.3 Biological activity of sTLR2 in vivo
2.3.1 Effect of sTLR2 on leukocyte recruitment
In order to evaluate the biological activity of sTLR2 and assess its potential as 
modulator of inflammation in vivo, the effect of sTLR2 on a well-established mouse 
model of acute peritoneal inflammation (Hurst et al., 2001; McLoughlin et al., 2003) 
was tested. This model is based on the intraperitoneal (i.p.) administration of a defined 
dose of a cell-free supernatant from S. epidermidis, termed SES. In this way, the 
progression of a S. epidermidis-induced peritonitis episode -  typically seen in end-stage 
renal failure patients on continuous ambulatory peritoneal dialysis -  is mimicked 
(Topley et al., 1996).
The SES-induced acute peritoneal inflammation was monitored over the time by 
determining the leukocyte count and the chemokine levels in the peritoneal lavages. As 
shown in Figure 2.3.1, A, intraperitoneal administration of SES to mice resulted in a 
fast and transient increase in the peritoneal levels of the neutrophil (PMN) 
chemoattractants, keratinocyte-derived chemokine (KC) and macrophage inflammatory 
protein-2 (MIP-2) -  murine functional counterparts of human IL-8 and GRO-a -  with 
peak levels occurring at 1 h post-injection. Corresponding determinations of PMN 
numbers recruited to the peritoneal cavity showed peak levels at 2-3 h (depending on 
the experiment) after SES administration (Fig. 2.3.1, B, left). The simultaneous 
administration of SES and sTLR2 (100 ng/mouse) resulted in reduced levels of KC and 
MIP-2. These levels were significantly reduced in the case of KC, but not MIP-2 (Fig.
2.3.1, A). Consistent with the inhibitory effect on PMN chemoattractants, sTLR2 
administration resulted in a marked reduction in PMN numbers recruited to the
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Figure 2.3.2. sTLR2 affects late apoptotic PMN numbers in a mouse peritoneal inflammation model.
Acute peritoneal inflammation in mice was induced with SES as described in Fig. 2.3.1. At the peak time of 
PMN influx (shown, 3 h), leukocytes present in the peritoneal lavages were annexin V-FITC/ propidium iodide 
(PI) stained and analysed by flow cytometry. The representative scatter plots shown are from analyses of gated 
PMN. Apoptotic cells were identified according to the annexin V+/PI' (lower right quadrant, early apoptosis) and 
annexin V+/PI+ (upper right quadrant, late apoptosis/necrosis) staining. The percentage of cells in the apoptotic 
quadrants is shown (mean ±SEM, n=5/condition; ***,p < 0.0001, significant reduction versus SES).
peritoneum either over the time course (Fig. 2.3.1, B, left) or at the peak time of their 
influx (Fig. 2.3.1, B, right).
The effect of sTLR2 on the SES-induced release of the mononuclear cell (MNC) 
chemoattractant, monocyte chemoattractant protein-1 (MCP-1), and on the subsequent 
recruitment of monocytes/macrophages was also tested. Figure 2.3.1, C shows that 
induction of MCP-1 reached a maximum level 2 h after injection of SES (left panel), 
and that the consequent recruitment of monocytes/macrophages reached peak levels 
approximately twenty two hours later (right panel). Notably, in this case, sTLR2 was 
found to exert a positive and significant effect on MCP-1 levels over the time period 
post-SES injection. The relatively late recruitment of MNC, however, was not found to 
be affected.
2.3.2 Effect of sTLR2 on PMN apoptosis
As macrophages are responsible for the removal of the dying PMN, the 
suppressive effect of sTLR2 on early (PMN), but not late (MNC) leukocyte recruitment 
posed the question of whether such a disproportionate leukocyte influx influences PMN 
survival and thus inflammatory resolution. Therefore, the apoptotic status of PMN at the 
peak of their peritoneal influx in SES-challenged mice was compared with that in mice 
challenged with SES + sTLR2. One of the earliest indications of apoptosis is the 
translocation of the membrane phospholipid phosphatidylserine from the inner to the 
outer leaflet of the plasma membrane, thus rendering binding sites on 
phosphatidylserine available to the protein annexin V, which binds to 
phosphatidylserine with high affinity. Thus, positive staining with annexin V indicates 
early or late cell apoptosis. During late apoptosis or early necrosis, propidium iodide
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Figure 2.3.3. Detection of mouse sTLR2 in mice peritoneal lavages.
Acute peritoneal inflammation in mice was induced with SES as described in Fig 2.3.1. In A, mouse sTLR2, but 
not His-rhsTLR2, was detected in the peritoneal lavages of mice i.p. inoculated with SES + 100 ng sTLR2. 
Western blot analysis was performed with an anti-His5 mAb or the anti-TLR2 polyclonal Ab, TLR2p. Purified 
His-rhsTLR2 (10 ng) was included as positive control (left track). Representative mouse sTLR2 detection from 
3h post-inoculation lavages is shown. B, The specificity of sTLR2 detection in the peritoneal lavages was 
confirmed by performing peptide competition by immunoblotting. The TLR2p Ab was preincubated (+) or not (- 
) with lOx mass excess of the peptide used for immunisation, and the samples were analysed by Western blotting 
with the TLR2p Ab. C, Western blot analysis of aliquots of peritoneal lavages taken at the indicated time points 
and tested for mouse sTLR2 release by blotting with the anti-TLR2 polyclonal Ab, TLR2p. Densitometric 
scanning of sTLR2 levels at the peak of PMN influx (3 h) is shown (right; n=5/condition,; *, p  < 0.05, SES + 
sTLR2 versus SES).
(PI) -  a fluorescent DNA intercalating agent -  can stain DNA, as it becomes accessible 
due to the loss of integrity of the plasma membrane.
Cells from lavages obtained at the peak time point of PMN recruitment (3 h) 
were double-stained with annexin V-FITC and PI, and gated PMN were analysed by 
flow cytometry (Fig. 2.3.2). Profile comparison of the annexin V/PI scatter plots 
showed no significant difference in the proportion of early apoptotic PMN (annexin V 
positive/PI negative, lower right quadrant) between SES- and SES + sTLR2-treated 
mice. Examination of the proportion of late apoptotic/early necrotic PMN (annexin V 
positive/PI positive, upper right quadrant), however, showed a marked reduction (~ 
50%) of their numbers in the SES + sTLR2-treated mice.
2.3.3 Effect of sTLR2 on the release of endogenous sTLR2
The effect of administering sTLR2 together with SES to mice on the levels of 
endogenous (mouse) sTLR2 in the peritoneal lavages was also tested, as our laboratory 
and others have demonstrated that sTLR2 release is affected by cell activation and 
infection (LeBouder et al., 2003; Heggelund et al., 2004; Kuroishi et al., 2007; 
Srinivasan et al., 2008). The detection of endogenous sTLR2 was facilitated by the 
absence of exogenous sTLR2 (His-rhsTLR2) in the peritoneal lavages (Fig. 2.3.3, A). 
The specificity of the detection was confirmed by the negative results of 
immunoblottings in the presence of the TLR2 peptide used to immunise the mice and 
generate the polyclonal anti-TLR2 Ab (TLR2p) used in this study (Fig. 2.3.3, B).
At 1 h post-injection, no differences in the levels of sTLR2 between SES- and SES + 
sTLR2-challenged mice were observed (Fig. 2.3.3, C). At 3 h, i.e. when PMN influx 
was high, mouse sTLR2 levels in the peritoneal lavages of the sTLR2-treated mice were
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Figure 2.3.4. sTLR2 reduces peritoneal PMN infiltration without compromising bacterial clearance.
Mice (n=5/condition) were i.p. inoculated with 5 x 107 CFU S. epidermidis alone or together with 100 ng sTLR2. 
At the indicated times, mice were sacrificed, blood samples were obtained by cardiac puncture and the peritoneal 
cavity was lavaged. PMN numbers in the lavages (A) were determined by differential cell counts on cytospin 
preparations. Bacterial titres in the peritoneal fluid and blood (B) were determined as described under Material 
& Methods (section 4.19.3 page 145). Values in A are expressed as the mean ±SEM (n=5/condition; ***, p  < 
0.0001, S epi. + sTLR2 versus S. epi.).
found increased. By 6 h post-injection, sTLR2 levels between sTLR2-treated and non­
treated mice were comparable and similar to those at the 1 h time point.
2.3.4 Effect of sTLR2 in a live infection model
The anti-inflammatory effects of sTLR2 observed in vivo using the SES model 
of mouse peritoneal inflammation raised the question of whether such negative effects 
would be detrimental to bacterial clearance during infection. To address this issue, an 
experimental model of acute peritoneal inflammation consisting of an i.p. challenge 
with live S. epidermidis in the absence or presence of sTLR2 was used. An innoculum 
of 5 x 107 CFU of S. epidermidis per mouse was administered. This dose allowed the 
mice to clear the infection almost completely by 12 h. PMN numbers in the peritoneum 
of mice injected with S. epidermidis showed peak levels at 12 h post-injection (Fig.
2.3.4, A, inset). In the presence of sTLR2, peritoneal neutrophil accumulation at the 
peak time of their influx was found significantly reduced (Fig. 2.3.4, A).
Having confirmed that sTLR2 exerts a negative regulatory effect on peritoneal 
inflammation during a live infection, a possible effect of sTLR2 on bacterial clearance 
was evaluated next. The bacterial load in the peritoneal cavity and blood over the 12 h 
period post-infection in the mice injected with S. epidermidis and S. epidermidis + 
sTLR2 was compared. No difference in bacterial count either in the peritoneal cavity or 
blood between sTLR2-treated and -non-treated mice was observed (Fig. 2.3.4, B).
2.3.5 Discussion
By using two mouse models of acute peritoneal inflammation, it was established 
that administration of sTLR2 reduced the level of PMN recruitment to the peritoneal
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cavity in animals challenged with either Gram-positive bacteria-derived microbial 
components or live Gram-positive bacteria.
In spite of sTLR2’s ability to control the inflammatory response, and its in vitro 
capacity to interfere with the phagocytic uptake of bacteria and bacteria-induced 
superoxide production, sTLR2 administration did not have a negative effect on the 
clearance of bacteria. This is likely to be due in part to the fact that TLR2 does not seem 
to play a critical role in bacterial clearance. Indeed, initial studies with TLR2- and 
MyD88-deficient mice indicated that TLR2 plays a role in the inflammatory response 
and bacterial clearance only at a high bacterial dose, and that other receptors might be 
involved (Takeuchi et al., 2000a). Subsequent studies with TLR2-deficient mice 
challenged with S. pneumonias (Knapp et al., 2004) or S. aureus (Mullaly and Kubes, 
2006) clearly demonstrated that TLR2 plays a critical role in the inflammatory response, 
but not in clearing the infection. Notably, a pivotal role for C5aR in bacterial clearance 
was demonstrated instead (Mullaly and Kubes, 2006). Additional recent work on the 
activity of the mycoplasma-derived FSL-1 lipopeptide in phagocytosis of bacteria also 
supported the conclusion that TLR2 does not function as a phagocytic receptor and is 
not involved in bacterial clearance (Mae et al., 2007). Furthermore, a number of 
humoral mediators that contribute to efficient bacterial clearance and killing, including 
complement components, mannose-binding lectin and immunoglobulins (Igs) as well as 
cell-surface Fc and scavenger receptors may counteract the activity of sTLR2. 
Consistent with this possibility is the observation that the negative effect of sTLR2 on 
phagocytosis in vitro described in this study was significantly reduced in the presence of 
serum. The possibility that sTLR2 affects bacterial clearance in certain pathologies (e.g.
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complement deficiency) or when higher bacterial doses are used, however, remains to 
be investigated. Notably, preliminary experiments conducted very recently did not show 
the modulatory effect of sTLR2 on PMN recruitment at early time points -  i.e 3h and 6h 
-  post-infection with live S. epidermidis. Confirmation of this finding would indicate 
that sTLR2 affects PMN recruitment only at the peak (12 h) of their influx, when the 
animals had cleared the infection almost completely (see Fig. 2.3.4).
Consistent with its negative effect on PMN recruitment, sTLR2 exerted a 
negative effect on the two major murine neutrophil chemoattractants, KC and MIP-2 
(Kobayashi, 2006). The effect on KC was marked and significant, whereas that on MIP- 
2 was very modest and statistically not significant. In this model of peritoneal infection, 
the marked effect on KC appeared to be sufficient to impact on PMN recruitment. There 
is conflicting evidence as to the individual importance of KC and MIP-2 in neutrophil 
recruitment. While studies on the effect of administering recombinant KC or MIP-2 in 
models of inflammation showed that each chemokine can cause substantial PMN influx, 
but that MIP-2 is the most efficient (McColl and Clark-Lewis, 1999; Zwijnenburg et al., 
2003), other studies showed that KC is the most important PMN chemoattractant in the 
response to Klebsiella and Aspergillus lung infections (Tsai et al., 1998; Mehrad et al., 
1999), fibrosis (Keane and Strieter, 1999), and atherosclerosis (Huo et al., 2001).
The reason for the very modest effect of sTLR2 on MIP-2 compared with that on KC is 
not known at present. It may be related to the recently reported finding that KC and 
MIP-2 synthesis is induced via TLRs through the MyD88-dependent pathway, but that 
MIP-2, not KC, is also synthetised as a direct product of the alternative TLR signalling 
pathway that uses TRIF as the adaptor protein (De Filippo et al., 2008). This pathway is
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selectively triggered by TLR3 and TLR4 -  but not TLR2 -  ligands, and thus cannot be 
affected by sTLR2.
By contrast to its inhibitory effect on PMN mobilisation to the site of injury, 
sTLR2 did not influence the recruitment of macrophages to the peritoneal cavity, 
despite causing increased production of MCP-1. Additional effects of sTLR2 on the 
complex chemokine network controlling MNC recruitment most likely account for 
these observations. Indeed, recent work using mouse models of pulmonary 
pneumococcal infections (Fillion et al., 2001; Dessing et al., 2006) and haemolitic- 
uremic syndrome (Keepers et al., 2007) demonstrated that the chemokines regulated 
upon activation, normal T-cell expressed, and secreted (RANTES/CCL-5) and 
macrophage inflammatory protein-la (MIP-la/CCL-3) also play a direct and substantial 
role in inducing monocyte/macrophage infiltration to the site of infection. It is thus 
possible that the positive effect of sTLR2 on MCP-1 is compensated for by these other 
mediators, whose production may have been negatively affected by sTLR2. 
Alternatively, sTLR2 may have negatively affected the expression of the MCP-1 
receptor, CCR-2. Further investigation will thus be required to test whether sTLR2 
affects RANTES and/or MIP-la production and CCR-2 expression, as well as to define 
the mechanism underlying the positive effect of sTLR2 on MCP-1 production. 
Nevertheless, the differential effect of sTLR2 on early (PMN) and late (macrophages) 
leukocyte recruitment, and the consequent skewing of the leukocyte influx in favour of 
the macrophages, appears to promote the more efficient removal of senescent PMN, as 
indicated by the substantially reduced proportion of late apoptotic/early necrotic PMN 
found in the peritoneal cavity of sTLR2-treated mice. This effect might ultimately 
favour more rapid resolution of inflammation.
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Notably, at the peak of PMN influx, mouse sTLR2 levels in the peritoneal 
lavages of the sTLR2-treated mice were found to have increased. The mechanism 
responsible for this positive effect of sTLR2 remains to be investigated. Nevertheless, 
this finding suggests that the administration of sTLR2 together with SES induced a 
positive feedback for the release of sTLR2, resulting in transiently higher local 
concentrations of endogenous sTLR2, which may well contribute to maintaining its 
regulatory effect on inflammation.
The modulatory capacity of sTLR2 observed in vivo and in vitro demanded 
further investigation of the underlying mechanisms. This issue was addressed in the 
next phase of this project.
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2.4 Study of the mechanism underlying sTLR2 activity
The fact that sTLR2 did not affect signalling via other TLRs, the IL-1R and non- 
TLR related receptors, or non-receptor-mediated signalling, suggested that the primary 
effect of sTLR2 is exerted upstream of signalling, proximal to TLR2 ligand recognition. 
To test this possibility, the capacity of sTLR2 to: 1) affect the mobilisation of TLR2 to 
lipid rafts, 2) act as a decoy receptor and, 3) disrupt the interaction between mTLR2 and 
mCD14 was tested.
2.4.1 Effect of sTLR2 on the mobilisation of mTLR2 to lipid 
rafts
It has been demonstrated that the TLR co-receptor CD 14 resides mainly in 
cholesterol and sphingolipid-rich detergent-resistant membrane microdomains, termed 
lipid rafts (Triantafilou et al., 2002). It has also been shown that, in resting conditions, 
TLR2 and TLR4 are localised mainly outside the lipid rafts in the detergent-soluble 
membrane fractions. Upon TLR ligand-induced cell stimulation, the specific TLR is 
recruited to lipid rafts where it is found in close proximity to CD 14 and other cell- 
surface molecules, thus forming a receptor cluster. The ligand-induced mobilisation of 
TLR2 and TLR4 to lipid rafts and their close proximity to CD 14 is believed to be 
critical for signalling (Pfeiffer et al., 2001; Triantafilou et al., 2004; Triantafilou et al., 
2006). It was therefore tested whether sTLR2 inhibited TLR2 triggering by affecting the 
ligand-induced clustering of mCD14 and mTLR2 in lipid rafts. Freshly-isolated human 
monocytes were PamsCys-stimulated in the presence or absence of sTLR2, and the cell 
lysates subjected to sucrose density gradient centrifugation. By this procedure, the high-
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Figure 2.4.1. sTLR2 prevents the ligand-induced mobilisation of mTLR2 to lipid rafts.
mCD14 and mTLR2 partitioning into lipid raft and non-raft fractions following stimulation of freshly-isolated 
monocytes (1 x 108 cells) with 5 pg/ml Pam3Cys in the absence or presence of 5 pg/ml sTLR2. Triton X-100 cell 
lysates were subjected to sucrose density gradient centrifugation. Fractions were then collected from the top of 
the gradient and analysed by Western blotting with anti-CD 14 (MY4) or anti-TLR2 (IMG319) mAbs. Dot blots 
(top) were used to determine the position of the raft marker - GM1 ganglioside - in the gradient, as detected by 
the binding of HRP-conjugated cholera toxin B. Similar results to those shown were obtained from four 
independent experiments.
density, detergent-soluble, subcellular fractions move to the lower fractions of the 
gradient, whereas the low-density, detergent-insoluble fractions -  which include lipid 
rafts -  move to the top of the gradient. To define the lipid raft-containing fractions in 
the sucrose gradient more precisely, aliquots of each fraction were analysed by dot 
blotting to determine the presence of the raft-associated ganglioside, GM1. As shown in 
Figure 2.4.1 (top), GM1 was detected in the fraction 2 of the gradient, thus indicating 
that lipid rafts were mainly located in this fraction. However, due to the heterogeneity 
of the lipid rafts, they may locate not in a single but in neighbouring fractions of the 
gradient.
Analysis of lipid raft preparations from non-stimulated (control) monocytes confirmed 
the preferential association of mCD14 with lipid rafts and mTLR2 with detergent- 
soluble (non-raft) fractions (Fig. 2.4.1, upper panels). Par^Cys stimulation resulted in 
an enrichment of mTLR2 in lipid rafts and reduced levels of mCD14 (Fig. 2.4.1, middle 
panels), most likely as a consequence of the activation-induced shedding of soluble 
CD 14 (Durieux et al., 1994). However, when cells were stimulated in the presence of 
sTLR2, the pattern of mCD14 and mTLR2 partition into membrane domains resembled 
that in non-stimulated cells (Fig. 2.4.1, lower panels), indicating that sTLR2 interferes 
with the ligand-induced mTLR2 mobilisation to lipid rafts for signalling, and 
consequently with the approximation of mTLR2 to mCD14 in the rafts.
2.4.2 Decoy bacterial receptor activity of sTLR2
A decoy activity would explain, at least in part, the interfering effect of sTLR2 
on the mTLR2 mobilisation to lipid rafts described previously. This possibility was 
tested, and it was found that sTLR2, but not an irrelevant control protein (CD46), binds
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Figure 2.4.2. sTLR2 can act as a decoy receptor.
A, Triplicate microtiter wells were coated with the indicated amounts of Pam3Cys or LPS and incubated (4h, 
37°C) with 5 pg/ml of His-rhsTLR2 or irrelevant control protein (CD46-Fc). His-rhsTLR2 bound to the wells 
was detected by incubation with an anti-His5 mAb followed by a biotin-conjugated anti-mouse IgG Ab, and 
CD46-Fc was detected with a biotin-conjugated anti-human IgG Ab, as described under Materials & Methods. 
All wells were incubated with streptavidin-HRP and then substrate. Colour development was measured at 450 
nm. B, Binding of sTLR2-Fc or irrelevant (CD46-Fc) fusion proteins (1 pg) to S. epidermidis (5 x 104) was 
tested for 30 min at room temperature. Bound protein was detected with a biotin-conjugated anti-IgG Ab 
followed by streptavidin-APC and analysis by flow cytometry, as described under Materials & Methods. 
Binding results are from one experiment representative of three (Pam3Cys) or five (5. epidermidis) experiments.
Pam3Cys lipopeptide in a ligand-concentration-dependent and saturable manner (Fig.
2.4.2, A), confirming previous reports (Iwaki et al., 2002; Vasselon et al., 2004). The 
interaction of sTLR2 with whole bacteria was also tested. A sTLR2-Fc fusion protein, 
but not an irrelevant control, specifically bound heat-killed S. epidermidis (Fig. 2.4.2, 
B).
2.4.3 Effect of sTLR2 on the natural association of mTLR.2 with 
mCD14
The ectodomain of TLR2 has been shown to interact with CD 14 (Iwaki et al., 
2005) and sTLR2 was found to co-immunoprecipitate with sCD14 from milk and 
plasma (LeBouder et al., 2003). It was therefore speculated that sTLR2 may also disrupt 
the close proximity of mCD14 to mTLR2 directly -  i.e. in the absence of ligand -  by 
interacting with mCD14. Alternatively, sTLR2 may interact with mTLR2 
(homodimerisation). To test these possibilities, co-immunoprecipitation experiments, 
FRET analysis and chemical crosslinking strategies were performed.
2.4.3.A Effect of sTLR2 on the co-immunoprecipitation of 
mCD14 and mTLR2
First, the effect of sTLR2 on the ligand-independent natural 
association of mTLR2 with mCD14 in the detergent-soluble fractions of normal human 
monocytes lysates was examined. As shown in Figure 2.4.3, A, the typical -110-kDa 
mTLR2 polypeptide band (LeBouder et al., 2003) was consistently detected by Western 
blotting in mCD14 immunoprecipitates from monocyte cell lysates (left track). In 
addition, faint TLR2 polypeptide bands most likely corresponding to an intracellular
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Figure 2.4.4. sTLR2 associates with the co-receptor mCD14, but not with mTLR2.
The indicated cells were incubated with 5 pg His-sTLR2 or irrelevant control protein His-sCD55. Crosslinking 
was carried out with the membrane-impermeable, non-cleavable crosslinker, BS3, as described under M aterials 
and M ethods (section 4.11 page 135). Crosslinked His-tagged proteins in the cell lysates were pulled-down by 
Ni-NTA precipitation, and the precipitates analysed by Western blotting with anti-CD14 (69.4) or -TLR2 
(sc8689) polyclonal Abs. Head arrows point at Ni-NTA-precipitated, CD14-crosslinked, polypeptide bands. 
Upper panels shows the mobility of sTLR2, mCD14 and mTLR2 monomers pulled-down (sTLR2) or 
immunoprecipitated (mCD14, mTLR2) from purified stock or CHO-CD14 and CHO-TLR2 transfectants, 
respectively. Results are representative of three crosslinking experiments.
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Figure 2.4.3. sTLR2 disrupts the natural association of mTLR2 with the co-receptor CD14.
A, Anti-TLR2 (IMG319 mAb) Western blots (W.B.) o f CD14 immunoprecipitates (MY4 mAb) from cell lysates 
of freshly-isolated human monocytes incubated with 5 pg/ml sTLR2, 10 pg/ml BSA or left untreated. Monocyte 
preparations from four donors gave identical results to those shown. H, mouse Ig heavy chain. B, FRET analysis 
were carried out on freshly-isolated monocytes incubated for lh in the absence or presence o f 5 pg/ml sTLR2 or 
BSA before labelling with the anti-CD 14 mAb MY4-Cy3 (acceptor) and anti-TLR2 mAb TL2.5-Alexa 488 
(donor). FRET between TLR2 and CD 14 was determined by the increase in donor fluorescence after acceptor 
photobleaching, as detailed under Materials & Methods. The threshold for significant FRET was determined 
with the acceptor isotype-matched control IgG2b-Cy3. Results are from five independent experiments.
('95 kDa) glycoform of the mature protein and to fully glycosylated ('83 kDa) and 
intracellularly located sTLR2 (LeBouder et al., 2003) were detected. The '110-kDa 
mTLR2 polypeptide band was not detected when the co-immunoprecipitation 
experiments were performed following preincubation of monocytes with sTLR2 (Fig.
2.4.3, A, middle track). This disrupting effect was specific of sTLR2, as it could not be 
reproduced using an irrelevant protein, BSA (Fig. 2.4.3, A, right track). These findings 
indicated that sTLR2 interfered with the natural association of mCD14 with mTLR2. 
The fact that sTLR2 did not prevent the co-immunoprecipitation of the intracellular 
forms of TLR2 with CD 14 suggested that such interference takes place at the cell 
surface.
2.4.3.B Effect of sTLR2 on the interaction between mCD14
and mTLR2
Confirming evidence of sTLR2’s interfering effect on the mCD14- 
mTLR2 interaction was obtained by fluorescence resonance energy transfer (FRET) 
studies. FRET was used as it allows for the evaluation of interactions between 
neighbouring molecules by determining their proximity within <10 nm range. FRET 
results from the (non-radioactive) transfer of energy from an excited donor to an 
acceptor fluorophore (Kenworthy, 2001). Here, FRET efficiency was measured between 
the anti-TLR2-Alexa488 (donor) and anti-CD 14-Cy3 (acceptor) mAbs, used to label 
mTLR2 and mCD14, following dequenching of donor fluorescence after 
photobleaching of the acceptor fluorophore. An increase in mTLR2 (donor, green) 
fluorescence after mCD14 (acceptor, red) photobleaching was detected in monocytes, 
indicating energy transfer, and thus close proximity between the two molecules (Fig.
100
H is-sTLR 2 C H 0-C D 14  C H 0-T L R 2 kDa——
150 -
100 - -  250
-  150
-  100
Pull-down/ I.P.: N i-NTA anti-CD14 anti-TLR2
W.B.: anti-TLR2 anti-CD 14 anti-TLR2
B S^ crosslinking
1---------------------------------------------------------------
CHO CHO CHO
CHO CD14 CD 14 TLR2
kDa
250 
150
100
Pull-down:   Ni -N TA  --------------------------------
W.B.:   anti -CD 14   an ti-T L R 2
+ H is-sTLR 2 + H is-sTLR2 + H is-sCD 55 + His-:
Figure 2.4.4. sTLR2 associates w ith the co-receptor m CD14, but not w ith m TLR2.
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2.4.3, B, upper panel). This was in agreement with the results of the co- 
immunoprecipitation experiments. In the presence of sTLR2, however, no increase in 
TLR2 fluorescence after mCD14 photobleaching was observed, and FRET efficiency 
between mTLR2 and mCD14 was reduced to almost background levels, i.e. 2% FRET, 
threshold for significant energy transfer defined with the acceptor isotype-matched 
control IgG2b-Cy3 (Fig. 2.4.3, B, lower panel). These findings thus confirmed that 
sTLR2 perturbs the mCD14-mTLR2 interaction.
2.4.3.C Association of sTLR2 with the co-receptor CD 14
The interfering effect exerted by sTLR2 in the absence of ligand 
raised the question of whether this effect results from an interaction of sTLR2 with 
mCD14 and/or mTLR2. To address this issue, chemical crosslinking experiments were 
performed. CHO, CHO-CD14 and CHO-TLR2 transfectant cells were incubated with 
His-sTLR2 or an irrelevant His-tagged soluble protein. Subsequently, a non-cleavable, 
membrane-impermeable, crosslinking reagent, BS3, was used to stabilise potential 
interactions between cell-surface molecules. The cells were then washed, lysed, and 
crosslinked His-sTLR2 in the cell lysates was pulled-down using Ni-NTA-coated beads. 
The precipitates were tested by Western blotting for the presence of CD 14 (CHO and 
CHO-CD14 cells) or TLR2 (CHO-TLR2 cells). Western blot analysis of control 
precipitates of His-sTLR2 (from purified stock), mCD14 and mTLR2 (from CHO- 
CD14 and CHO-TLR2 cell transfectants, respectively) showed bands of the expected 
sizes, -72kDa (His-sTLR2), -55 kDa (mCD14) and -110 kDa (mTLR2; Fig. 2.4.4, 
upper panels). Incubation of CHO-CD14 transfectants with His-sTLR2 followed by 
chemical crosslinking, Ni-NTA-bead pull-down from the CHO-CD14 cell lysates, and
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anti-CD14 Western blotting revealed bands of - 125-130 kDa and -250 kDa, i.e. of 
lower mobility than that of mCD14 (Fig. 2.4.4, lower panels). The size of these bands 
was consistent with that estimated for CD14/sTLR2 heterodimers (-72+-55=-127 kDa) 
and CD14/sTLR2 dimer of dimers (-254 kDa). To test for an interaction of sTLR2 with 
mTLR2, the same crosslinking strategy was applied to CHO-TLR2 cell transfectants 
preincubated with His-sTLR2. Here, however, Ni-NTA-bead pull-down followed by 
anti-TLR2 immunoblotting did not show any crosslinked TLR2 polypeptide band (Fig.
2.4.4, right track).
2.4.4 Discussion
The results presented in this section indicate that sTLR2 can act as a decoy 
bacterial receptor and also disrupt the close proximity between the co-receptor, CD 14, 
and the receptor, TLR2 -  which is critical to efficient signalling. Such disruption is 
likely to result from the capacity of sTLR2 to interact with CD 14.
The results of the in vitro studies presented in section 2.2 suggested that the 
primary effect of sTLR2 is exerted upstream of signalling, proximal to ligand 
recognition. It was therefore tested whether sTLR2 affects the ligand-induced clustering 
of mCD14 and mTLR2 in lipid rafts, which is believed to be critical to signalling. It was 
found that sTLR2 indeed interferes with the ligand-induced mobilisation of mTLR2 to 
lipid rafts. Such interference would be explained, at least in part, by the sTLR2’s 
capacity to act as a decoy microbial receptor, as demonstrated in this study. However, it 
was also found that sTLR2 disrupts the close proximity of mCD14 to mTLR2 in the 
absence of ligand by associating with mCD14, as indicated by the co-
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Figure 2.4.5. Postulated m echanism s underly ing sTLR2 inhibitory activity.
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B, sTLR2 m ay m odulate T LR 2 triggering  by associa ting  w ith m C D 14 and/or sC D 14 and disrup ting  the close 
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immunoprecipitation, FRET and chemical crosslinking experiments. Such close 
proximity is crucial to CD14’s co-receptor function and highly efficient TLR2 
signalling. Thus, sTLR2’s capacity to interfere with the mCD14-mTLR2 interaction and 
disrupt the co-receptor function by associating with CD 14, together with sTLR2’s 
decoy receptor activity may affect the mobilisation of mTLR2 to lipid rafts for 
signalling upon cell stimulation, and lead to reduced pro-inflammatory responses, which 
in turn result in the observed reduction in PMN recruitment to the site of infection. A 
schematic representation of the mechanisms underlying sTLR2’s modulatory capacity 
discussed here is shown in Figure 2.4.5.
The ability of sTLR2 to affect the co-receptor activity of CD 14 raises the 
question of why TLR4- and TLR3-mediated monocyte responses -  that also require 
CD 14 for efficient signalling -  are not affected, as indicated by the absence of a 
negative effect of sTLR2 on LPS or poly I:C stimulated Mono Mac-6 cells (see section
2.2.3, Fig. 2.2.4, page 85). It is possible that, when the effect of sTLR2 depends solely 
on its capacity to interact with CD 14 (no decoy activity, i.e. TLR3 and TLR4 
signalling), the extent of sTLR2 inhibition critically depends not only on the local 
concentration of sTLR2, but also on the expression levels of CD 14 (mCD14 or sCD14) 
and the mTLR involved (i.e. TLR3 or TLR4/MD2) as well as on the affinity and 
stoichiometry of the interactions of mTLR, CD 14 and sTLR2 and those of the ligand 
with mTLR and CD 14. In support of this possibility, results of very recent experiments 
in our laboratory show that overexpressing sTLR2 in human astrocytoma (U373) cell 
transfectants -  which express very low levels of TLR4, do not express mCD14 and 
require sCD14 for sensitive signalling -  significantly reduces CD 14-dependent LPS- 
induced (TLR4-mediated) NF-kB activation (Fig. 2.4.6), suggesting that sTLR2 may be
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Figure 2.4.6. Overexpression of sTLR2 renders U373 cells hyposensitive to CD 14-dependent TLR4-mediated 
stimulation.
Triplicate cultures (3 x 105 cells/well) of U373 cells stably expressing sTLR2 (U373 + sTLR2) or the empty 
vector (U373-EV), were transiently transfected with firefly and Renilla luciferase reporter plasmids. Forty-eight 
hours post-transfection, the cells were stimulated (8 h) with LPS (60 ng/ml) in the presence of the indicated 
concentrations of sCD14. Subsequently, luciferase activity was measured as indicated under Materials and 
Methods (section 4.16, page 141). Results shown are of one experiment (±SD) representative of three. 
Differences in NF-kB activity between U373-EV and U373-sTLR2 were significant: *, p < 0.05.
targeting sCD14. Clearly, a better knowledge of the parameters governing the 
interactions beween TLRs, CD 14, the ligands, and sTLR2, will improve our 
understanding of the sTLR2’s activity. With regard to TLR3, its mostly intracellular 
location and function (Lee et al., 2006) may limit the activity of sTLR2.
The demonstrated capacity of sTLR2 to interact with CD 14 and disrupt its co­
receptor activity left open the question of which region(s) of the TLR2 ECD are 
involved in such interaction. It was anticipated that the identification of such region (s) 
could inform the design of novel tools to reduce pro-inflammatory responses, which 
might work by exclusively blocking CD14’s co-receptor function. The next phase of 
this study addressed that possibility.
104
2.5 Identification and functional characterisation of the 
TLR2 ECD regions involved in the TLR2-CD14 
interaction
It was considered important to identify the region(s) of the TLR2 molecule 
involved in its interaction with the co-receptor, CD 14, not only because it would 
improve our understanding of the mechanisms underlying the modulatory activity of 
sTLR2, but also because it would have therapeutic potential. Indeed, it was reasoned 
that such identification would enable the design of soluble peptides, incorporating the 
critical amino acid sequences, that could be tested for their ability to disrupt the CD14’s 
co-receptor activity by binding to CD 14. In this way, TLR2-mediated pro-inflammatory 
responses would be reduced -  thus avoiding the deleterious effects associated with 
excessive inflammation -  while TLR2’s capacity to recognise and respond to microbial 
ligands would be preserved.
2.5.1 Mutational analysis of the TLR2 ECD
2.5.1.A Generation and expression of TLR2 LRR mutants
The human TLR2 ECD contains a total of twenty leucine-rich repeats 
(LRR; Fig. 1.3 and Fig. 2.5.3), which are known to be critically involved in protein- 
protein interaction and ligand recognition. Thus, in order to identify the TLR2 LRRs 
involved in the interaction with CD 14, the systematic point mutation of each of the 20 
LRRs of the TLR2 ectodomain was conducted, and then the capacity of the mutants to 
mediate ligand-induced cell activation in the absence and presence of CD 14 was 
evaluated.
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Figure 2.5.1. Expression of LRR TLR2 mutants.
A, Cell-surface expression of LRR TLR2 mutants and WT TLR2 in HEK293 cells (3 x 105 cells/well) transiently 
transfected with the indicated amounts of the WT and mutant cDNAs. Surface expression of the different TLR2 
proteins was assessed by flow cytometry using the anti-TLR2 mAbs T2.5 (this figure) or TL2.1 (not shown) 
A488-conjugated. Results are representative of 3 independent experiments. The dotted line indicates the 
minimum level of expression selected to carry out subsequent functional experiments. B, Detection of LRR2 
TLR2 and WT TLR2 mRNAs following extraction of total RNA from the corresponding HEK293 cell 
transfectants (3 x 106 cells), reverse transcription, and cDNA amplification using human TLR2 specific primers, 
as described under Materials and Methods (section 4.20, page 146). The expected size of the corresponding PCR 
product is 557 pb.
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The strategy for the mutation of the LRRs consisted in substituing valine for 2 or 
3 leucine residues of a particular LRR. Valine was chosen for substitutions as it is a 
non-polar, neutral amino acid, structurally close to leucine. This strategy thus 
minimised possible changes in the tertiary structure of the protein, which could affect 
the mutants functional activity. The 20 LRR mutated TLR2 cDNAs were obtained by 
PCR using an appropriate pair of primers and the pCRII®-TOPO® plasmid containing 
the full-length TLR2 cDNA as a template {Materials and Methods, section 4.20, page 
145).
The expression in HEK293 cells (which do not express native TLR2, TLR4 or 
CD 14) of the TLR2 cDNAs coding for the TLR2 mutant and wild-type (WT) proteins 
was tested next. A comparable level of expression between the mutants and WT TLR2 
was required to make possible the comparison between the functional activity of the 
TLR2 mutants and that of WT TLR2. To this aim, cells were transiently transfected 
with increasing concentrations of each TLR2 cDNA (mutants and WT, 0.062-0.5 pg), 
and the amount of cDNA required to reach a comparable and significant level of 
expression (MFI = 20-30) of the different TLR2 proteins was determined by flow 
cytometry. Figure 2.5.1, A shows a representative TLR2 cDNA titration experiment. 
Based on this experiment, 0.5 pg cDNA/well (3 x 105 cells) was used in subsequent 
studies. Notably, the result of the TLR2 cDNA titration also indicated that the LRR2 
TLR2 mutant (Fig. 2.5.1, A) as well as LRR3, 4, 5, 7, 12, 13, 14, 15, 16, 18 and 20 
TLR2 mutants (not shown) were not expressed at the cell surface at levels detectable by 
flow cytometry. This was confirmed by using two different human TLR2-specific mAbs 
(TL2.1 and T2.5), indicating that the lack of detection of these mutants was most likely 
not due to the loss of the epitope recognised by the mAb in the mutants. However, RT-
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Figure 2.5.2. Effect of TLR2 LRR mutations on ligand recognition and CD14 co-receptor activity.
HEK293 cells transiently expressing the wild-type (WT) TLR2 protein or a TLR2 mutated at the indicated 
leucine-rich repeat (LRR) were stimulated (16 h) with Pam3Cys lipopeptide (50 ng/ml) or whole heat-killed 
Listeria monocytogenes (HKLM; 10:1, bacteria:cell ratio) in the absence or presence of 500 ng/ml sCD14. Cell 
activation was measured by using an NF-kB reporter assay. Results are from one experiment (±SD) 
representative of three. Arrows point at LRR TLR2 mutants showing a marked effect of the mutation on co­
receptor activity.
PCR analysis of RNA extracted from each TLR2 mutant and WT cell transfectants 
showed readily detectable levels of the corresponding TLR2 mRNA. Figure 2.5.1, B, 
shows a representative example of the detection of the mRNA of one of the TLR2 
mutants whose cell-surface expression was undetectable (LRR2 TLR2 shown) and that 
of WT TLR2. This finding indicated that the lack of cell-surface expression of a number 
of mutants was not due to a deficient transfection or transcription of the corresponding 
cDNAs. The study, therefore, focused on the functional activity of the cell-surface 
expressed mutants LRR1, 6, 8, 9, 10, 11, 17 and 19 of TLR2.
2.5.l.B Selection of candidate regions of the TLR2 ECD to be 
involved in the CD14-TLR2 interaction
In order to identify the human TLR2 LRR(s) involved in the 
interaction with the co-receptor CD 14, a comparative study of the capacity of WT 
TLR2 and each mutant to mediate ligand-induced NF-kB activation in the absence and 
presence of sCD14 was performed next. The TLR2-mutants whose cell-surface 
expression was undetectable were included in the study as controls.
Figure 2.5.2, A and B, shows that HEK293 cells transiently transfected with WT 
TLR2 were sensitive to stimulation with either the TLR2 agonist synthetic bacterial 
lipopeptide Par^Cys (Fig. 2.5.2, A) or the whole Gram-positive bacterium heat-killed 
Listeria monocytogenes (HKLM; Fig. 2.5.2, B), as judged by the activation of the 
transcription factor NF-kB. Sensitivity to stimulation was enhanced in the presence of 
the co-receptor, sCD14. Most cell-surface expressed TLR2 mutants were sensitive to 
stimulation by Par^Cys and HKLM. However, the enhancing effect of the co-receptor 
was found affected in the LRR6 TLR2 and LRR9 TLR2 mutants (Fig. 2.5.2). The
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mutation of the LRR6 made the HEK-LRR6 TLR2 transfectants less responsive to 
P a rley s stimulation, but more dependent on sCD14’s co-receptor activity, as 
compared to the wild-type TLR2 cell transfectants (Fig. 2.5.2, A). The responsiveness 
of this mutant to HKLM, either in the absence or presence of sCD14, was completely 
lost (Fig. 2.5.2, B). The mutation of the LRR9 affected only the co-receptor-dependent 
cell sensitivity of LRR9 TLR2, since the response of the HEK-LRR9 TLR2 
transfectants to Pam^Cys or HKLM in the absence of sCD14 was comparable to that of 
WT TLR2 transfectants, while their response to either of the two ligands was not 
enhanced by sCD14 (Fig. 2.5.2). LRR1 and LRR11 TLR2 mutants did not mediate cell 
activation in response to either Pan^Cys or HKLM (Fig. 2.5.2), suggesting that these 
LRRs may be involved in ligand recognition by TLR2. Indeed, previously published 
work showed the involvement of LRR1 in PGN recognition (Mitsuzawa et al., 2001). 
Pam3Cys or HKLM did not induce activation of the LRR2, 3, 4, 5, 7, 12, 13, 14, 15, 16, 
18 and 20 TLR2 cell transfectants. This finding was consistent with the observation that 
cell surface expression of these mutants was not detected (see previous section).
Given the effect of the mutations in LRR6 and LRR9 on co-receptor activity, the 
LRR6 TLR2 and LRR9 TLR2 mutants were selected for further studies.
2.5.2 Functional activity of TLR2-derived peptides
2.5.2.A Effect of peptides representing TLR2 LRRs on TLR2- 
mediated cell activation
It was reasoned that the mutations in LRR6 and 9 may have affected 
the activity of the co-receptor directly, by modifying the TLR2 ECD regions primarily 
involved in the TLR2-CD14 interaction, or indirectly, by inducing a modification in the
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Figure 2.5.3. The human TLR2 molecule.
Schematic representation of the human TLR2 protein showing the 20 leucine-rich repeats (LRR) present in the 
extracellular domain (the separation shown between LRRs is representative of the distance between domains). 
Arrows point at the LRR tested for their involvement in the TLR2-CD14 interaction (Figs. 2.5.2, 2.5.4, and 
2.5.5.). N-ter and C-ter, N-terminus and C-terminus of the TLR2 protein.
Table 2.5.1. Human TLR2 ECD-derived peptide sequences.
TLR2LRR  
(amino acid position*) Corresponding peptide sequence
Peptide 
molecular mass (Da)
LRR6 (173-196) LTFLEELEIDASDLQSYEPKSLKS 2756.08
LRR9 (247-275) TNSLIKKFTFRNVKITDESLFQVMKLLNQ 3457.13
LRR10 (276-305) ISGLLELEFDDCTLNGVGNFRASDNDRVID 3298.62
LRR15 (412-434) LKNLTNIDISKNSFHSMPETCQW 2707.1
LRR17 (456-476) PKTLEILD V SNNNLNLFSLNL 2371.74
LRR20 (522-545) FHTLKTLEAGGNNFICSCEFLSFT 2680.08
* Position of the amino acids on the human TLR2 precusor sequence -  i.e. including the signal peptide (Met1 to 
Glu2°).
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Figure 2.5.4. Effect of TLR2 ECD-derived peptides on TLR2-mediated cell activation.
Triplicate cultures (1.5 x 105 cells/well) of Calu-3 (A) or Mono Mac-6 (B) cells were stimulated (16h) with a 
suboptimal concentration of 250 ng/ml (Calu-3) or 400 ng/ml (Mono Mac-6) of Pam3Cys in the presence or 
absence of the indicated concentrations of TLR2 ECD-derived peptides representing the indicated LRR of 
human TLR2. Following incubation, the cell culture supernatants were tested for IL-8 levels by ELISA. Results 
are expressed as % inhibition of IL-8 release induced by each peptide compared to that exerted by the anti-CD 14 
mAb MY4 (10 pg/ml) -  which blocks CD14 co-receptor activity completely — used as 100% inhibition control. 
Results are from one experiment (±SD) representative of four.
tertiary structure of TLR2 that results in increased (LRR6 mutation) or decreased 
(LRR9 mutation) capacity (avidity) to interact with the co-receptor. Therefore, to test 
whether the LRR6 and LRR9 were directly involved in the interaction with CD 14, the 
peptides corresponding to LRR6 and LRR9 were generated (Table 2.5.1) and first tested 
for their capacity to inhibit the ligand-induced TLR2-mediated activation of cells that 
naturally express both CD 14 and TLR2: 1) the human respiratory epithelial cell line 
Calu-3, which expresses very low levels of CD 14 and TLR2, and 2) the human 
monocyte-like cell line, Mono Mac-6, which expresses high and moderate levels of 
CD 14 and TLR2, respectively. Although LRR15 TLR2 and LRR20 TLR2 mutants 
could not be expressed and tested (see section 2.5.1.A), the peptides corresponding to 
LRR 15 and LRR20 were also generated and tested, as the LRR 15 of human TLR2 
shows considerable sequence similarity to that of mouse TLR2 and human and mouse 
TLR4 -  suggesting that LRR 15 is involved in a critical function -  , and LRR20 is 
closest to the immediate juxtamembrane region of the ectodomain, which appears to be 
involved in receptor interactions and signalling (Gay et al., 2006; Fig. 2.5.3 and Table 
2.5.1). In addition, the peptides corresponding to LRR 10 and LRR 17 were generated 
and used as negative controls (Fig. 2.5.3; Table 2.5.1), as mutations in these LRR did 
not affect the sensitivity of the corresponding cell transfectants (Fig. 2.5.2).
Figure 2.5.4, A and B, shows that only the peptides corresponding to LRR6 (peptide 6) 
and LRR20 (peptide 20) exerted a marked inhibition on the PamsCys-mediated release 
of the typical pro-inflammatory chemokine, IL-8, by Calu-3 and Mono Mac-6 cells, as 
compared to that exerted by the anti-CD 14 mAb MY4 — which blocks CD 14 co- 
receptor activity completely -  used as 100% inhibition control. Peptide 9 (LRR9) did 
not affect cell activation at the two concentrations tested, indicating that LRR9 is not
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Figure 2.5.5. Peptides 6 and 20 specifically inhibit CD14 co-receptor activity.
Triplicate cultures (1.5 x 105 cells/well) of HEK-WT TLR2 cell transfectants were stimulated (16 h) with 
Pam3Cys (50 ng/ml) in the absence or presence of sCD14 (500 ng/ml), the anti CD 14 mAb MY4 (10 pg/ml) and 
the indicated concentrations of TLR2 ECD-derived peptides. Following incubation, the cell culture supernatants 
were tested for IL8 by ELISA. Results are from one experiment (±SD) representative of three. Arrows point at 
peptides 6 and 20, which inhibited the CD 14-dependent, but not the CD 14-independent cell activation.
directly involved in the TLR2-CD14 interaction, and that the loss of the enhancing 
effect of CD 14 in the ligand-induced activation of the HEK-LRR9 TLR2 transfectant 
(Fig. 2.5.2) most probably resulted from an indirect effect of the mutation on the 
structure of the TLR2 molecule.
2.5.2.B Peptides 6 and 20 specifically inhibit CD 14 co-receptor
activity
In order to confirm that the inhibitory effect of peptides 6 and 20 on 
the lipopeptide-induced cell stimulation described previously (Fig. 2.5.4) resulted from 
the specific disruption of CD 14 co-receptor activity, the effect of peptides 6 and 20 on 
the PamsCys-induced stimulation of HEK-WT TLR2 cell transfectants in the absence 
and presence of sCD14 was tested (Fig. 2.5.5). The PamsCys-induced release of IL-8 by 
HEK-TLR2 cells was substantially enhanced by sCD14. This enhancing effect was 
completely abrogated by the anti-CD 14 mAb MY4, as the levels of IL-8 released were 
reduced to those in the absence of the co-receptor (Fig. 2.5.5, left). Peptides 6 and 20 -  
at two concentrations -  did not affect PamsCys-induced IL-8 release in the absence of 
sCD14 (Fig. 2.5.5, centre), since the levels of IL-8 were similar to those released by the 
cells in the presence of the control peptides, and comparable to those released by cells 
stimulated in the presence of Par^Cys only. However, in the presence of sCD14, 
peptides 6 and 20, but not the control peptides, inhibited cell stimulation in a dose- 
dependent manner (Fig. 2.5.5, right). These results confirmed that LRR6 and LRR20 are 
directly involved in the TLR2-CD14 interaction, and that peptides 6 and 20 are capable 
of modulating TLR2-mediated cell activation and pro-inflammatory responses by 
specifically targeting the TLR co-receptor, CD 14.
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2.5.3 Discussion
In the last phase of this project, the systematic mutation of the twenty LRR 
domains of the human TLR2 molecule was conducted to define the regions involved in 
the interaction of TLR2 with the co-receptor, CD 14. The results presented in this 
section demonstrated that LRR6, 9 and 20 are involved in such interaction. LRR9, 
however, seems to be indirectly involved, since a peptide representing LRR9 did not 
reproduce the effect of the mutation.
The mechanism underlying the inhibitory effect of peptide 6 and peptide 20 
remains to be determined and a number of experiments are being conducted to address 
this issue (see Concluding Remarks and Future Work, page 119, (8)). It is possible that 
peptides 6 and 20 inhibit the enhancing effect of CD 14 on cell activation by binding to 
the co-receptor, like sTLR2, and thus affect CD14’s capacity to interact with mTLR2. It 
is also possible that one or both peptides interfere with the binding of the microbial 
ligand to the co-receptor. In this regard, it is interesting to note that the region of CD 14 
involved in its interaction with TLR2, i.e. amino acids 57-64 (Iwaki et al., 2005), is 
within the N-terminal side of the molecule, which is involved in ligand binding.
Nevertheless, peptide 6 and peptide 20 proved to be capable of reducing the 
TLR2-mediated activation of cells that naturally express both CD 14 and TLR2, i.e. 
Calu-3 and Mono Mac-6 cells, as well as that of HEK-TLR2 cell transfectants. 
Significant levels of inhibition in Mono Mac-6 and HEK-TLR2 cells were obtained by 
using higher doses of peptide (0.25 and 2.5 pg/ml) than those used for Calu-3 cells (0.12 
and 1.25 pg/ml). The higher level of mTLR2 expression in Mono Mac-6 and HEK-
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TLR2 cells compared with that in Calu-3 cells most likely requires a higher amount of 
peptide to compete favourably with mTLR2 for interaction with CD 14.
The inhibitory capacity of peptides 6 and 20, as well as that of peptide 9, 
remains to be tested in vivo. The findings described in this section, however, pave the 
way for future studies to evaluate the strategy of using peptides, or small molecules 
mimicking the peptides’ activity, to target and neutralise the TLR co-receptor CD 14, 
thus reducing pro-inflammatory responses.
Most of the therapeutic strategies to control TLR responses tested so far are 
based on the use of TLR antagonists to inhibit TLR ligand recognition. The antagonists 
can be structural analogs of agonists that bind to the TLR but fail to signal, TLR 
blocking antibodies, or small molecule antagonists selected from compound libraries 
(Kanzler et al., 2007). Alternative strategies use small molecules to target intracellular 
TLR signal intermediates (O'Neill, 2003). Many of these approaches have failed due to 
factors such as cost, toxicity, high dose requirements, the half-life of the antagonist or 
negative effects on bacterial clearance. Current trials still using such approaches are at 
the pre-clinical or phase I to III stages. A phase I trial of an anti-human CD 14 mAb has 
been conducted although a very high mAb dose is required for effect (Verbon et al., 
2001). Current therapeutic approaches increasingly aim to reduce the side effects 
resulting from potentially excessive TLR-mediated inflammatory responses without 
abrogating TLR’s capacity to recognise and respond to the invading microorganism. In 
this context, the results presented in this section define a potential strategy to reduce 
inflammation without abrogating TLR recognition capacity that is novel in that it targets 
the co-receptor molecule by using small peptides. By modulating TLR triggering, this 
strategy is expected to preserve TLR ligand recognition, and by extension, microbial
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clearance capacity, while reducing the level of the inflammatory response. By targeting 
the co-receptor and not the microbial ligand, this strategy offers the possibility of 
modulating responses to three different TLRs, TLR2, 3 and 4, by targeting their 
common co-receptor. Notably, this strategy has the advantage of using small peptides, 
thus avoiding the high cost of Ab production and the problems associated with the use 
of high doses of relatively large proteins.
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CONCLUDING REMARKS 
and
FUTURE WORK
Following the initial description of the crucial involvement of TLRs in acute 
inflammation and septic shock (Poltorak et al., 1998; Hoshino et al., 1999) and the more 
recent well-documented observations implicating TLRs in a number of autoimmune and 
chronic inflammatory diseases -  such as lupus, arthritis, inflammatory bowel disease 
(IBD) and atherosclerosis (Zuany-Amorim et al., 2002; Barrat et al., 2005; Tobias and 
Curtiss, 2007) -  it has become clear that TLR overactivation plays a prominent role in 
the pathogenesis of a variety of acute and chronic inflammatory conditions (Kanzler et 
al., 2007). The different levels at which TLR activity can be regulated highlight the 
importance of such regulation to the maintenance of immune homeostasis. sTLR2 is the 
only soluble form of a mammalian TLR so far identified that occurs naturally. It has 
been hypothesised that sTLR2 may protect the host from deleterious TLR2-mediated 
innate immune responses by preventing the excessive initial triggering of TLR2 (Zuany- 
Amorim et al., 2002; LeBouder et al., 2003; Heggelund et al., 2004; Liew et al., 2005). 
This study was therefore conducted to test this hypothesis by: 1) evaluating the full 
extent of sTLR2’s regulatory capacity and its biological relevance in vivo, 2) studying 
the mechanism underlying such regulatory capacity, and 3) evaluating the therapeutic 
potential of sTLR2’s activity.
The results of this study demonstrated that sTLR2 regulates TLR2-mediated pro- 
inflammatory responses induced by microbial components and whole Gram-positive 
bacteria in vitro and in vivo, and that sTLR2 also has the potential to modulate critical 
effector functions, namely phagocytosis and superoxide production. Notably, the 
modulatory capacity of sTLR2 does not seem to affect bacterial clearance. Two 
mechanisms contributing to such regulatory activity were identified; firstly, the capacity 
of sTLR2 to act as a decoy microbial receptor, and secondly its capacity to disrupt the
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interaction of TLR2 with its co-receptor, CD 14, by binding to CD 14. The therapeutic 
potential of these findings was highlighted by the identification of three LRRs of TLR2 
which appear to be involved in the interaction with CD 14 -  namely LRR6, 9 and 20 -  
and the demonstration that peptides representing LRR6 and LRR20 are capable of 
reducing CD 14-dependent TLR2-mediated pro-inflammatory responses in vitro, most 
likely by targeting CD 14 and disrupting its co-receptor activity. These findings thus 
establish sTLR2 as a regulator of TLR2-mediated inflammatory responses and pave the 
way for future studies evaluating novel therapeutic strategies to control inflammation.
Future work will address a number of issues and questions raised by the present
study:
1. The improvement of the yield of rhsTLR2 will be the subject of future 
work. Recently, the crystallographic structure of the TLR2-TLR1 heterodimer was 
achieved using a novel strategy for the production of soluble TLRs that is based on the 
generation of hybrid molecules consisting of fragments of TLRs and hagfish variable 
lymphocyte receptors fused at conserved sites (Jin et al., 2007). The use of this strategy 
will be evaluated in our laboratory.
2. The elution profile of sTLR2 was monitored using anti-His and anti-TLR2 
Abs and showed a major -72-kDa polypeptide band, and additional minor -83-kDa and 
-90-kDa bands only detectable by the anti-TLR2 (polyclonal) Ab. By contrast, the 
Coomassie blue staining of the eluted fractions and final preparations showed the ~90- 
kDa sTLR2 isoform as the main sTLR2 polypeptide. Based on previous findings (Iwaki 
et al., 2002; LeBouder et al., 2003; Weber et al., 2004), it is speculated that the three
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sTLR2 isoforms may be glycoforms, sharing the same backbone polypeptide -  the 
TLR2 ectodomain. To test this possibility, deglycosylation experiments of purified 
sTLR2 followed by immunoblotting with anti-His and anti-TLR2 Abs, as well as 
Coomassie blue staining, may be conducted.
3. The results of the in vitro studies show that sTLR2’s modulatory effect is 
not limited to the release of IL-8, since NF-kB activation -  which results in the 
induction of a number of immune mediators -  was markedly affected by sTLR2. 
Notably, the modulatory effect on NF-kB appears to be stronger than that on IL-8 
release. Differences in sensitivity between the ELISA (used for IL-8 determinations) 
and the NF-kB reporter assay may contribute to the observed difference in modulatory 
effect. It is also possible, however, that this difference reflects a differential effect of 
sTLR2 on the signalling pathways leading to IL-8 release. It would therefore be of 
interest to test and compare the effect that sTLR2 exerts on NF-kB and AP-1 -  
transcription factor activated through the MAP kinases pathway, whose activation may 
also lead to IL-8 production (Hipp et al., 2002; Kang et al., 2007).
4. For the in vivo studies, two mouse models of acute peritoneal inflammation 
were used to prove the concept that sTLR2 can have a significant modulatory effect on 
bacterial-induced pro-inflammatory responses. The use of these models also showed 
that sTLR2 can perform this activity without compromising bacterial clearance. The 
mouse models were based on the peritoneal injection of a S. epidermidis-derived cell- 
free supernatant or live S. epidermidis (5 x 107 CFU). Current work in our laboratory is
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addressing the issue of whether sTLR2 can show a similar modulatory effect when a 
higher bacterial innoculum is used or when other bacterial strains are tested.
5. The demonstrated capacity of sTLR2 to regulate pro-inflammatory 
responses poses the question of whether sTLR2 confers protection during bacterial- 
induced sepsis. Comparative survival rate studies in mouse models of Gram-positive 
sepsis will help to address this question. Home Office authorisation is being sought to 
perform these studies.
6. sTLR2 may not only modulate an acute inflammation, but also influence 
the course of chronic inflammatory conditions. It would therefore be of interest to test 
the effect of sTLR2 in mouse models of chronic inflammatory processes such as 
atherosclerosis, arthritis, and IBD.
7. The study of the mechanism responsible for sTLR2's modulatory effect 
demonstrated the capacity of sTLR2 to act as a decoy microbial receptor. TLR2 is 
known to heterodimerise with TLR1 or TLR6 for lipopeptide recognition (Takeuchi et 
al., 2001; Takeuchi et al., 2002), and crystallographic studies showed that Pam3Cys 
serves as a link or bridge between TLR2 and TLR1 (Jin et al., 2007). It is therefore 
possible that sTLR2 performs its decoy activity, in our experimental systems, by 
binding to TLR1 in the presence of the tri-acyl lipopeptide and consequently preventing 
TLR1 from associating with mTLR2 -  which is crucial to signalling. This possibility 
may be tested by evaluating the effect of sTLR2 on the lipopeptide-induced stimulation 
of cells from TLR 1-deficient mice.
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8. The description of peptides capable of reducing CD 14-dependent TLR2- 
mediated responses poses the question of the underlying mechanism. At present, 
experiments are being conducted in our laboratory to test: 1) the binding of peptide 6 
and peptide 20 to CD 14 (Biacore and plate assays), 2) the possible disruption of the 
interaction between mCD14 and mTLR2 by peptide 6 and/or 20 (FRET and co- 
immunoprecipitation experiments), and 3) the effect of peptides 6 and 20 on the binding 
of P a rle y s  to CD 14 (flow cytometry analysis of the binding of biotinylated Par^Cys 
to CHO-CD14 transfectants in the presence and absence of the peptides).
9. The therapeutic potential of using peptides to target the co-receptor, CD 14, 
deserves further investigation: 1) It will be important to test the modulatory capacity of 
peptides 6, 9 and 20 in the in vivo models of acute inflammation used here to study 
sTLR2, as well as in models of chronic inflammation (e.g. arthritis, IBD, 
atheroschlerosis). 2) The use of small molecules, selected from compound libraries, 
with the capacity to mimic the effect of peptides 6 and 20 is being considered. This 
would avoid the problems associated with the use of peptides, i.e. high dose, solubility 
and short life span.
10. The demonstrated capacity of sTLR2 and peptides 6 and 20 to modulate 
inflammatory responses by targeting CD 14 and disrupting its co-receptor activity 
suggested that sTLR2 and/or the peptides may be used to modulate responses mediated 
not only by TLR2, but also by TLR3 and TLR4, by targeting their common co-receptor. 
The results of recent preliminary experiments showing the hyporesponsiveness of LPS- 
stimulated cells overexpressing sTLR2 (section 2.4.4, Fig. 2.4.6) supports this
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possibility. Thus, following confirmation of these preliminary findings, the effect of 
sTLR2 and peptides 6, 9 and 20 on mouse models of LPS -  or live Gram-negative 
bacteria -  induced acute peritoneal inflammation will be tested.
In conclusion, this study defines sTLR2 as an efficient regulator of TLR2- 
mediated inflammatory responses, as it is capable of reducing inflammation by 
controlling PMN influx while preserving monocyte/macrophage recruitment and 
without compromising bacterial clearance. The capacity of sTLR2 and peptides derived 
from its ectodomain to exert regulatory effects by targeting the TLR co-receptor, CD 14, 
may inform the design of novel therapeutics against acute and chronic inflammatory 
conditions that will aim at disrupting the co-receptor's activity, thus blunting, but not 
abrogating, microbial recognition and host immune responses.
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MATERIALS and METHODS
Table 4.1. List of antibodies and immunoreagents
Antibodies to Clone/code Isotype Source
Human CD14 MY4 (and MY4-FITC) Mouse IgG2b Coulter, Luton, U.K.
Human CD14 69.4 Rabbit Igs Sanofi-Synthelabo, France (Labeta et al., 2000)
Human TLR2 peptide 
(N-terminus 20-mer 
peptide
18s k e e s s n g a s l s g d r n
GIGK37)
TLR2p Rabbit Igs
Provided by Prof. B.P. Morgan, Dept.
of Medical Biochemistry and 
Immunology, Cardiff University,U.K. 
(Le Bouder et al., 2003)
Human TLR2 peptide 
(N-terminus 17-mer 
peptide)
sc8689 Goat IgG Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.
Human TLR2 IMG 319 Mouse IgGl Imgenex, San Diego, CA, U.S.A.
Human TLR2 TL2.1 (and T2.1-PE) Mouse IgG2a eBioscience, San Diego, CA, U.S.A.
Human/mouse TLR2 TL2.5 (and T2.5-A488) Mouse IgGl eBioscience
cMyc epitope 9E10 Mouse IgGl Sigma-Aldrich, Dorset, U.K.
His5 tag anti-Hiss mAb Mouse IgGl Qiagen Valencia, CA, U.S.A.
Mouse F4/80 CI:A3-1-FITC Rat IgG2b Serotec, Oxford, U.K.
Mouse C D llb M1/70-APC Rat IgG2b BD Bioscience, Oxford, U.K.
Mouse IgGs
HRP-conjugated anti 
mouse IgG Ab Rabbit Igs
Amersham/GE Healthcare, 
Little Chafont, U.K.
Biotin-conjugated anti 
mouse IgG Ab Dako Ltd, High Wycombe, U.K.
Rabbits IgGs HRP-conjugated anti rabbit IgG Ab Mouse Igs Amersham/GE Healthcare,
Human IgGs Biotin-conjugated anti human IgG Ab Mouse Igs
Southern Biothec. Birmingham, AL, 
U.S.A.
Immunoreagents Clone/code Isotype Source
Mouse IgG (purified) MOPC-21 IgGl Sigma-Aldrich
Mouse IgG (purified) UPC-10 IgG2a Sigma-Aldrich
Mouse IgG (purified) MOPC-141 IgG2b Sigma-Aldrich
Mouse IgG-A488 - IgGl eBioscience
Mouse IgG-PE UPC-10 IgG2a Sigma-Aldrich
Rat IgG-FITC MCA1125F IgG2b Serotec
Rat IgG-APC A95-1 IgG2b BD Bioscience
HRP-conjugated cholera 
toxin B - -
List Biologicals, Campbell, CA, 
U.S.A.
HRP-conjugated
streptavidin - -
Jackson Immunoresearch Lab., PA. 
U.S.A.
APC- conjugated 
streptavidin - - Southern Biotech
4.1 Antibodies and reagents
The antibodies and immunoreagents used and their sources are listed in Table 
4.1. RPMI-1640, DMEM and Express Five SFM media, L-glutamine, sodium pyruvate, 
non-essential amino acids (NEAA), penicillin, streptomycin and insulin were from 
Invitrogen Ltd (Paisley, U.K.). Bac Vector Insect Cell Medium and X-gal were from 
Novagen (San Diego, CA, U.S.A.). Low-endotoxin foetal calf serum (FCS) was from 
Hyclone (Logan, UT, USA; < 0.06 U/ml endotoxin). Ficoll-Histopaque-1077, bovine 
serum albumin (BSA), protein G-Sepharose, Nonidet P-40 (NP-40), Triton X-100, 
PM A, ionomycin and ampicillin were from Sigma-Aldrich (Dorset, U.K.). Ni- 
nitrilotriacetic acid (Ni-NTA) Superflow resin was from Qiagen (Valencia, CA, U.S.A). 
Hygromycin B was from Calbiochem (San Diego, CA, U.S.A.). Ultra-pure LPS 
(Escherichia coli 0111:B4 strain), heat-killed Listeria monocytogenes (HKLM), 
peptidoglycan (PGN), polyinosinic-polycytidylic acid (poly I:C) and flagellin were 
purchased from Invivogen (San Diego, CA, U.S.A.). The synthetic bacterial lipopeptide 
Pam3 -Cys-Ser-(Lys) 4  HC1 (Pan^Cys) was from EMC microcollections GmbH 
(Tubingen, Germany). The human cytokines IL-ip and TNF-a were from R&D 
Systems (Minneapolis, MN, U.S.A.). All chemicals were reagent grade.
4.2 Cells and cell cultures
Sf9 and High Five ovarian insect cells (Invitrogen Ltd) -  derived from 
Spodoptera frugiperda and Trichoplusia ni, respectively -  were cultured at 27°C in Bac 
Vector Insect Cell Medium (Sf9) and Express Five SFM (High Five) medium as 
adherent (Sf9) or suspension (High Five) cultures.
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Chinese hamster ovary (CHO), mouse RAW264 (American Type Culture Collection- 
ATCC, Rockville, MD, U.S.A), and CHO-CD14 (previously generated in our 
laboratory, Labeta et al., 2000) cells were cultured in RPMI-1640 medium 
supplemented with 10 % FCS (Hyclone), 2 mM glutamine, and specific additives for 
the CHO-CD14 cells: 1 mM pyruvate, 0.5% (v/v) NaHCC>3 , and 50 pg/ml L-proline. 
Human embryonic kidney (HEK) 293 cells, the astrocytoma cell line U373 (ATCC), 
and the human airway epithelial cell line Calu-3 (kindly provided by Prof K.P. Jones, 
School of Health Sciences, University of Wales Institute, Cardiff, U.K.) were cultured 
in DMEM medium supplemented with 10% FCS. The medium was further 
supplemented with 200 pg/ml hygromycin B for culturing HEK-TLR2, U373-TLR2 
and U373-TLR2/sTLR2 cell transfectants. The human monocytic cell line, Mono Mac-6 
(kindly provided by Prof. H.W.L. Ziegler-Heitbrock, Dept, of Immunology, Leicester 
University, U.K.), was cultured in RPMI-1640 medium supplemented with 10 % FCS, 2 
mM glutamine, 1 mM pyruvate, 1 % non-essential amino acids and 10 pg/ml insulin. 
Human peritoneal mesothelial cells were isolated by serial tryptic digestion of omental 
tissue from consenting patients undergoing elective abdominal surgery, and cultured as 
previously described (Topley et al., 1996).
Peripheral blood mononuclear cells (PBMC) were obtained following Ficoll density- 
gradient centrifugation of buffy coats from heparinised blood of healthy donors (Welsh 
Blood Bank, Cardiff, U.K.). The blood was diluted 1:1 with room temperature RPMI- 
1640 medium, overlaid (12 ml) onto 8 ml of room temperature Ficoll-Histopaque to a 
blood:Ficoll final ratio of 3:2, and centrifuged at 750 x g for 20 min at room 
temperature. The upper (plasma) and lower (red cells and PMN) phases were discarded, 
and the interphase containing the PBMC was recovered and washed three times at room
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temperature with RPMI-1640 medium (first wash, 370 x g, 12 min; second, 190 x g, 10 
min; third, 120 x g, 8 min). Monocytes were obtained by adherence (2 h, 37°C) of 
PBMC resuspended in RPMI-1640 medium supplemented with 1% FCS, penicillin (50 
U/ml) and streptomycin (50 pg/ml). The purity of the monocyte preparations was 
always > 95%, as evaluated by flow cytometry with anti-CD 14, -CD 19 and -CD3 
mAbs.
Human neutrophils (PMN) were prepared by dextran sedimentation and Ficoll density- 
gradient centrifugation of citrated blood from healthy donors (60 ml). Blood (12 x 5 ml) 
was incubated (90 min, 37°C) with 12 x 350 pi of citrate buffer (76 mM citric acid, 169 
mM sodium citrate, pH 5.6) and 12 x 1 ml 70% dextran (Baxter Healthcare, Newbury, 
U.K.), and the lower erythrocyte plasma layer was discarded. The upper, platelet and 
leukocyte-rich, layers were pooled and washed with PBS (2 x, 300 x g, 8 min, room 
temperature). Cells were then resuspended in 5 ml of PBS and overlaid onto 5 ml of 
Ficoll Hypaque (Amersham/GE Healthcare, Little Chafont, U.K.). After centrifugation 
(400 x g, 35 min, room temperature), the interface (MNC) was discarded and the pellet 
(PMN) was washed with PBS (2 x, 300 x g, 8 min, room temperature). Erythrocytes 
contaminating the PMN preparations were removed by hypotonic lysis (3 ml of ice cold 
0.2% NaCl, 1 min). To restore iso-osmolarity, 1.6% NaCl (3 ml) was added prior to 
washing with PBS (2 x, 300 x g, 8 min, room temperature). PMN were then 
resuspended in PBS (4 x 106 cells/ml) in preparation for superoxide production assays 
(section 4.18). The purity of the PMN preparation was always > 95%, as evaluated by 
differential cell count on cytospin preparations.
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4.3 Cell transfections
Cells were transfected using the Lipofectamine™ Transfection system 
(Invitrogen), according to the manufacturer’s instructions. For all transient transfection 
experiments, cells (HEK293 or HEK-TLR2) were seeded in a 24-well plate (1.5 x 105 
cells/well) and transfected 24 h later (approximately 3 x 105 cells/well) using 2 pi of 
Lipofectamine™ per well and 2 pi of Plus Reagent™ per pg of construct.
For NF-kB reporter assays, HEK293, HEK-TLR2, U373-EV or U373-sTLR2 cells were 
transiently transfected with 0.25 pg of a construct directing the expression of the firefly 
luciferase reporter gene under the control of the N F-kB promoter (pNF-icB-Luc; 
Stratagene, La Jolla, CA, U.S.A.) and 0.05 pg of a construct directing the expression of 
the Renilla luciferase independently of N F-kB (pRL-SV40; Promega, Southampton, 
U.K.). Twenty four hours post-transfection, cell activations and N F-kB measurements 
were conducted as described below (section 4.16).
4.4 SDS-PAGE, Western blotting and Coomassie blue 
staining
SDS-PAGE was carried out using the Bio-Rad Mini Protean II gel apparatus 
(Bio-Rad, Hercules, CA, U.S.A). All samples were diluted with Laemmi reducing 
sample buffer (2% SDS, 100 mM DTT, 50 mM Tris-HCl, pH 6.8, 10 % glycerol and 
0.1% bromophenol blue, final concentration) and boiled for 4 min prior to 10% SDS- 
PAGE. Pre-stained molecular weight markers (Bio-Rad) were run in parallel. 
Electrophoresis was carried out using SDS running buffer (25mM Tris base, 192 mM
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Table 4.2. List of antibodies used for Western blotting and corresponding experimental condition
Specificity of primary Ab Blocking * 
conditions
Primary Ab dilution * / 
BSA concentration
Secondary Ab *  
(1:2000 in 2% milk)
His5 (mAb) 3%BSA 1/1000 in 3%BSA Anti-mouse-HRP
Human TLR2 (TLR2p, polyc. Ab) 2% milk 1/3000 in 2% milk Anti-mouse-HRP
Human TLR2 (IMG319, mAb) 5% milk 1/500 in 2% milk Anti-mouse-HRP
Human TLR2 (sc8689, polyc. Ab) 5% milk 1/2000 in 2% milk Anti-goat-HRP
Human CD14 (MY4, mAb) 5% BSA lpg/ml in 2% BSA Anti-mouse-HRP
Human CD 14 (69.4, polyc. Ab) 5% BSA 1/2000 in 2% BSA Anti-rabbit-HRP
cMyc (mAb) 5% milk 1/500 in 2% milk Anti-mouse-HRP
HRP-conjugated cholera toxin B 2% milk 1/1000 in 2% milk -
*Reagents were diluted in PBS-T
glycine, 0.1% SDS). Gels were briefly washed twice with PBS, before processing to 
Western blotting or Coomassie blue staining.
In preparation for Western blots, following electrophoresis, the gels were incubated 
with transfer buffer (48 mM Tris base, 39mM glycine, 20% (v/v) methanol) at room 
temperature for a total of 20 min with 3 changes of buffer. Extra thick filter paper (Bio- 
Rad) and the nitrocellulose membrane (Hybond ECL, Amersham Pharmacia Uk Ltd., 
Little Chafont, U.K.) used for transfer were kept in transfer buffer for 20 min before 
transfers. Electrotransfer was conducted in a semi-dry transfer cell apparatus (Transblot 
SD, Bio-Rad) for 30 min at 13 volts. Following transfer, the membranes were blocked 
for 1 h at room temperature with blocking buffer consisting of PBS/0.1% Tween-20 
(PBS-T) supplemented with BSA as indicated in Table 4.2. Membranes were then 
washed ( 1 x 1 5  min and 2 x 5  min) and incubated with the appropriate first Ab (Table 
4.2) overnight at 4°C with gentle rocking, and following washing (see above), the 
membranes were incubated (1 h, room temperature) with the second Ab-horseradish 
peroxidase (HRP) conjugated (ECL system, Amersham). Subsequently, the membranes 
were washed (PBS-T, 1 x 1 5  min and 4 x 5  min at room temperature) before detection 
by enhanced chemiluminescence (ECL system, Amersham).
To test the specificity of the detection of sTLR2 in the mice peritoneal lavages, peptide 
competition experiments were performed (Fig. 2.3.3). Before immunoblotting, TLR2p 
was incubated (2 h, room temperature) with a 10 x mass excess of the peptide used for 
immunisation or BSA as a control.
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Table 4.3. List of primers
Name
Position 
<5* -»  3’)
Sequence 
(5* -► 3’)
Use
TLR2 -77 (fwd.) - 77 -> - 58 AGGTACCTGTGGGGCTCATT Sequencing
TLR2 158 (fwd.) TLR2: 158 —> 177 CTGTAAAAAGCCTTGACCTG
Sequencing,
screening
TLR2 527 (rev.) TLR2: 548 -> 527 GCATCAATCTCAAGTTCCTCAA
Sequencing,
screening
TLR2 638 (fwd.) TLR2: 638 -> 658 TGCTGGAGATTTTTGTAGATG Sequencing
TLR2 1048 (fwd.) TLR2: 1048 1068 CTGGTTCCTTGTTT ACTTTC A Sequencing
TLR2 1195 (rev.) TLR2: 1215 —» 1195 GGTTTTTTCCAATGATGCCAA Sequencing
TLR2 1598 (fwd.) TLR2: 1598 —» 1618 ATAACTTCATTTGCTCCTGTG Sequencing
TLR2 1737 (rev.) TLR2: 1755 —> 1737 ACATTCCGACACCGAGAGG Sequencing
TLR2 2094 (rev.) TLR2: 2114 —» 2094 TCAGAAAGCACAAAGACAGTT Sequencing
M 13 5 ’ (fwd.) pCRII-TOPO™ (5’) CATTTTGCTGCCGGTC Sequencing
M 13 3’ (rev.) pCRII-TOPO™ (3’) T A AT ACG ACTC ACT AT AGGG Sequencing
Or -
CCAGTGAGCAGAGTGACGA 
GGACTCGAGCTCA AGC(T) 17
RT
pdN6 - Random hexamer RT
pDR2 5’ (fwd.) pDR2AEFla™ (5’) CAAGCCTCAGACAGTGGTTC Sequencing,screening
pDR2 3 ’ (rev.) pDR2AEFla™ (3’) ATGTCTGGATCGGTGCGGGC Sequencing
Table 4.4. Thermal cycling settings for PCR
Step T°C Time Nr of cycles
Initial denaturation 95°C 5 min 1
Denaturation 94°C 40 sec
30Annealing a55°C-68°C 40 sec
Extension 72°C bl-2 ,/2min
Final extension 72°C 10 min 1
a The annealing temperature depended on the melting T°C of primers. 
b The extension time depended on the size of the PCR product (minimum 1 min/1000 bases)
For protein stainings, following electrophoresis, the gels were Coomassie blue 
stained (Coomassie Brilliant Blue R-250 Staining Solutions Kit, Bio-Rad) according to 
the manufacturer’s instructions. The sensitivity of the Coomassie blue staining was 
between 8 and 28 ng of protein.
4.5 Polymerase Chain Reaction (PCR)
To screen bacterial colonies for the presence of the pMel Bac B-His rhsTLR2 or 
pDR2AEFla-TLR2 mutant constructs (sections 4.8 and 4.20, respectively), individual 
colonies were picked from the LB/Agar plates and resuspended into 20 pi of water. 10 
pi of this solution was then used as a template, and amplified using the TLR2-specific 
primer TLR2 158 (forward; pMel Bac B-His rhsTLR2) or the pDR2AEFla 5’ primer 
(forward; pDR2AEFla-TLR2 mutant) and the TLR2 527 (reverse). The sequences and 
positions of the primers are given in Table 4.3.
To amplify the TLR2 mutant cDNA from total RNA by PCR, a mixture of 2 pi 
of pdN6 and 2 pi of Qt reverse-transcribed RNA was used as template, and amplified 
using the TLR2-specific primers 638 (forward) and 1195 (reverse; Table 4.3).
For PCR, mixtures (50 pi) containing 0.3 mM dNTPs (Bioline), 1 mM MgC^ 
(Bioline), 25 pmol of forward and reverse primers (Table 4.3), and 2.5 U of Taq DNA 
polymerase (Bioline) in PCR buffer (Bioline, 16 mM (NH ^SO^ 0.01% Tween-20, 67 
mM Tris-HCl pH 8.8), were subjected to the cycling conditions shown in Table 4.4. All 
PCRs were performed using a Hybaid Omnigene thermocycler (Hybaid Ltd., 
Teddington, U.K.). PCR products were analysed by DNA agarose gel electrophoresis.
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4.6 DNA agarose gel electrophoresis
DNA products were resolved on a 1% (w/v) agarose (Invitrogen) gel in TAE 
buffer (40 mM Tris Acetate pH 7.2, 1 mM EDTA). Agarose was dissolved in TAE 
buffer by boiling. The solution was allowed to cool to approximately 55°C before 
ethidium bromide (Sigma-Aldrich) was added at a final concentration of 50 ng/ml. The 
solution was poured into the gel casting tray of an Electro-4 gel tank (Hybaid Ltd.), and 
left for at least 30 min to set. The gel was transferred to the gel tank and TAE buffer 
was added. Before loading, DNA products were mixed with DNA loading buffer 
(0.25% (w/v) bromophenol blue, 30% glycerol in dHzO) at a final DNA product: 
loading buffer ratio of 10:1. Electrophoresis was carried out at constant voltage (100 V) 
until separation of the DNA fragments. The SmartLadder (Eurogentec, Southampton, 
U.K.) was used as a DNA size marker. PCR products were visualised, and cut out from 
the gel using an UV transilluminator lamp. DNA was purified using a DNA-binding 
column (QIAquick® gel extraction kit, Qiagen) following the manufacturer's 
instructions. The extent of the purification was evaluated by performing 1% gel agarose 
electrophoresis.
4.7 DNA sequencing
DNA sequences were verified using the ABI Prism® Big Dye™ Terminator 
Cycle Sequencing Ready Reaction kit with AmpliTaq® Polymerase FS (PerkinElmer, 
Waltham, MA, U.S.A.). The PCR mixture (8 pi final volume) contained 700 ng of 
plasmid, 5 pmo\ of primer (Table 4.3), and 3 pi of Terminator mixture containing the 
enzyme, the buffer, dNTPs and the Big Dye Terminators. Thermal cycling (25 cycles)
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conditions were: denaturation, 96°C for 30 secs; annealing, 50°C for 15 secs; extension, 
60 C for 4 min. Following thermal cycling, 40 pi of sterile water was added, and the 
PCR product was precipitated by adding 5 pi 3 M Na acetate buffer pH 5.4, 140 pi of 
ethanol, and incubating 20 min at —70°C. The sample was then centrifuged at 16,000 x g 
for 20 min at room temperature, and the precipitated DNA was washed with 75% (v/v) 
ethanol. DNA sequencing was carried out in our DNA sequencing facility (CBS, 
Cardiff University, School of Medicine) by using an automated ABI 377 DNA 
sequencer (Applied Biosystems, Warrington, U.K.). TLR2 mutants sequences were then 
compared to the reported “Homo sapiens toll-like receptor 2 sequence” (NCBI: NM 
003264) using the sequence comparison software: Megalign™ DNA.
4.8 Production of recombinant human sTLR2 
(His-rhsTLR2)
4.8.1 Generation of the His-rhsTLR2 cDNA
To generate His-rhsTLR2, the baculovirus expression system was used. A TLR2 
construct consisting of the putative human TLR2 extracellular domain (Glu21-Arg587) 
with a C-terminal 6x histidine (His) tag tail was generated. The TLR2 cDNA was 
obtained by RT-PCR using RNA isolated from Mono Mac-6 monocytes, and cloned 
into the pCR®II-TOPO® cloning vector, as previously described (LeBouder et al., 2003). 
The plasmid pCR®II-TOPO® containing the full-length TLR2 cDNA was used as a 
template to generate a PCR fragment corresponding to amino acids 21-587 of TLR2 
with a C-terminal His tag. The sense and antisense primers used were:
5 ’ -CGCGGA TCCGGAATCCTCCAATCAGGCTTCT-3 ’ and
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5 *-CGCAA GCTTC TAGTGATGGTGATGGTGATGGAGGGGGCCTTGAAAC 
AG AACTTCT AACCTGTG AC ATTCCG AC ACCG AG AGGCG-3 ’, underlined and 
bold type are the His tag and PreScission-Amersham-protease cleavage site, 
respectively. In italics, are the BamHI (GGATCC) and Hindlll (MGCTT) restriction 
sites. PCR products were analysed by DNA gel electrophoresis (1768 base pairs) 
followed by DNA extraction and purification.
The purified PCR products were then digested in a 30 pi final reaction mixture 
containing 3 pi of NEB2 buffer (10 mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, 1 mM 
dithiothreitol, pH 7.9, New England Biolabs (NEB) Ltd., Hitchin, U.K.), 3 pi of lOx 
BSA (10 mg/ml, NEB), 1.5 pi of BamHI (15 U/pl, Amersham Pharmacia) and 1.5 pi of 
Hindlll (12 U/pl, Bioline, London, U.K.). The mixture was incubated 2 h at 37°C, and 
the digestion was stopped by incubating the samples for 15 min at 65°C. The digested 
PCR products were purified using the QIAquick® Nucleotide removal kit (Qiagen) 
following the manufacturer’s instructions. In preparation for cloning, 1 pg of pMelBac 
B expression vector was digested in a 20 pi mixture containing 2 pi of NEB2 buffer, 2 
pi of lOx BSA, 1 pi of BamHI and 1 pi of Hindlll. The mixture was incubated 2 h at 
37°C, and the reaction was stopped by incubating 15 min at 65°C. One microlitre of 
Calf Intestinal Phosphatase (CIP) (10 U/pl, NEB) was added, and the vector was 
dephosphorylated for 90 min at 37°C. The digested and dephosphorylated plasmid was 
then purified using the Geneclean® III DNA purification kit (Anachem UK Ltd., Luton, 
U.K.) according to the manufacturer’s instructions.
The ligation was carried out by mixing 55 ng of the digested purified pMelBac B 
plamid with 50 ng of the purified His-rhsTLR2 PCR products (1:3, plasmid: insert 
molar ratio, approximately), 1.5 pi of ligase buffer (30 mM Tris-HCl pH 7.8, 10 mM
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CGCGGArCCGGAATCCTCCAATCAGGCTTCTCTGTCTTGTGACCGCAATGGTATCTGCAAGGGCAGCTCAGGATCTTTAAACTCC
ATTCCCTCAGGGCTCACAGAAGCTGTAAAAAGCCTTGACCTGTCCAACAACAGGATCACCTACATTAGCAACAGTGACCTACAGA
GGTGTGTGAACCTCCAGGCTCTGGTGCTGACATCCAATGGAATTAACACAATAGAGGAAGATTCTTTTTCTTCCCTGGGCAGTCT
TGAACATTTAGACTTATCCTATAATTACTTATCTAATTTATCGTCTTCCTGGTTCAAGCCCCTTTCTTCTTTAACATTCTTAAAC
TTACTGGGAAATCCTTACAAAACCCTAGGGGAAACATCTCTTTTTTCTCATCTCACAAAATTGCAAATCCTGAGAGTGGGAAATA
TGGACACCTTCACTAAGATTCAAAGAAAAGATTTTGCTGGACTTACCTTCCTTGAGGAACTTGAGATTGATGCTTCAGATCTACA
GAGCTATGAGCCAAAAAGTTTGAAGTCAATTCAGAATGTAAGTCATCTGATCCTTCATATGAAGCAGCATATTTTACTGCTGGAG
A TTTTTGTAGA TGTTA CAAGTTCCGTGGAATGTTTGGAACT GCGA GA TA CTGATTTGGA CA CTTTCCA TTTTTCAGAACTA TCCA
CTGGTGAAACAAATTCATTGATTAAAAAGTTTACATTTAGAAATGTGAAAATCACCGATGAAAGTTTGTTTCAGGTTATGAAACT
TTTGAATCAGATTTCTGGATTGTTAGAATTAGAGTTTGATGACTGTACCCTTAATGGAGTTGGTAATTTTAGAGCATCTGATAAT
GACAGAGTTATAGATCCAGGTAAAGTGGAAACGTTAACAATCCGGAGGCTGCATATTCCAAGGTTTTACTTATTTTATGATCTGA
GCACTTTATATTCACTTACAGAAAGAGTTAAAAGAATCACAGTAGAAAACAGTAAAGTTTTTCTGGTTCCTTGTTTACTTTCACA
ACATTTAAAATCATTAGAATACTTGGATCTCAGTGAAAATTTGATGGTTGAAGAATACTTGAAAAATTCAGCCTGTGAGGATGCC
TGGCCCTCTCTACAAACTTTAATTTTAAGGCAAAATCATTTGGCATCATTGGAAAAAACCGGAGAGACTTTGCTCACTCTGAAAA
ACTTGACTAACATTGATATCAGTAAGAATAGTTTTCATTCTATGCCTGAAACTTGTCAGTGGCCAGAAAAGATGAAATATTTGAA
CTTATCCAGCACACGAATACACAGTGTAACAGGCTGCATTCCCAAGACACTGGAAATTTTAGATGTTAGCAACAACAATCTCAAT
TTATTTTCTTTGAATTTGCCGCAACTCAAAGAACTTTATATTTCCAGAAATAAGTTGATGACTCTACCAGATGCCTCCCTCTTAC
CCATGTTACTAGTATTGAAAATCAGTAGGAATGCAATAACTACGTTTTCTAAGGAGCAACTTGACTCATTTCACACACTGAAGAC
TTTGGAAGCTGGTGGCAATAACTTCATTTGCTCCTGTGAATTCCTCTCCTTCACTCAGGAGCAGCAAGCACTGGCCAAAGTCTTG
ATTGATTGGCCAGCAAATTACCTGTGTGACTCTCCATCCCATGTGCGTGGCCAGCAGGTTCAGGATGTCCGCCTCTCGGTGTCGG
AATGTCACAGGTTAGAAGTTCTGTTTCAAGGCCCCCTCCATCACCATCACCATCACTAGAAGCrTGCG
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Figure 4.1. Cloning o f  the H is-rhsTLR2 cDNA into the pM elBac B vector.
The cDNA coding for the H is-rhsTLR2 was cloned into the pM elBa B vector using the BamHI and H indlll 
restriction enzym es (restriction sites in red and italics). An extra nucleotide (G, green and bold) was inserted 
after the BamHI restriction site for the His6-rhsTLR2 to be in frame with the honeybee-m ellitin (HM B) signal. 
The stop codon (blue and bold), the cleavage sequence (black and bold) and the 6x histidine tag (underlined) are 
indicated. HBM signal, H oneybee melitin signal; PPH, Polyhedrin promoter.
MgCh, 10 mM DTT, 1 mM ATP; Promega), and 1.5 pi of ligase (1 U/pl; Invitrogen). 
The reaction mixture (15 pi final volume) was incubated overnight at 16°C. An aliquot 
(2 (al) was electroporated into 100 pi of electrocompetent DH5a Escherichia coli at 2.5 
kV, 25 pF and 200 £2 using a Bio-Rad Gene pulser™ II. After electroporation, 200 pi of 
SOC medium (2% (w/v) Bacto-Tryptone, 0.5% (w/v) Yeast extract, 10 mM NaCl, 2.5 
mM KC1, 10 mM MgCU, 20 mM Glucose, pH 7) were immediately added, and bacteria 
were incubated 30 min at 37°C. Bacteria were then spread on Luria Bertani (LB)/Agar 
plates (1% (w/v) Bacto-Tryptone, 0.5% (w/v) Yeast extract, 172 mM NaCl, pH 7.7 / 
1.5% (w/v) Agar) containing 100 pg/ml ampicillin and 50 pg/ml X-gal, and incubated 
overnight at 37°C. The following day, five clones were screened by PCR using TLR2- 
specific primers (Table 4.3) to test for the presence of the His-rhsTLR2 construct. A 
positive clone was selected, cultured, and the pMelBac B-His-rhsTLR2 construct (Fig. 
4.1) was extracted and purified using the QIAprep® spin miniprep kit (Qiagen) 
following the manufacturer’s instructions. The full sequence of the His-rhsTLR2 cDNA 
was then verified by sequencing.
4.8.2 Production of His-rhsTLR2
Sf9 cells were co-transfected with 3 pg of the recombinant pMelBac B-His- 
rhsTLR2 cDNA construct and 0.5 pg of Bac-N-Blue™ DNA by using the Bac-N- 
Blue™ transfection and expression system (Invitrogen), according to the manufacturer’s 
instruction. After 72 h, supernatants from the infected Sf9 were collected and tested 
(plaque assays) to determine the titre of, and select the recombinant virus from the 
remaining wild-type virus, as indicated by the manufacturer. Once the presence of 
recombinant virus in the initial supernatant was confirmed, high-titre viral stocks were
prepared. This was carried out by series of low-multiplicity infections of Sf9 cells, 
following the Bac-N-Blue™ transfection and expression protocol. Briefly, Sf9 cells 
were infected with the initial viral stock to increase the viral titre, and after 72 h the cell 
supernatant was collected, and the viral titre determined by a plaque assay. This step 
was repeated until having a supernatant with an optimal viral titre, i.e. 5 x 107 to 2 x 108 
PFU/ml.
The cells were infected with viral stock of a known titre, and the volume of viral stock 
to be used was determined by the following formula:
V= (n x MOI)/1
Where V is the volume (ml) of viral stock to be used for the infection, n the number of
cells to be infected, MOI the multiplicity of infection (for a low multiplicity of
infection, MOI=0.3) and t, the titre of the viral stock (PFU/ml).
High Five cells were used to produce the recombinant sTLR2 protein, and the 
volume of high-titre viral stock to be used for the infection was determined according to 
the formula described previously. Unlike the generation of the high-titre viral stock, for 
protein production a higher MOI was used (MOI=5). This ensured a synchronous 
infection of all cells in the culture, thus allowing maximum amounts of recombinant 
protein to be harvested at a given time point. Exponentially growing High Five cell 
cultures (2.5 x 106 cells/ml) were infected with the appropriate volume of viral stock,
cultured for 3 days (27 C, 120 rpm), and the supernatants were then collected and
processed in preparation for His-rhsTLR2 purification.
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4.9 Purification of His-rhsTLR2
After a 72-hour infection, the High Five culture supernatants (typically, 200 ml) 
were collected, filtered (22 pm filters) and concentrated 25 times using Centricon Plus 
70 (Millipore, Billerica, MA, U.S.A.; 2000 x g, 4°C). The concentrated supernatant was 
then dialysed (Seamless cellulose tubing, high retention, 23 mm diameter, Sigma- 
Aldrich) in the binding buffer (50 mM NaH2PC>4 , 300 mM NaCl, 10 mM imidazole pH 
8.0). Buffer exchange was achieved by 2 x 90 min and 1 x 16 h dialysis at 4°C (1:250, 
supernatant: binding buffer ratio).
His-rhsTLR2 was batch-purified by metal-affinity chromatography using nickel- 
nitrilotriacetic acid (Ni-NTA)-coated beads. Routinely, 200 pi of beads (bead volume) 
were used to purify His-rhsTLR2 contained in the concentrated supernatant 
corresponding to 200 ml of High Five cell supernatant. Prior to binding, the beads were 
washed 5 times with 400 pi of binding buffer (1000 x g, 30 sec), and then added to the 
dialysed and concentrated supernatant. After a 2 h incubation at 4°C with gentle 
rotation, the beads were collected by centrifugation (1000 x g , 2 min), and washed 16 
times with 250 pi of binding buffer (1000 x g, 30 sec).
Preliminary experiments were carried out to determine the optimal concentration 
of imidazole in the binding and washing buffers. While a low concentration of 
imidazole in the washing buffer ensures efficient elimination of contaminants non- 
specifically bound to the Ni-NT A resin, a relatively high concentration may lead to a 
loss of His-tagged protein in the washes. Thus, preliminary washing experiments with 
buffer supplemented with 10, 20 or 40 mM imidazole were conducted following 
binding. The presence of His-rhsTLR2 and proteins in the washes -  a total of 16 -  was 
monitored by Western blotting with an anti-TLR2 specific polyclonal Ab (TLR2p) and
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Figure 4.2. The effect of different concentrations of imidazole in the washing buffer.
A, Western blot analysis following 10% SDS-PAGE of the last two washes (W15 and W16) of the Ni-NT A- 
coated beads carried out -  following binding -  with washing buffer supplemented with 10, 20 or 40 mM 
imidazole. Immunoblottings were performed with the anti-TLR2 polyclonal Ab, TLR2p. The approximate 
molecular mass of the sTLR2 polypeptides is indicated. A duplicate 10% SDS-PAGE gel run in parallel was 
Coomassie blue stained and is shown in B.
Coomassie blue G250 staining (Fig. 4.2). As shown in Figure 4.2, A, the Western blot 
analysis revealed the presence of significant amounts of His-rhsTLR2 polypeptides in 
the last two washes carried out with buffer supplemented with either 20 or 40 mM of 
imidazole. By contrast, a negligible amount of His-rhsTLR2 was detected in the washes 
when 10 mM imidazole was used. These observations were confirmed by Coomassie 
blue staining of the washes (Fig. 4.2, B). Therefore, a 10 mM imidazole concentration 
in the binding and washing buffer was used.
Following washing, the His-rhsTLR2 was eluted from the Ni-NT A beads by increasing 
the concentration of imidazole in the buffer to 250 mM. The beads were washed 4 times 
(1000 x g, 30 sec) with 200 pi of elution buffer (binding buffer supplemented with 250 
mM imidazole), and the 4 fractions collected were pooled (800 pi total) and dialysed 
twice (90 min, 4°C) in 500ml of PBS using a dialysis chamber (D-tube™ Dialyser Midi, 
MWCO: 6-8 kDa, Novagen).
The protein content of the preparation was determined (Dc Protein Assay, Bio-Rad) 
before aliquoting and storage at -70°C until use. Typically, 200 ml of High Five cell 
culture supernatant yielded 200-240 pg of purified His-rhsTLR2. The purity of the 
preparation was analysed as described in Results, section 2.1.2 page 79.
4.10 Co-immunoprecipitation experiments
For mCD14-mTLR2 co-immunoprecipitation experiments, 5 x 106 freshly- 
isolated human monocytes were washed and resuspended in phenol red-free RPMI- 
1640 medium, and incubated for 30 min at 37°C in the presence of 5 pg/ml His- 
rhsTLR2 or 10 pg/ml BSA. After washing, the cells were lysed for 30 min at 4°C with 
lysis buffer (1% (v/v) Nonidet P-40, 50 mM Tris-HCl, 150 mM NaCl, 1 pg/ml
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leupeptin and pepstatin, 1 mM PMSF, pH 7.4). The cell lysate was precleared by 
incubation (overnight, 4°C, orbital rotation) with 80 pi of a 50% suspension of protein 
G-Sepharose, followed by a further 1 h, 4°C incubation with 4 pg of the isotype- 
matched control, mouse IgG2b (MOPC-141), and finally with protein G-Sepharose (50 
pi, 1 h, 4°C, orbital rotation). The precleared samples were incubated (1 h, 4°C) with 5 
pg of the anti-CD 14 mAb, MY4, and the immunocomplexes precipitated with 50 pi of 
the protein G-Sepharose bead suspension. Following washing, samples were analysed 
by Western blotting with the anti-TLR2 mAb, IMG 319.
4.11 Crosslinking experiments
For chemical crosslinking experiments, 5 x 106 cells were resuspended in 500 pi 
of cold phenol red-free RPMI-1640 medium and incubated with 5 pg of His-rhsTLR2 
or the irrelevant His-tagged soluble protein sCD55 (kindly donated by Dr. C. Harris, 
Dept, of Medical Biochemistry and Immunology, Cardiff University, U.K.) for 30 min 
at room temperature. Immediately after washing (cold RPMI-1640), 3 mg/ml (final 
concentration) of the membrane impermeable and non-cleavable crosslinker, 
bis(sulfosuccinimidyl)suberate (BS3, Pierce, Perbio Science, Northumberland, U.K.) 
were added to the samples, and the mixture was incubated for an additional 30 min at 
room temperature. Crosslinking was stopped by the addition of 10 mM Tris-HCl pH 7.4 
buffer and incubation on ice for 15 min. The cells were then lysed as described in 
section 4.10, and the cell lysates incubated with 10 pi Ni-NTA beads per 100 pi lysate 
(2 h, 4°C, orbital rotation). The beads were then washed, and the protein eluted with 
Laemmli reducing sample buffer containing 250 mM imidazole. The eluate was
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analysed by 7.5 % SDS-PAGE and Western blotting using an anti-CD14 (69.4) or anti- 
TLR2 (sc8689) polyclonal Ab.
4.12 Preparation of lipid rafts
Freshly-isolated human monocytes (1 x 108 cells) were resuspended at 1 x 107 
cells/ml in warm phenol red-free RPMI-1640 medium and stimulated (lh, 37°C) with 5 
pg/ml P a r le y s  in the absence or presence of 5 pg/ml sTLR2. Subsequently, protein 
solubilisation was carried out with lysis buffer (1% (v/v) Triton X-100, 150 mM NaCl, 
50 mM Tris-HCl, 1 mM PMSF, 1 pg/ml leupeptin and pepstatin pH 7.4) for 1 h at 0°C. 
Cell lysates (1.5 ml) were then mixed with an equal volume of cold 90% sucrose 
solution (45% final concentration) prepared in sucrose gradient buffer (50 mM Tris- 
HCl, 150 mM NaCl pH 7.4) and placed at the bottom of a centrifuge tube. Samples 
were overlaid with 7 ml of 30% followed by 2 ml of 5% cold sucrose solutions (both in 
sucrose gradient buffer) and centrifuged at 200,000 x g for 16 h at 4°C. One millilitre 
fractions were gently removed from the top of the gradient, and the non-ionic detergent, 
n-octylglucoside (60 pM final concentration), was added to each fraction. Equal 
aliquots of each fraction were run in 10% SDS-PAGE gels and analysed by Western 
blotting using the anti-CD 14 mAb, MY4, or the anti-TLR2 mAb, IMG 319.
To define the lipid raft-containing fractions in the sucrose gradient, aliquots of each 
fraction were analysed by dot blotting to determine the presence of the raft-associated 
ganglioside, GM1. Presence of GM1 in the blots was tested with HRP-conjugated 
cholera toxin B (List Biologicals, Campbell, CA), and the detection visualised by 
enhanced chemiluminescence (ECL system, Amersham)
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4.13 Fluorescence resonance energy transfer (FRET) 
experiments
4.13.1 Sample preparation for FRET
For FRET experiments, human monocytes (3 x 106 cells/spot) were allowed to 
adhere (1 h, 37°C) to multi-spot slides (Shandon Multi-spot, Thermo Electron Corp. 
Basingstoke, U.K.) in the presence of 5 pg/ml sTLR2 or BSA in phenol red-free RPMI- 
1640 medium. Subsequently, the cells were incubated with 20 % normal rabbit serum 
for 15 min at room temperature before washing (2 x brief washes with PBS-0.01% 
NaNs). Labelling (1 h, 4°C) with the anti-CD 14 mAb My4-Cy3 or its isotype-matched 
IgG2b-Cy3 control (acceptor fluorophore, 0.25 pg/spot) was performed in the absence 
or presence of 5 pg/ml His-rhsTLR2 or BSA. Both antibodies were Cy3-conjugated 
using the FluoroLink mAb Cy3 labeling kit (GE healthcare U.K. Ltd, Bucks, U.K.) 
following the manufacturer’s instructions. The slides were then washed as described 
previously, fixed (2% paraformaldehyde, 15 min, room temperature) and washed again 
before staining with the anti-TLR2 mAb, T2.5-Alexa 488 (donor fluorophore), as 
described for MY4-Cy3. After washing and fixing, the slides were mounted 
(Vectashield mounting fluid, Vector, laboratories, Peterborough, U.K.) in preparation 
for FRET analysis.
4.13.2 FRET data acquisition and analysis
FRET was measured by the release of quenched donor fluorescence after 
acceptor photobleaching using a previously described technique (Kenworthy, 2001). In
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Figure 4.3. Absence of correlation between FRET efficiency and acceptor fluorescence or FRET efficiency and 
bleaching efficiency.
Percentage of FRET efficiency between TLR2 (T2.5-A488) and CD14 (MY4-Cy3) on the surface of human 
monocytes, in resting conditions and in the absence of sTLR2. Each dot represents a cell event. Results are of 
one experiment representative five. Calculation of the linear correlation coefficient (R2) between FRET 
efficiency and acceptor fluorescence (before bleaching) (A), or FRET efficiency and bleaching efficiency (B), 
shows no correlation between these parameters (-0.1< R2 <0.1). This indicates that the energy transfer observed 
between TLR2 and CD14 results from a genuine interaction, and not from random proximity.
this technique, the donor fluorescence intensity before and after acceptor 
photobleaching -  in the same cell -  is compared. FRET efficiency was quantified by:
E (%) = [ ( I d a - I d b ) / I d a ]  x 100, where E represents % FRET efficiency; I d a  and I d b ,  the 
donor’s intensity after and before photobleaching of the acceptor, respectively. As 
bleaching of the acceptor fluorophore constitutes the basis of this FRET technique, the 
events for which the bleaching of the acceptor was unsuccessful, i.e. the intensity of the 
acceptor after bleaching was superior or equal to the intensity before bleaching, were 
not considered in the data analysis of the present study. The cells (100-150 
cells/condition) were imaged using a Leica TCS SP2 spectral confocal and multiphoton 
system (Leica Microsystem Ltd., Bucks, U.K.).
Random proximity effects that arise from confining donors and acceptors to a 
surface can lead to substantial non-specific energy transfer. A hallmark of FRET 
arising from such random proximity is a characteristic increase in E (% FRET 
efficiency) as a function of acceptor surface density. In contrast, E for specifically 
interacting proteins should not depend on acceptor surface density (Kenworthy, 2001) 
or bleaching efficiency. To confirm that the transfer of energy observed in the 
experiments described in this study was due to a genuine interaction between CD 14 and 
TLR2, and not to a random proximity effect, the correlation between E  and acceptor 
intensity (Fig. 4.3, A), and between E  and bleaching efficiency (Fig. 4.3, B) was 
determined. Figure 4.3 shows that there was no correlation between E and acceptor 
intensity nor between E  and bleaching efficiency, indicating that the transfer of energy 
observed was due to a genuine interaction between CD 14 and TLR2.
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4.14 Binding of sTLR2 to Pam3Cys, LPS and bacteria
4.14.1 Binding to Pam3Cys and LPS
Triplicate wells of microtiter well plates (high binding, Costar, Coming, NY, 
U.S.A.) were coated (20 pi) with the indicated amounts (Fig. 2.3.2) of Pau^Cys or LPS 
dissolved in ethanol. Following solvent evaporation at room temperature, non-specific 
binding in the wells was blocked by incubation (2 h, room temperature) with a PBS 
solution containing 1% BSA, 5% sucrose and 0.05% sodium azide. The plates were 
then washed three times with washing buffer (PBS/0.05% Tween-20) and incubated (4 
h, 37°C) with 5 pg/ml of His-rhsTLR2 or sCD46-Fc (50 pl/well; kindly provided by Dr. 
C. Harris) diluted in 0.05% Tween-20, 0.1% BSA, 20 mM Trizma base, 150 mM NaCl 
pH 7.3. Subsequently, the wells were washed and incubated with an anti-Hiss mAb (0.2 
pg/ml) or biotin-conjugated anti-human Igs Ab (0.5 pg/ml) for 2 h at room temperature. 
Following washing, the wells incubated with sTLR2 and the anti-His mAb were 
incubated further (2 h, room temperature) with a biotin-conjugated anti mouse IgG Ab, 
before washing and incubation (20 min, room temperature) with streptavidin-HRP (2 
pg/ml). The wells were then washed before adding 100 pl/well of tetramethylbenzidine 
substrate (TMB, SureBlue™, KPL, MD, U.S.A.). The colour reaction was stopped (1 M 
HC1; 50pl/well), and colour developed measured at 450 nm.
Binding of LPS to the wells (used in control experiments) was confirmed by the 
binding of purified sCD14 to the wells (250 ng/well), which was detected using the 
biotin-cojugated anti-CD 14 mAb, MY4, followed by incubation with streptavidin-HRP 
and TMB substrate, as described previously.
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4.14.2 Binding to bacteria
In order to test the binding of sTLR2 to bacteria, 5 x 104 heat-killed 
Staphyloccocus epidermidis PCI 1200 strain were resuspended in 100 pi of PBS/0.5% 
BSA and preincubated (30 min, room temperature) with 500 ng of sCD14. 
Subsequently, 1 pg of recombinant mouse sTLR2-human Fc (R&D Systems) or control 
CD46-Fc fusion protein was added, and the samples were incubated for a further 30 min 
at room temperature. Following washings (2 x PBS/ 0.5% BSA), samples were 
incubated (0°C, 30 min) with 0.5 pg of a biotin-conjugated anti-human IgG Ab. 
Following washing and fixing (2 % paraformaldehyde, 10 min, room temperature), 
APC-conjugated streptavidin (0.1 pg) was added, and the samples were incubated for 
20 min on ice before washing and analysis by flow cytometry.
4.15 Immunofluorescence and flow cytometry
In preparation for flow cytometric analyses, cells were washed twice and 
resuspended in binding buffer (PBS, 0.5% BSA, 0.05% NaNa), at a density of 5 x 106 
cells/ml, and 100 pi aliquots were distributed in wells of round bottom 96-well plates. 
Fc receptors on monocytes and neutrophils were blocked by incubating the samples 
with a 20% normal rabbit serum solution (in binding buffer; 100 pi/ 5 x 105 cells) for 15 
min at room temperature. Subsequently, cells were incubated with the specific mAbs 
(0.5 pg mAb per 5 x 105 cells in 100 pi binding buffer) for 30 min at 4°C. Following 
incubation and washes (2 x 200 pi binding buffer), samples were fixed in 2% p- 
formaldehyde (Sigma-Aldrich). The stained cells were analysed by flow cytometry, 10 
000 events were acquired for each sample using a FACSCalibur cytometer (Becton 
Dickinson, San jose, CA), equiped with the CellQuest™ Pro software.
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4.16 Cell activation
For all activation experiments, cells were resuspended in phenol red-free RPMI- 
1640 medium, and cultured in round bottom 96-well plates, unless stated otherwise.
For the cell activation experiments shown in Figure 2.2.2 (Results, effect of 
overexpressing sTLR2) and Figures 2.5.4 and 2.5.5 (Results, effect of the TLR2-derived 
peptides), 1.5 x 105 cells/well were cultured in serum-free medium supplemented or not 
with 500 ng/ml sCD14 (purified from human milk, as previously described, Labeta et 
al., 2000) and stimulated with the indicated amounts of the different TLR2 ligands 
(PamsCys, PGN, HKLM). For the experiments testing the effect of the TLR2-derived 
peptides (Figs. 2.5.4 and 2.5.5), the peptides were solubilised in an acetonitrile/water 
solution according to their solubility characteristics, before aliquoting and storage at -  
70°C (10 mg/ml stock solution) until further use. After a 16 h incubation (37°C), cell 
culture supernatants were collected, and the IL-8 concentration was determined by 
ELISA (Human CXCL8/IL-8 DuoSet, R&D Systems) according to the manufacturer’s 
instructions.
For the cell activation experiments described in Figure 2.2.3 (Results, effect of 
purified rhsTLR2), cell aliquots (1.5 x 105 cells/well) were cultured in serum-free 
medium supplemented or not (Mono Mac-6) with 500 ng/ml sCD14 and stimulated with 
the indicated concentrations of TLR ligands, non-TLR ligands or PMA + ionomycin. 
Cells were stimulated in the absence or presence of 5 pg/ml purified rhsTLR2. 
Following overnight (16 h) incubation, the cell culture supernatants were tested for IL-8 
by ELISA.
For NF-kB reporter assays, HEK293, HEK-TLR2, U373-EV and U373-sTLR2 
cells were seeded at 1.5 x 105 cells/well in 24-well plates the day before transfection and
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then transiently transfected with reporter genes (as well as TLR2 constructs, HEK293 
and HEK-TLR2) as indicated previously (section 4.3). Twenty-four hours post­
transfection, HEK293 and HEK-TLR2 cell transfectants were stimulated (16 h, 37°C) 
with the indicated amounts of Parr^Cys or HKLM, in the absence or presence of 
500ng/ml of sCD14 and 5 pg/ml of purified rhsTLR2, as indicated in the corresponding 
Results section. U373-EV and U373-sTLR2 cell transfectants were stimulated (8 h, 
37°C) with 60 ng/ml of LPS and the indicated concentrations of sCD14 (Fig. 2.4.6) 
Luciferase activity was measured using the Dual-Luciferase® reporter assay system 
(Promega), following the manufacturer’s instructions.
4.17 Phagocytosis experiments
To evaluate the effect of sTLR2 on phagocytosis, RAW264 murine macrophages 
(4 x 105) were resuspended in 400 pi of binding buffer (phenol red-free RPMI-1640, 1% 
sodium azide, 2.5% HEPES) and incubated with FITC-labelled S. epidermidis 
(Molecular Probes, Leiden, The Netherlands) at a bacteria:cell ratio of 10:1 for 30 min 
at either 0°C or 37°C, to test for bacteria binding or phagocytosis, respectively. To test 
the effect of sTLR2, the bacterial suspension was preincubated with 5 pg/ml sTLR2 or 
BSA (2x sTLR2 molarity) for 30 min at 37°C. Following binding, the samples were 
washed (4x) with cold washing buffer (PBS, 1% sodium azide), the cells were 
resuspended in 100 pi of washing buffer, fixed (2% paraformaldehyde, 15 min, room 
temperature), and analysed by flow cytometry. To distinguish between cell-surface 
bound and phagocytosed bacteria, the cell-surface fluorescence was quenched by adding 
125 pg/ml trypan blue to the samples before analysis.
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4.18 Superoxide production experiments
For superoxide production assays, 150 pi of assay buffer (13 mM Na2HP04, 3 
mM NaH2P04, 120 mM NaCl, 4.8 mM KC1, 1.2 mM MgS04, 11 mM dextrose, 0.71 
mM CaCl2 pH 7.4) containing 5 pg/ml Par^Cys or heat-killed S. epidermidis strain PCI 
1200 (ATCC; 5 x 106/well) , with or without 5 pg/ml sTLR2, were added in triplicate to 
microtiter well plates (microlite 2, Thermo LabSystems, Franklyn, MA) and kept at 
37°C. To this mixture, 2 pM Luminol (from 10 pM stock solution) and freshly-isolated 
human PMN (2 x 105) resuspended in 50 pi PBS were added, and the 
chemiluminescence generated was immediately measured, and then every 2 min for 1 h 
using a fluorometer (Fluostar Optima plate reader, BMG Labtech, Aylesbury, U. K.).
4.19 In vivo experiments
Inbred 8 to 12-week-old C57/BL6 mice (Harlan U.K. Ltd, Oxon, U.K.) were 
maintained under barrier conditions and pathogen free, as assessed by regular 
microbiological screenings. All procedures were carried out following Home Office 
approval, under project license number PPL-40/2131.
4.19.1 Preparation of S. epidermidis cell-free supernatant (SES)
Cell-free supernatant from S. epidermidis, termed SES, was prepared as 
previously described (Hurst et al., 2001). Briefly, suspension cultures of S. epidermidis 
-  isolated from an end-stage renal failure patient under continuous ambulatory 
peritoneal dialysis -  were centrifuged, filtered and dialysed (H20). Fractions were 
freeze-dried and aliquots stored at -70°C until use. SES preparations were free from live
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bacteria, as assessed by the lack of bacterial growth on DST agar (Oxoid Ltd, 
Basingstoke, U.K.). SES preparations were reconstituted in PBS prior to in vivo use, 
and their potency standardized by quantifying the release of IL-6 by RAW264 cells 
exposed to defined doses of SES.
4.19.2 SES-induced peritoneal inflammation model
SES-induced mouse peritoneal inflammation was induced by i.p. injection of a 
defined 500 pi dose of SES with or without 100 ng of sTLR2. Control animals were 
administered sterile PBS, with or without 100 ng of sTLR2. At the indicated time 
points, mice were sacrificed, and their peritoneal cavities lavaged with 2 ml of ice-cold 
PBS. Neutrophil and monocyte numbers in the lavages were assessed by differential cell 
count on cytospin preparations and Coulter counting (Coulter Z2, Beckman-Coulter, 
High Wycombe, U.K.), or by double staining of leukocytes with a FITC-conjugated 
anti-mouse F4/80 mAb (macrophages) and an APC-conjugated anti-mouse CD llb mAb 
(macrophages/monocytes) followed by flow cytometry analysis. To evaluate PMN 
survival in the peritoneal cavity, leukocytes were double stained with Annexin V-FITC 
(1/40) and propidium iodide (1/20; BD Bioscience), and analysed by flow cytometry. 
Levels of KC, MIP-2, and MCP-1 in the cell-free peritoneal lavage samples were 
quantified by ELISA (R&D Systems). To test for mouse sTLR2 in the peritoneal 
lavages, equal aliquots were diluted with 3x concentrated Laemmli reducing sample 
buffer and analysed by Western blotting using the TLR2-specific polyclonal Ab, 
TLR2p.
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Table 4.5. Pairs of primers used to generate TLR2 LRRs valine for leucine point substitutions
ZMSfe •- v  . v . " /
LRRl ForwardReverse
GCTGTAAAAAGCGTTGACGTGTCCAACAACAGG
CCTGTTGTTGGACACGTCAACGCTTTTTACAGC
LRR2 Forward
Reverse
AGGTGTGTGAACGTCCAGGCTGTGGTGGTGACATCCAATGGA
TCCATTGGATGTCACCACCACAGCCTGGACGTTCACACACCT
LRR3 Forward
Reverse
TCTTTTTCTTCCGTGGGCAGTGTTGAACATGTAGACTTATCCTAT
ATAGGATAAGTCTACATGTTCAACACTGCCCACGGAAGAAAAAGA
LRR4 Forward
Reverse
T CCCAGTAAGTTTACGAATGTTACAGAAGAAACGGGCTTGAACCA  
TGGTTCAAGCCCGTTTCTTCTGTAACATTAGTAAACTTACTGGGA
LRR5 ForwardReverse
CTTTTTTCTCATGCTCACAAAAGTGCAAATCGTGAGAGTGGGAAT  
ATTCCCACTCTCACGATTTGCACTTTTGTGAGCATGAGAAAAAAG
LRR6 Forward
Reverse
GATTTTGCTGGAGTTACCTTCGTTGAGGAAGTTGAGATTGATGCT
AGCATCAATCTCAACTTCCTCAACGAAGGTAACTCCAGCAAAATC
LRR7 Forward
Reverse
AACGTAAGTCATGTGATCGTTCATATGAAGCAG
CTGCTTCATATGAACGATCACATGACTTACGTT
LRR8 ForwardReverse
T CC GT GGAATGTGT GGAAGTGCGAGATACTGAT 
ATCAGTATCTCGCACTTCCACACATTCCACGGA
LRR9 ForwardReverse
GAAACAAATTCAGTGATTAAAGTGTTTACATTTAGA  
T CTAAAT GTAAACACT T TAATCACTGAATTTGTTTC
LRR10 Forward
Reverse
CAGAT T T C T GGAGT GGTAGAAGTAGAGT T T GAT GAC 
GTCATCAAACTCTACTTCTACCACTCCAGAAATCTG
LRR11 Forward
Reverse
AAAGT GGAAACGGTAACAATCCGGAGGGT GCATATTCAAAGG  
CCTTTGAATATGCACCCTCCGGATTGTTACCGTTTCCACTTT
LRRl 2 ForwardReverse
TTATTTTATGATCTGAGCACTTTATATTCACTTACAGAAAGA  
T C T T T C T GTAAGT GAAT AT AAAGT GC T C AGAT CAT AAAATAA
LRRl 3 ForwardReverse
CAAATTTTCACTGACATCCACGTATTCTACTGATTTTAAATG  
CAT T TAAAAT CAGTAGAATACGT GGAT GT CAGT GAAAAT T T G
LRRl 4 Forward
Reverse
GCCTGGCCCTCTGTACAAACTGTAATTGTAAGGCAAAATCAT  
ATGATTTTGCCTTACAATAACAGTTTGTACAGAGGGCCAGGC
LRRl 5 ForwardReverse
GGAGAGACT T T GGT CAC T GT GAAAAAC GT GACTAACAT T GAT 
AT CAAT GT TAGT CACGT T T T T CACAGT GAC CAAAGT CT C T CC
LRRl 6 Forward
Reverse
AAGAT GAAATAT GT GAAC GTAT CCAGCACAC GA 
TCGTGTGCTGGATACGTTCACAATTTTCATCTT
LRRl 7 Forward
Reverse
ATTCCCAAGACAGTGGAAATTGTAGATGTTAGCAAC  
GTTGCTAACATCTACAATTTCCACTGTCTTGGGAAT
LRRl 8 ForwardReverse
AATTTATTTTCTGTGAATGTGCCGCAAGTGAAAGAACTTTAT  
ATAAAGTTCTTTGACTTGCGGCACATTCACAGAAAATAAATT
LRRl 9 ForwardReverse
GATGCCTCCCTCGTACCCATGGTACTAGTAGTGAAAATCAGTAGG
CCTACTGATTTTCACTACTAGTACCATGGGTACGAGGGAGGCATC
LRR20 ForwardReverse
TCATTTCACACAGTGAAGACTGTGGAAGCTGGT
ACCAGCTTCCACAGTCTTCACTGTGTGAAATGA
4.19.3 Live bacteria-induced peritoneal inflammation model
Peritoneal inflammation was also induced in mice by i.p. injection (500 pi) of 5 
x 107 CFU S. epidermidis PCI 1200 strain (ATCC) in the absence or presence of sTLR2 
(100 ng). At the indicated time points, the mice were sacrificed and their peritoneal 
cavity lavaged, as described above. Blood was obtained by cardiac puncture. Bacterial 
CFU were determined by culturing blood and peritoneal lavage samples on Mueller- 
Hinton agar plates (Oxoid) overnight at 37°C. PMN numbers in the peritoneal lavages 
were determined as described for the SES model.
4.20 Generation of TLR2 mutants
The 20 leucine-rich repeats (LRR) TLR2 mutants were generated by point 
mutation, the strategy consisted in substituting a valine for 2 or 3 of the leucines of a 
particular LRR to create a TLR2 mutant cDNA. Twenty pairs of mutated 
complementary primers were designed, so that the 2 or 3 point mutations were centered, 
with 12 non-mutated bases at each end of the primer (MWG Biotech, London, U.K; 
Table 4.5). Point mutations were obtained using the Quick Change II™ kit (Stratagene), 
following the manufacturer’s instructions. Briefly, the pCRII®-TOPO® vector 
containing the TLR2 WT cDNA (TOPO-TLR2 WT), previously generated in our 
laboratory (LeBouder et al., 2003), was used as a template and the desired point 
substitutions were introduced by PCR using the appropriate pair of mutated primers. 
PCR conditions were: initial denaturation: 95°C, 1 min followed by 18 cycles of : 
denaturation (95°C, 50 sec), annealing (50°C, 50 sec), extension (68°C, 7 min 30 sec), 
and a final extension step (68°C, 7 min). The PCR products were then digested (37°C, 
90 min) with 10 U of Dpnl (Promega) to cut the non-methylated TOPO-TLR2 WT used
BamHlpUC ori
Amp R
pCRII-TOPO-TLR2
6.4kpb
Kan R
fl ori
Human TLR2 
insert (2340 pb)
BamHl/Xbal double digestion
+
Ligati on
Amp R f t F l a
ColEI ori
pDR2 AEFI a-TLR2
9.0 kbp Human TLR2 
insert (2340 pb)
BamHl
Figure 4.4. Subcloning o f  the human TLR2 cDNA from the pCR®II-TOPO® transfer vector into the 
pDR2AEFla mammalian expression vector.
The cDNAs encoding WT TLR2 or LRR TLR2 mutants were subcloned from the pC®RII-TOPO® plasmid - 
used as a template to carry out the point mutation - to the pDR2AEFla plasmid - used to transfect HEK293 cells 
-  using the Xbal and BamHl restriction enzymes.
as a template. Chemically competent bacteria were transfected with the Dnpl-digested 
PCR product and screening of individual colonies was carried out by DNA sequencing 
to check that the point mutation was introduced. The full TLR2 mutant sequence was 
then similarly verified.
The TLR2 mutants cDNAs were transferred from the pCR®II-TOPO® cloning 
vector to the pDR2AEFla mammalian expression vector using the BamHl and Xbal 
restriction enzymes (Fig. 4.4), as previously described for the subcloning of His- 
rhsTLR2 cDNA into the pMelBac™ B vector (section 4.8.1). The pDR2AEFla plasmid 
contains the ampicillin and hygromycin resistance genes, allowing the selection of 
transformed bacteria and transformed eukaryotic cells, respectively. The expression of 
the gene inserted in the vector is under control of the elongation factor-la (EFla)
promoter, which allows gene transcritpion in mammalian cells (Fig. 4.4).
To test for the presence of WT TLR2 or LRR mutant TLR2 mRNAs in transfected 
cells, total RNA was extracted from the HEK293 cells (used as a control), HEK-WT 
TLR2 or HEK-TLR2 mutant transfectants (3 x 106 cells) using the RNA extraction kit: 
RNeasy Mini® from Qiagen, according to the manufacturer’s instructions.
The TLR2 mutants cDNA was obtained by reverse transcription (RT) of the extracted 
mRNAs, using the Omniscript™ Reverse Transcriptase kit (Qiagen). To eliminate any 
secondary structures, total RNA was incubated for 5 min at 70°C and then ice-cooled 
for 5 min. RT was carried out on 3 pg of denaturated total RNA in the presence of 30 U 
RNasin (Promega), 0.5 mM dNTPs (Qiagen kit), 150pmo\ of random hexamer primers 
(pdN6) or 40 pmo\ of oligo-dT primers (QT) (Table 4.3), and 6 U Omniscript™ Reverse
Transcriptase (Qiagen kit) in RT buffer (Qiagen kit). RT was performed at 42°C for 90
146
min in a 30 pi final reaction volume. The RT-PCR products were then analysed by PCR 
for the presence of TLR2 mutants or TLR2 WT cDNA (section 4.5).
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